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ABSTRACT 
 
Background:  Pharmacoepidemiologic research is a valuable tool to enable one to understand 
medication utilization patterns, beneficial/harmful outcomes of drug therapy, and to evaluate the 
impact of other interventions on outcomes of drug therapy in “real-world” settings. 
Objectives:  This dissertation aimed to apply pharmacoepidemiologic methods to examine (1) 
changes in utilization patterns of cholesterol-lowering medications following the release of the 
guidelines and evidence-based data, (2) the associations between statin use and gait speed 
decline in older adults, and (3) the associations between aspirin, non-aspirin nonsteroidal anti-
inflammatory drugs or acetaminophen and risk of ovarian cancer. 
Methods:  The study samples were from two sources including (1) community-dwelling older 
adults in the Health, Aging and Body Composition Study, and (2) 902 women with ovarian 
cancer and 1,802 controls in a population-based case-control study.  An interrupted time-series 
analysis, multivariable generalized estimating equations, and multivariable logistic regression 
were used to examine our three objectives, respectively.   
PHARMACOEPIDEMIOLOGIC STUDIES: AN INTERRUPTED-TIME SERIES 
ANALYSIS ON DRUG UTILIZATION AND EVALUATION OF BENEFICIAL OR 
ADVERSE DRUG EFFECTS  
Wei-Hsuan Lo-Ciganic, PhD 
University of Pittsburgh 
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Results: First, the use of cholesterol-lowering medication increased substantially over a decade 
in older adults, but was not related to a change in level or trend following the release of the 
evidence-based guidelines.  Secondly, statin use had a decreased risk of gait speed decline.  
Thirdly, risk reductions of ovarian cancer were observed with the use of aspirin or selective 
COX-2 inhibitors. 
Conclusion: These findings suggest that further studies are needed to investigate risk-benefit 
balance of cholesterol-lowering therapy and the potential benefits/barriers of the treatment 
among adults aged ≥ 80 years.  Moreover, further investigations are warranted to confirm the 
risk-benefit balance of statin use and physical function decline in older adults.  Future research 
on the associations between aspirin use and the risk of ovarian cancer should better characterize 
accompanying medical conditions, health and lifestyle behaviors, genetic susceptibility, and the 
overall risk-benefit balance.  The public health relevance of these findings is that understanding 
the utilization patterns of cholesterol-lowering therapy and potential benefits of statins on 
physical function may prevent cardiovascular disease and disability in older adults.  In addition, 
aspirin or COX-2 inhibitors may be potential agents for the prevention of ovarian cancer, the 
second leading gynecologic cancer in the US. 
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1.0  INTRODUCTION 
1.1 PHARMACOEPIDEMIOLOGY 
Pharmacoepidemiology is the application of epidemiologic knowledge, methods, measurements, 
analysis, and reasoning to study the uses, beneficial and adverse effects of drugs (including 
biologics, vaccines, and therapeutic devices) in defined human populations.1  It is an applied 
field bridging between clinical pharmacology (including pharmacokinetics and 
pharmacodynamics) and epidemiology.2  Moreover, pharmacoepidemiology integrates with 
therapeutic risk management to minimize risks throughout the whole life cycle of a drug (i.e., 
from the time when it is first discovered or synthesized until it is no longer sold as a drug), and 
optimize its benefit/risk balance.1,3  
In the United States (US), the current drug approval process includes preclinical testing 
followed by three phases of clinical testing.  Phase I trials are generally conducted in a few 
healthy volunteers to determine the pharmacologic and pharmacokinetic actions, a safe dosage 
range of a drug, and to exclude any extremely common toxic reactions which are unique to 
humans.  The goals of Phase II trials are to obtain more information on the pharmacokinetics, 
common adverse reactions, initial possible efficacy, and to determine daily dosage of a drug in a 
small number of patients (typically up to 300).  The goals of Phase III trials are to rigorously 
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evaluate and confirm earlier efficacy studies and identify common adverse effects in a much 
larger number of patients (approximately 500-3,000).1,2  To meet Food and Drug Administration 
(FDA) standards, at least one (traditionally two) of the Phase III trials needs to be a randomized 
clinical trial (RCT).  However, the pre-marketing studies are inherently limited to detect a drug’s 
long-term effects, uncommon or delayed adverse effects, adverse drug withdrawal events, 
relative effectiveness in special populations (e.g., children, pregnant women or elderly), 
modifiers of efficacy (i.e., with concurrent drugs, disease severity, and lifestyle), and 
consequences due to misuse of the drugs by prescribers or patients.1  Once marketing approval of 
a drug is granted, phase IV studies (or post-marketing surveillance), which are usually non-
experimental epidemiologic studies, play a role to monitor its use and effectiveness in the usual 
clinical care conditions.  
The traditional field of pharmacoepidemiology primarily focuses on the study of adverse 
drug effects and drug utilization.  During the past two decades, the field of 
pharmacoepidemiology has increasingly shifted to study beneficial or harmful effects, 
pharmacoeconomics, pharmacogenetics, quality of life, meta-analysis of drug use, and health 
service research on studying if interventions improve drug use.  The potential contributions of 
pharmacoepidemiology include: (1) supplemental information to premarketing studies and better 
quantifying the incidence of known adverse and beneficial effects in certain populations not 
studied prior to marketing (e.g., elderly, children, or pregnant women), (2) new types of 
information not available from premarketing studies (e.g., undetected adverse and beneficial 
effects, patterns of utilization), and (3) reassurances about drug safety and fulfillment of ethical 
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and legal obligations.2   In summary, questions that pharmacoepidemiologic studies can answer 
include: 4 
(1) How and why is drug therapy being used/misused or prescribed?  
(2) What are the beneficial and harmful outcomes of drug therapy?  
(3) What interventions are effective in modifying the use and outcomes of drug therapy? 
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1.2 STUDY DESIGNS USED IN PHARMACOEPIDEMIOLOGY 
Figure 1. Study Designs Used in Pharmacoepidemiology 
 
The types of study designs applied in pharmacoepidemiology differ with respect to several 
dimensions including direction of outcome measurement (e.g., prospective or retrospective), the 
unit (individual or group), number (one or more) of observations made, and methods and timing 
of data collection.5  In Figure 1, case report, case-series, secular trend analysis (also called 
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ecologic study), cross-sectional, case-control and cohort studies are observational studies.6,7  In 
observational studies, investigators do not control the therapy, but simply observes and evaluates 
the results of ongoing medical care.  Case reports, case series, analyses of secular trends and 
cross-sectional studies are also referred to as descriptive studies.  Through the use of descriptive 
study designs in pharmacoepidemiology, investigators may establish drug utilization patterns and 
quality of drug use in a population and provide data to be used not only for health policy and 
planning, but also as preliminary information to consider possible associations between exposure 
and outcome.7   Due to intrinsic limitations that are described later, descriptive studies are 
sometimes called “hypothesis generating” studies, in which the proposed association will need to 
undergo further study.7  Case-control studies, cohort studies, and RCTs all have control groups, 
and are considered to be analytic studies (i.e., hypothesis testing).  Randomized clinical trials 
(RCTs) are experimental studies in which investigators control the therapy to participants.8  In 
addition to the applications of traditional epidemiologic study designs, methodological advances 
in the design and analysis (e.g., nested case-control, case-cohort, multitime case-control, cross-
over design) were developed to solve specific challenges in the conduct of research on drug 
effects during the past two decades.  Moreover, quantitative synthesis studies including meta-
analysis and decision analysis takes part of the medical literature or clinical experience, attempt 
to create an answer to a defined problem, resolve uncertainty and facilitate decision making in 
health care.9 
In order to clarify different study designs used in pharmacoepidemiology, each study 
design and its characteristics, advantages, disadvantages and examples will be discussed in turn 
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and summarized in Table 1.   The details of bias and confounding in pharmacoepidemiology will 
be discussed in Section 1.5.   
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Table 1. Summary of Study Designs Used in Pharmacoepidemiology Research 
Study Design Characteristics Measures of 
Association 
Advantages Disadvantages Main Applications/Examples (Ex) 
Case series, 
case reports 
• Observational, 
descriptive 
• Participants identified 
based on outcome 
• Generate information 
on natural history of 
disease and case 
definition 
Not available • Identifying new/rare 
disease/condition  
• Cheap and easy method 
for generating hypothesis 
• No control group 
• Rates or measures of 
association cannot be 
calculated 
• Monitor or capture adverse drug 
events or drug-drug interactions 
after marketing or in specific 
populations 
• Post-marketing spontaneous 
pharmacovigilance report 
• Ex: SSRIs induced serotonin 
syndrome in children10,11 
• Ex: Moxifloxacin-wafarin drug 
interaction12 
Analyses of 
secular trends 
(ecological 
studies) 
• Observational, 
descriptive 
• Trends in drug use and 
outcomes coinciding 
overtime for groups 
Correlation • Can provide rapid 
answers 
• Relatively quick and 
inexpensive 
• No control of 
confounding 
• Ecologic fallacy 
• Changes in diagnosis, 
coding systems overtime 
• Correlations between drug use 
and outcome overtime for 
groups 
• Ex: MMR immunization and 
autism occurrence among young 
children in California, US 13 
Cross-sectional  • Observational, 
descriptive 
• Study the distributions 
of drug use and disease 
in a populations 
Prevalence • Relatively quick and 
inexpensive 
• Valuable to estimate 
prevalence of drug use 
and disease 
• Temporal association 
cannot be established 
• Limited generalizability if 
choosing a convenience 
sample 
• Drug utilization study or snap-
shot of the possible 
beneficial/harmful effects of 
drugs 
• Ex: Whether statin use was 
associated with a higher 
prevalence of musculoskeletal 
pain using NHANES data 14 
Case-control  • Observational, analytic 
• Participants identified 
based on outcome 
• Can study rare 
outcomes or outcomes 
with long latency 
periods 
OR • Can study multiple 
exposures 
• Logistically easier and 
faster, cheaper than 
RCTs 
• Problematic control 
selection  
• Possibly biased exposure 
data 
• Recall limitation, recall 
bias, selection bias, 
temporal bias 
• Study relative rare outcome 
related to certain medication use 
• Ex: Use of diethylstilbestrol in 
pregnant women and the risk of 
vaginal cancer in the off-spring15 
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Table 1 (Continued) 
Study 
Design 
Characteristics Measures of 
Association 
Advantages Disadvantages Main Applications/Examples 
Cohort  • Observational, analytic 
• Participants identified 
based on exposure 
• Can study relatively rare 
exposures 
Absolute risk 
(NNT/NNH), 
RR,  
• Can study multiple outcomes 
• Temporal association 
established 
• Unbiased exposure data 
• Generally cheaper than RCTs 
• Immortal-time, loss-to-
follow-up biases, 
misclassification 
• Time-consuming if done 
prospectively 
 
• Post-marketing surveillance 
studies or study potential effects 
of drugs use or factors to 
influence medication use 
• Ex: statin use and cholesterol 
associations with incident 
dementia and mild cognitive 
impairment 16 
Nested case-
control 
• Efficient sampling 
designs within a cohort 
• A type of case-control 
study 
• Controls are matched by 
certain variables and time 
of enrollment of cases 
Allow to 
estimate 
absolute risk 
(NNT/NNH) 
and RR 
• Minimize recall or selection 
bias (baseline data were 
obtained on exposure status) 
• Cost-intensive tests of 
biological samples can be 
carried out in a subset of 
cohort 
• Loss-to-follow-up 
• May not be representative 
of all controls if outcome of 
interest is not rare 
• Drug use may change over 
time 
• Ex: Whether statin use was 
associated with risk of cancer 
using 574 UK general practices 
cohort 17 
Case-cohort 
(case-base) 
• Efficient sampling 
designs within a cohort 
• A type of case-control 
study 
• Controls are randomly 
selected from the rest of 
cohort 
Allow to 
estimate 
absolute risk 
(NNT/NNH) 
and RR 
• Same as nested case-control 
studies, plus 
• Controls may be used for 
multiple case groups 
• Loss-to-follow-up 
• May need to select more 
controls since some controls 
who develop the diseases of 
interest may enter the study 
as cases 
• Drug use may change over 
time 
• Ex: Associations of maximum 
prescribed daily opioid dose and 
dosing schedule with the risk of 
opioid overdose death among 
patients with cancer, chronic 
pain, substance use disorders 
using Veteran Health 
Administration Database18 
Multitime 
case-control 
• Efficient sampling 
designs within a cohort 
• A type of case-control 
study 
• Measure drug exposure at 
different time points to 
increase “numbers of 
observations per control” 
Allow to 
estimate 
absolute risk 
(NNT/NNH) 
and RR 
• Improve the precision of the 
RR and power without 
additional controls and cost 
• Not suitable for chronic or 
cumulative drug exposure 
• Must correct for within-
subject correlation 
• For acute/transient drug 
exposure 
• Antibiotic use associated AMI 
1:1 case-control:  OR=2 (95% CI: 
1.16–3.44); 1: 10 case-control: 
OR=2.13 (95% CI: 1.48-3.05); 
multitime case-control: OR=1.99 
(95% CI: 1.36-2.90)19 
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Table 1 (Continued) 
Study Design Characteristics Measures of 
Association 
Advantages Disadvantages Main Applications/Examples 
Case-crossover  • Assess the exposed 
versus unexposed 
periods of a drug in the 
same individuals  
• Study a transient 
exposure and acute 
events 
OR • Control for time-invariant 
confounders since each 
person serves as his/her 
control 
• Statistically efficient 
(require less sample size) 
• Recall or selection bias 
• Not feasible for curative or 
rapid changing conditions 
• Inefficient if exposure does 
not shift frequently 
• Limited use in claim data  
• Need to specify the length of 
the effect period 
• Examine the effects of drug 
use in patients with disease that 
worsen over time, various 
disease severity among 
patients, or the intermittent 
drug use 
• Ex:  Study the association 
between sumatriptan and MI20 
Case-time 
control  
• Extension of case-
crossover design 
• Controls are selected 
from a cohort with 
similar synchronization 
with cases 
OR • Similar to case-crossover 
• Situations where trends 
that may change overtime 
may be adjusted  
• May not be valid when time-
dependent confounders exist 
• Control the time-trend in drug 
use and indication for drug use 
or disease severity 
• Ex:  Examine the use of 
inhaled β-agonists and asthma 
death.21 
Self-controlled 
case series 
• Study a transient 
exposure and acute 
events 
• Drug exposure 
distribution doesn’t 
need to be stationary 
• Adjust time-invariant 
confounders by self-
controlled method 
RR • Efficient and cheaper 
• Allow temporal 
confounders (e.g. season), 
multiple risk periods and 
repeat exposures  
• Able to handle automated 
data, indefinite exposure 
(timeline is not censored 
at end-point) 
• Would fail if outcome only 
occur at a determined age 
• May bias results if reporting 
strongly depend on the time 
interval between exposure 
and event 
• Mainly use in vaccine 
surveillance 
• Ex: Study the influenza 
vaccine and acute asthma 
exacerbations in the 2 weeks 
following exacerbation22 
Randomized 
clinical trial 
• Experimental study 
• Investigator controls 
the exposure or therapy 
• A gold standard among 
all study designs 
• Also useful in post-
marketing surveillance 
Absolute risk 
(NNT/NNH), 
RR 
• Only design which can 
control for unknown or 
unmeasured confounders 
• Most expensive 
• Limited generalizability 
• Logistically most difficult 
• Ethical objections for proven 
therapies 
• Can be used for post-marketing 
RCTs or comparative 
effectiveness research 
• Ex: A prospective study, 
ALLHAT, compared the four 
antihypertensive medications 
in those with hypertension and 
multiple comorbidities.23 
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Table 1 (Continued) 
Study Design Characteristics Measures of 
Association 
Advantages Disadvantages Main Applications/Examples 
Quantitative 
Synthesis 
study: Meta-
analysis  
• Aims to resolve 
uncertainty and 
facilitate decision 
making 
• Systematically assess 
and combine the results 
of previous studies in 
order to draw 
conclusions about the 
body of research 
For RCTs: 
Absolute risk 
(NNT/NNH), 
RR; 
For 
observational 
studies: RR 
or OR  
• Increasing sample size and 
power to detect benefits 
and harms 
• Good source for evidence-
based clinical decision 
making 
• Ability to assess 
subgroups effects and rare 
events 
• Save time/resources/ 
money 
• Susceptibility of the original 
studies to bias 
• Publication bias, 
dissemination bias 
• Practical difficulties of 
combining results 
• May have paradoxical results 
• Potential biased results from 
manipulation of study 
selection and analytic 
strategies 
• A meta-analysis on the 
effectiveness and safety of 
atypical antipsychotic 
medications for off-label uses 
in adults24 
Quantitative 
Synthesis 
study: Decision 
analysis 
• Aims to resolve 
uncertainty and 
facilitate decision 
making 
• 4 types of economic 
decision analyses: cost-
minimization, cost-
benefit, cost-
effectiveness, and cost-
utility analyses. 
ICER for 
cost-
effectiveness 
analysis; 
ICUR for 
cost-utility 
analysis 
• Assist health care 
professionals having a 
better understanding the 
risk-benefit trade-off of 
different treatment options 
• May incorporate patients’ 
values into decision when 
utilities are obtained from 
patients (e.g., visual 
analog) 
• Difficult to represent all 
choices and chance 
occurrences in the model 
• Patients cannot experience 
multiple outcomes at the 
same. 
• May require some events 
only occur for a set and 
limited amount of time 
• Obtaining utilities from 
patients can be challenging 
• The assumptions which were  
made from the diverse and 
imprecise data influence the 
quality and results 
• A cost-utility analysis of the 
effects of aspirin 
therapy, statin therapy, 
combination therapy with both 
drugs, and no pharmacotherapy 
for the primary prevention of 
CHD events in men 25 
Abbreviation: AMI: acute myocardial infarction; ALLHAT: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; CHD: coronary heart disease; CVD: cardiovascular disease; 
ICER: Incremental cost-effectiveness ratio; ICUR: incremental cost-utility ratio; MI: myocardial infarction; MMR: measles-mumps-rubella; NHANSE: National Health and Nutrition Examination 
Survey; NNH: number needed to harm; NNT: number needed to treat; OR: odds ratio; RCT: randomized clinical trials; RR: relative risk; SSRI: selective serotonin reuptake inhibitors
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1.2.1 Case Report or Case Series and Post-Marketing Spontaneous Pharmacovigilance 
Reporting Systems          
Recently, pharmacovigilance has been widely used to denote post-marketing safety activities and 
is defined by the World Health Organization (WHO) as “the science and activities relating to the 
detection, assessment, understanding and prevention of adverse effects or any other drug-related 
problems.”26  The goal of a post-marketing spontaneous pharmacovigilance reporting system 
(briefly called spontaneous reporting systems) is to identify drug-related adverse events or 
adverse drug reactions (ADRs) that were not identified prior to approval, to refine knowledge of 
the known adverse effects of a drug, and to better understand the conditions under which the safe 
use of a drug can be assured.27 
A case report or case series describes one or a number of interesting clinical cases who 
were exposed to a particular drug(s), usually having an adverse outcome, and observed by health 
care professionals from a single hospital or a specific geographic region.5,6    Case reports or case 
series provide clinical descriptions after patients receive a particular drug.  All  voluntary case 
reports of adverse events or ADRs from health care professionals, patients/consumers  or 
manufacturers that are received by regional or national monitoring systems are called 
spontaneous reports.27,28  Once reports are received and entered into adverse events or ADR 
databases, these databases can then be inspected for drug safety signals, which form the basis of 
further study, necessary regulatory action or both.    In the US, the individual spontaneous 
reports of ADRs, medication errors and product quality problems are sent directly to the FDA 
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through the MedWatch program or to the manufacturer, and then indirectly from the 
manufacturer to the FDA.28  In addition, two international reporting and database systems are 
available: EudraVigilance in the European Union (run by the European Medicines Agency, 
EMA)29 and WHO VigiBase, which pools data from the approximately 100 member countries of 
the WHO International Drug Monitoring Program (run by the Uppsala Monitoring Centre, 
UMC).30 
Assessment of the drug-adverse event causality for a particular case report or series in the 
databases can be quite challenging.  Useful factors for assessing causality between a drug and 
reported adverse events include: (1) chronology of administration of a drug (including beginning 
and ending of treatment and adverse event onset), (2) course of adverse event when the suspected 
agent continued or discontinued, (3) etiologic roles of agents and diseases in relation to adverse 
event, (4) response to re-challenge of agent, (5) laboratory test results, and (6) previously known 
toxicity of agent.28,31  Naranjo’s ADR causality algorithm is the method commonly used in 
clinical pharmacy to evaluate the probability of ADRs.31  Rarely, definitive inference about 
causality can be made base on case reports or case series or from a spontaneous reporting 
database.   In the absence of a control group, one cannot determine with certainty which features 
in the description of the patients are unique to the drug exposure.  Measures such as incidence or 
prevalence rates cannot be calculated, as complete counts of all cases and/or the population at 
risk are usually not available.5  
Reports detected from spontaneous reporting databases have several advantages 
including their large-scale, inexpensiveness, coverage of the population represented (including 
special subgroups), ability for signal detection, hypothesis generation, providing an opportunity 
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for healthcare professionals or the public to report adverse events/ADRs, and lack of interference 
with prescribing habits27,32,33  Some limitations of spontaneous reporting include difficulties with 
adverse event recognitions, quality of reports (e.g., require detailed clinical information for a 
thorough case evaluation), under-reporting due to voluntary systems, inability to calculate 
population-based incidence of adverse events/ADRs (reporting ratio  is used), non-uniform 
temporal trends in reporting (i.e., the frequency of adverse events/ADR reports per unit of drug 
utilization is not likely to be constant over time), and duplicated reports.27,28,33  Due to the above 
limitations, interpretation of spontaneous reports always requires careful analysis and clear 
communication of results, conclusions, and limitations.    
For example, numerous case reports of serotonin syndrome, a potentially life-threatening 
condition, in children being treated with selective serotonin reuptake inhibitors triggered the 
need to study the safety of antidepressants in children.10,11  Furthermore, an example of a case 
series is the description of five cases of moxifloxacin-warfarin drug interaction, which resulted 
elevated international normalized ratios, prolonged hospitalization in two cases and clinically 
significant hemorrhage in one case.  This case series helped health professionals detect this 
potential interaction, which was not indicated in the moxifloxacin product monograph at that 
time, and subsequently prevent this interaction in future patients.12   
1.2.2 Analyses of Secular Trends (or Ecological Studies) 
Analyses of secular trends (or ecological studies) examine trends in exposure (drug use) and 
outcomes when they coincide over time for groups (i.e., communities, counties or population 
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level) or across geographic boundaries.6,34  One of the best-known sources of data on drug 
utilization is Intercontinental Marketing Services (IMS), tracking more than 80% of global 
pharmaceutical sales activity.35  Vital statistics, such as National Death Index, are often used as a  
source of disease incidence in these studies.6  The measure of association for an analysis of 
secular trends is correlation.7  Analyses for secular trends are useful for rapidly providing 
evidence for hypothesis generation and preliminary research.  However, a major limitation of 
this study design is “ecologic fallacy”, a term used to represent the fact that associations 
observed at the level of the group or population may not represent the association at the 
individual level.7  Thus, analyses of secular trends are unable to differentiate which factor is 
likely to be the true cause  of the outcome of interest and establish a causal relationship between 
the drug exposure and the outcome of interest on an individual level.6,7  Other potential problems 
using vital statistics include changes in diagnostic methods or terminology, coding systems, and 
population demographics overtime.36   
For example, Dales et al. conducted a study in California, US to determine if a correlation 
exists between measles-mumps-rubella (MMR) immunization coverage among young children 
and autism occurrence between 1980 and 1994.13  The study did not find a positive correlation 
between MMR immunization and autism occurrence among young children. 
1.2.3 Cross-Sectional studies 
Cross-sectional studies (also called prevalence studies) are useful when investigators are 
interested in gathering information on drug use and the extent of disease in a particular 
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population or in characterizing or comparing populations.5  Information on drug use and/or 
disease are usually collected in a single visit or through a survey.37  Cross-sectional studies are 
often quick, easy, inexpensive, and can be effectively estimate the prevalence of disease and/or 
drug exposures.  They provide information on distributions of drug use and diseases in 
populations and can allow clinicians, public health professionals, and health policy makers to 
design and implement appropriate interventions or to allocate resources effectively.  However, 
major limitations include the inability to establish a temporal association and sometimes the 
necessary restriction to studying rare diseases or diseases with short duration.5,7    In addition, 
investigators sometimes elect to study a convenience sample, which may limit the reliability and 
generalizability of the study results.7   
An article published in 2008 provides an example of a cross-sectional study using data 
from the National Health and Nutrition Examination Survey (NHANES) 1999-2002.14  
Investigators sought to evaluate whether statin use was associated with a higher prevalence of 
musculoskeletal pain in a nationally representative sample.  In this study, statin users were 
significantly more likely to report musculoskeletal pain.  
1.2.4 Case-Control Studies 
Case-control studies are analytic observational studies that compare cases with a disease (or an 
adverse event) to controls without the disease, looking for differences in preceding drug(s) use.34  
The common sources for selecting cases with the outcome of interest include case-control 
surveillance and registries.36  It is critical to select representative controls that have the same risk 
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of exposure as cases.  Poor choice of controls can lead to both wrong results and possible 
medical harm.  Controls can be recruited from known or unknown study populations (or study 
group or base).  In general, when a study population is known, a sample of the population can be 
used as controls by using a population roster or techniques such as random-digit dialing.  If study 
population is unknown, hospital controls, neighborhood controls, and friend, associate, or 
relative controls can be used.38-42   However, it is challenging to define the group or population 
from which controls should come.  For example, since endometriosis needs an operation for the 
diagnosis, investigators frequently select women having laparoscopy or laparotomy without 
diagnosis of endometriosis.  But women having operations are unlikely to be representative of all 
those at risk of developing endometriosis, since operations do not occur at random.43 
Case-control studies are advantageous to assess relatively rare outcomes (e.g., ovarian 
cancer), outcomes with long latency periods, or multiple possible causes of a single outcome.7,34 
Other advantages of case-control studies include being less expensive and quicker to complete 
than RCTs.  Potential biases while conducting case-control studies may include selection, recall, 
and/or temporal biases.44  One of the common limitations in case-control studies is the validity of 
retrospectively collected drug use information, which is mainly obtained by administering 
questionnaires or interviews.  In addition, selecting cases and controls properly can be 
challenging and inappropriate control selection can lead to a selection bias and invalid results.6,34  
However, when case-control studies are done well, subsequent well-designed cohort studies or 
RCTs can generally confirm their results.6  In case-control studies, one cannot determine the size 
of either the populations with or without drugs exposure (i.e., denominators) from which the 
cases and controls were drawn.  Therefore, incidence rates of disease among individuals with or 
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without drugs exposure are not calculable.  Thus, the measure of association obtained from a 
case-control study is an odds ratio (OR).7  In addition, attributable risk cannot be directly 
calculated from a case-control study since incidence rates are not available.   
One of the seminal case-control studies was conducted by Herbst et al., who examined 
the association between the use of diethylstilbestrol (DES) in pregnant women (for the 
prevention of spontaneous abortion) and the risk of vaginal cancer in the off-spring.15  This study 
included 8 cases and 32 age-matched controls.  The association between DES and vaginal cancer 
was very strong (7 of the 8 cases, but none of the 32 controls were prenatally exposed to DES). 
Even this small sample size provided sufficient power to reach statistical significance.  
1.2.5 Cohort Studies 
Cohort studies are essential to pharmacoepidemiology since they form the basis for the 
quantification of drug risk and benefit assessments.  Cohort studies are studies that identify 
subsets of a defined population, based on the presence or absence of a particular drug use, and 
follow them over time, looking for differences in the outcome of interest.6,34  Cohort studies 
generally are used to compare drug-exposed patients to unexposed patients, but they can be used 
to compare one drug use to another drug or treatment.  The major sources of information about 
drug exposures are billing claims or automated databases, physicians (e.g., sent questionnaires in 
the prescription event monitoring in UK), pharmacies (e.g., pharmacy-based surveillance), and 
self-reports from patients.36   
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Cohort studies can be performed prospectively, retrospectively or ambispectively.34  
Prospective cohort studies have fewer problems with validity compared to retrospectively 
collected drug data.6  Retrospective cohort studies use historical data to reconstruct an 
individual’s past drug use status at baseline (or time zero) and subsequent outcomes that have 
occurred and have been recorded prior to the study.45  The ambispective cohort design is a blend 
of the retrospective and prospective designs; retrospective data are used to determine drug status, 
and participants are then followed into the future to obtain outcome status.45  Retrospective and 
ambispective cohort studies require reliable historical drug use data in order to be considered 
effective.    
Cohort studies are particularly useful to study multiple possible outcomes and relatively 
infrequent drug use.  They can be used in post-marketing drug surveillance studies to look at any 
possible effect of a newly marked drug.6  However, they are not practical to study rare outcomes 
as the sample size needed to detect such outcomes would be extremely large.46  In addition, 
prospective cohort studies can require a prolonged time period to study delayed drug effects.6  
Further, cohort studies may be susceptible to immortal-time bias, loss-to-follow-up bias, and 
misclassification of drug use (especially drug use changes during a period of follow-up 
duration).45,46  Incidence rates can be calculated within a cohort study which enables estimation 
of risks such as the relative risk and attributable risk (also called risk difference or excess risk).  
The relative risk is the ratio of the incidence rate of an outcome in the drug exposed group to that 
in the unexposed group.  The relative risk is more important in considering questions of 
causation.  The attributable risk is more important in considering the public health impact of an 
association, as it represents the absolute increased rate of disease due to the drug exposure.  It is 
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simply the arithmetic difference between the risk in the treatment group and the risk in the 
control group.  A statistic that is directly related to the absolute risk but that offers a different 
prospective is the number needed to treat (NNT) or number needed to harm (NNH).  NNT tells 
us how the many persons would have to be given a beneficial intervention to prevent 1 case of 
disease.  NNH tells us how many people would have to be given a harmful intervention to cause 
1 excess of disease.  The NNT or NNH is equal to the inverse of the absolute risk difference.47,48  
For example, treating 10,000 women with estrogen plus progestin for 1 year yields 8 excess 
cases of breast cancer.  Thus, one would need to treat 10,000/8 = 1,250 women for 1 year to 
cause a single excess case.  Although the risks to a given women are small, the overall public 
health impact could be large if many women were taking hormone therapy. 
For example, Beydoun et al. examined statin use and cholesterol associations with 
incident dementia and mild cognitive impairment using the data from Baltimore Longitudinal 
Study of Aging (a prospective cohort study).16  1604 and 1345 eligible participants were 
followed after age 50 for a median time of 25 years to examine the incidence dementia and mild 
cognitive impairment.   The authors found that statin users had about 60% risk reduction of 
developing dementia, but not mild cognitive impairment, when considering “time-dependent” 
statin use with propensity score model adjustment.  This association remained significantly 
independently of serum cholesterol levels.  The authors suggest statins may have multifactorial 
effects on dementia.  
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1.2.6 Efficient Sampling Designs within a Cohort Study 
Conducting a cohort study in pharmacoepidemiology is constrained by the following challenges: 
(1) expensive and time-consuming to collect data on all cohort members; (2) may require 
additional and validated data to control the confounding when using automated databases; (3) 
technically infeasible in data analysis of a cohort with multiple and time-dependent drug 
exposures, particularly if the cohort size and number of outcome events are large.49  To 
overcome these difficulties, three sampling designs within a cohort (i.e., nested case–control, 
case–cohort designs, and the multi-time case–control) have been proposed and applied 
successfully in pharmacoepidemiology.  Different from the traditional case-control and cohort 
studies, these sampling designs within a cohort permit the precise estimation of relative risk 
measures with negligible losses in precision.50,51    
In nested case-control studies, cases are usually matched by certain variables such as 
sex, age, and “time of enrollment” into the cohort.44,50  Matching on calendar time is crucial in 
studies where the drug prevalence and outcome incidence both vary substantially over time, 
which is not uncommon in pharmacoepidemiology.51  A control may later become a case, 
however, this does not typically occur when the outcome of interest is uncommon.50 A major 
advantage of this study design is that since baseline drug use and other clinical data were 
obtained, certain biases such as recall and selection biases may be minimized.52  The design of 
nested case-control allows for the estimation of absolute and relative risk.53  Limitations with this 
study design may arise; for example, if controls are samples at the end of the study period, issues 
such as loss to follow-up and representation of all controls may need to be considered.53  In 
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addition, it is challenging when subjects are possibly selected more than once in the sample when 
the drug exposure and covariate factors are time-dependent, particularly when the data are 
obtained by questionnaire where the respondent would have to answer questions regarding 
multiple time points in their history.49  An example of nested case-control studies is a series 
of studies conducted covering 574 UK general practices investigating the effect of statins on 
cancer incidence.17  Within the cohort, cases were patients with primary cancers diagnosed 
between 1998 and 2008.  Each case was linked to 5 controls alive and registered with the 
practice at the time of diagnosis of the case and matched by age, sex, and practice and calendar 
time. The study showed that prolonged use of statins was not associated with an increased risk of 
cancer at any of the most common sites, except for colorectal cancer, bladder cancer and lung 
cancer, while there was a reduced risk of hematological malignancies. 
Unlike a nested case-control study where controls are usually matched to cases on time of 
entry into the cohort, in a case-cohort study (also called case-base study) every individual in 
the cohort has an equal probability of being a control since the control groups are randomly 
selected (or called unmatched nested case-control design).50   Similar to nested case-control 
studies, case-cohort studies allow investigators obtain certain information for only a subset of all 
controls, potentially saving time and money and minimizing certain biases in traditional case-
control studies.44,50  The group of individuals serving as controls may be used for multiple case 
groups.50  Controls that later develop the outcome(s) of interest may become cases; therefore, 
investigators have to select more controls for each case than they would in a traditional case-
control study to attain the same level of statistical precision.50  Potential limitations of case-
cohort studies are loss to follow-up and the possibility of drug use changing over time.44,50  The 
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analytic method must take into account the overlap of cohort members induced by the sampling 
strategy.49  Bohnert et al. recently published a case-cohort study to examine the association of 
maximum prescribed daily opioid dose and dosing schedule (i.e., as needed, regularly scheduled 
or both) with the risk of opioid overdose death among patients with cancer, chronic pain, acute 
pain and substance use disorders.18    In this study, 750 incident cases of unintentional 
prescription opioid overdose decedents in a Veteran Health Administration database from 2004-
2008 were sampled, in addition to a random sample (n=154,684) who used  medical services in 
2004 or 2005 and received opioid therapy for pain from this same cohort.   Among patients 
receiving an opioid prescription for pain, higher opioid doses were associated with an increased 
risk of opioid overdose death.  The risk of opioid overdose should continue to be evaluated 
relative to the need to reduce pain and suffering and should be considered along with other risk 
factors. 
The case–cohort design has some advantages over the nested case–control design: (1) 
simpler in sampling; (2) flexible to use the same sample to study several different types of events 
and each can be analyzed with the same “control” subcohort (whereas the nested case–control 
design requires different control groups for each type of event because the selection depends on 
event times); (3) case–cohort design allows one to change the primary time axis of analysis from 
calendar to disease time and vice versa; and (4) easier to perform external comparisons.49,54 
Conversely, the nested case–control design has some advantages over the case–cohort design: (1) 
easier to perform power calculation or equivalently sample size determination (whereas a case–
cohort design requires more complicated calculation due to the overlap in risk-sets); (2) data on 
time-dependent exposure and covariates need only be collected up to the time of the risk-set 
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(while the collection must be exhaustive for the case–cohort); and (3) despite the accessibility of 
software for data analysis of case–cohort data, these can quickly become surpassed and even 
infeasible with larger sample sizes and time-dependent exposures. In this situation, the nested 
case–control design, with its single risk-set per case, is not only advantageous but also the only 
solution.49,54  
Suissa et al. recently proposed the multitime case–control design as an alternative 
strategy to improve the precision of the OR in a case–control study with “acute or transient” 
time-varying exposures, especially when increasing the number of control subjects is too 
costly.19  This approach measures drug exposure at many different points in time to increase “the 
number of observations per control subject”, which must however be corrected for within-subject 
correlation.19  Traditionally, case–control studies usually collect extensive data on time-
dependent drug exposures, but only use a portion of these data in calculating OR.  The advantage 
of a multitime case-control study is to improve the precision of OR and increase the power 
without adding additional controls and costs.  However, the multitime case-control design is not 
suitable for chronic or cumulative drug exposure because the OR varies as a function of the 
duration of drug exposure.  For example, in a nested case–control study within a cohort of 
12,090 patients with chronic obstructive pulmonary disease, there were 245 incident cases of 
acute myocardial infarction (AMI) that occurred during follow-up, for whom 1 and 10 controls 
per case were identified. The OR of AMI associated with use of antibiotics in the month prior to 
the index date was 2.00 (95% CI: 1.16–3.44) with one control per case. The precision (as 
reflected in the confidence intervals) was improved by increasing to 10 controls per case with a 
rate ratio of 2.13 (95% CI: 1.48–3.05).  Alternatively, keeping only one control patient per case, 
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but increasing the number of control time windows per subject from 1 to 10 (taken as 10 control 
exposure measures, one for each of the 10 months prior to the index date) also improved the 
precision with a rate ratio of 1.99 (95% CI: 1.36–2.90). 19 
1.2.7 Case-Crossover, Case-Time-Control, and Self-Controlled Case Series Studies 
Pharmacoepidemiology is frequently faced with the assessment of the risk of acute adverse 
events resulting from transient drug effects.  For example, this is the case in trying to study the 
risk of ventricular tachycardia, from hypokalemia and prolonged Q-T intervals, associated with 
the use of inhaled β-agonists in asthma.51  Traditional study designs may be challenging because 
of the acuteness of the adverse event, difficulties in determining the timing of drug exposure, and 
possible confounding by indications.  Three other study designs were devised to counter these 
complexities in pharmacoepidemiology: case-crossover study, case-time-control study and 
self-controlled case series study.6,34,55   
A case-crossover study is similar to an experimental study in that the same individual is 
assessed during the periods of a specific drug exposure and periods without that exposure 
(control period).56-58  In other words, the case has the outcome of interest and serves as its own 
control.   Two assumptions need to be held for the case-cross over study, including: (1) the effect 
of the drug exposure is not cumulative nor does not extend beyond the risk period, and (2) the 
outcome of interest is without a preclinical stage that may influence the exposure.55,57,59,60  In 
addition, the outcome of interest must be a discrete event, a risk period (between drug exposure 
and outcome) should be specified, and the data on the usual drug use pattern are necessary to 
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determine the typical probability of exposure during the time window of effect.49,55,57  The design 
is particularly useful for examining the effects of drug use in patients with diseases that worsen 
over time or vary in severity from patient to patient or require intermittent drug use.56,59  Another 
advantage of this design is that it eliminates the problem of time-invariant measurable (e.g., 
gender, race) or unmeasurable confounders (e.g., genetic factors).  Limitations of case-crossover 
studies include selection bias (if case selection is related to the drug exposure), information bias 
(if differential quality of recent and past drug exposure data is present), restrictions of  using 
automated data due to logistical issues, confounders that change over time that cannot be 
controlled for, and having the assumption of the absence of a time trend in the drug exposure 
prevalence.34,51,55,57   Ottervanger et al. conducted a case-crossover study to examine the 
association between sumatriptan and myocardial infarction (MI) in the Netherlands.20  
Sumatriptan is used to abort an acute migraine (transient basis) and has a relatively fast onset of 
action (12 minutes, injectable formulation) and about 2-4 hours duration of action.61  The 
investigator asked the subjects whether they took sumatriptan during the 2-4 hours immediately 
before the MI (risk period).   Then the subjects were asked if they took sumatriptan 1 week 
before the MI (control period).  The investigators found that young age, hypertension, general 
complaints of abdominal pain, and a family history of myocardial infarction are associated with 
an increased risk of chest pain attributed to sumatriptan. Sex is an effective modifier of risk 
factors of sumatriptan-induced chest pain.  In particular, hypertension is a strong risk factor in 
men.                                                    
 The case-time-control study design is an extension of the case-crossover design. In 
1995, this study design was proposed for controlling for confounding by indication (e.g., disease 
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severity), which was not measured because of the within-subject analysis.21  It is used to examine 
associations that may exist between drug use and an outcome in situations where trends that may 
change over time (such as prescribing patterns or disease severity) could confound the 
association.59,60  For example, a standard case-crossover study is not suitable for studying events 
related to drug use during pregnancy because drug use often changes during gestation.  A control 
group is selected within a cohort and with an approximate synchronization with cases.  Both 
cases and controls are examined for drug exposure status during the control period and during 
the time period corresponding to the outcome of interest.57  As cases and controls were selected 
from approximately the same time period, changes in trends over time may be adjusted for, 
although this is not guaranteed and may itself introduce other bias.57  An example of the use of a 
case-time-control design was the study to examine the use of inhaled β-agonists and its potential 
association with asthma death.  In Spitzer et al’s previous work, the used of inhaled β-agonists 
were associated with the increased risk of asthma death.62   However, they argued that one 
potential explanation for the increase in deaths (despite adjustment of potential confounders) 
may be a natural increase in the use of inhaled β-agonists overtime (e.g., due to increase in 
physician prescribing, more evidence of drug efficacy and better compliance with the drug). The 
same group of investigators conducted a case-time-control study and showed that inhaled β-
agonists may not play the leading role attributed to the risk of fatal or near-fatal asthma, as was 
previously suspected.21  
Self-controlled case series studies can be used to study the temporal association 
between a time-varying drug exposure and an adverse event using data on cases only.55  Self-
controlled case series studies require the following three key assumptions to be applicable: (1) 
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events arise in a non-homogeneous Poisson process; (2) the occurrence of an event must not alter 
the probability of subsequent exposure; and (3) the occurrence of the event of interest must not 
censor or affect the observation period.55   Data are usually collected during a predefined study 
period given in terms of calendar time and possibly age boundaries, typically determined by the 
availability of database records.  The main advantages are that it often has high efficiency 
relative to the cohort method and that is self-controlled for time-invariant confounders (such as 
gender, location, genetics, and underlying health status).55  Time varying confounders such as 
age and season can be allowed for in the baseline incidence.  For example, ages at vaccination 
are regarded as fixed, and the random variable of interest is the age at adverse event, conditioned 
on its occurrence within a pre-determined observation period.55    The self-controlled case series 
method shares in all the benefits of the case-crossover method, but has two important advantages 
over the case-crossover method.  The first is that there is no requirement of stationary or 
exchangeability of times of exposure (e.g., vaccination).63  For example, the case-crossover 
method would not be appropriate for the seasonal influenza vaccination.  Secondly, in conditions 
of high vaccine coverage, the method is nearly as powerful as a full cohort analysis.63  This is 
because non-cases contribute very little information about the vaccine effect.  However, it would 
fail in the unlikely event that the adverse event could only occur at a determinate age, since no 
within-individual variation would then be possible.  If on the other hand vaccination times were 
determinate, then age and vaccine effects would be confounded, and an unvaccinated group of 
cases would be required to disentangle their independent effects.  Generally, the greater the 
variability in vaccination ages within the observation period, the more powerful the study.63   
Kramarz et al. investigated whether administration of influenza vaccine to asthmatic children 
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(aged < 6 years) caused acute asthma exacerbations in the 2 weeks following vaccination in 
1993-1996.22  Using the self-controlled case series analysis, which automatically adjusts 
completely for underlying disease severity, the vaccine appears to be protective.   
1.2.8 Randomized Clinical Trials (RCT) 
A RCT is an experimental study in which investigators control the intervention and randomly 
allocate patients among the study groups.  The major strength of this approach is random 
assignment, which is the only way to ensure that the study groups are comparable in potential 
unknown or unmeasurable confounding variables.  RCTs are considered to be the most 
scientifically rigorous method for hypothesis testing and remain the “gold standard” against 
which other studies are judged.6,64   However, investigators may be limited in their ability to use 
a RCT design because of issues related to feasibility, sample size, length of follow-up, ethics, or 
cost.64  If the incidence of an adverse event is very rare or if the adverse event only arises in the 
long term, this potential safety issue will not be detected through RCTs.  In addition, RCTs are 
more expensive and may not generalize to population.   In the past, RCTs are used less after 
marketing; however, there is an increased concern about relying solely on non-experimental 
methods to study drug safety after marketing.  Therefore, large RCTs are emerging as a part of 
post-marketing surveillance.6 
 Moreover, comparative effectiveness research (CER) has become the spotlight after the 
introduction of the American Recovery and Reinvestment Act, which provided $US1.1 billion 
over two years to support CER.65  CER has two major components including the comparison of 
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two or more agents or interventions that are considered true therapeutic alternative, and the 
examination of effects (or outcomes) in actual practice.66  CER may include prospective clinical 
trials (also called large simple clinical trials or pragmatic clinical trial), observational studies, or 
synthesis studies.  A traditional phase III RCT, which is an explanatory trial, aims to establish 
the efficacy of a new drug in narrowly selected population in a controlled setting.   They usually 
compares the new drug with placebo or an inferior treatment option rather than legitimate 
alternative treatment option.  Explanatory RCTs often evaluate a single main measure of clinical 
outcomes, which are often short-term, surrogate or intermediate endpoints.66,67   
In contrast, pragmatic clinical trials, which may be randomized or non-randomized, aim 
to demonstrate effectiveness of a drug in a diverse population and heterogeneous practice 
settings, and answer the questions faced by decision makers.  Pragmatic clinical trials may use 
wide range of outcomes which are more informative for decision makers (e.g., participants, 
funders, communities, and healthcare practitioners).66-68  For example, in trials of back pain, the 
Cochrane Collaboration recommends that outcomes should include pain, functional status, ability 
to work, and satisfaction with treatment.  However, increasing the number of measures in a trial 
increases the probability that one will reach statistically significance on the basis of chance 
alone.  This needs to be taken into account in the sample size calculation.  In general, more 
subjects are needed when several outcomes are being measured. 
An example of a comparative effectiveness trial is Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial (ALLHAT study).69   ALLHAT compared the 
effectiveness of four antihypertensive medications in general population with hypertension and 
multiple comorbidities.  The primary outcome was combined fatal CHD or nonfatal myocardial 
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infarction, rather than surrogate measures.  Findings of the ALLHAT have influential effects on 
the treatment of hypertension in current practice.  For example, thiazide-type diuretics are 
superior in preventing one or more major forms of cardiovascular disease and are less expensive. 
They should be preferred for first-step antihypertensive therapy.23 
1.2.9 Quantitative Synthesis Studies: Meta-analysis, Decision analysis, and Cost-
Effectiveness Analysis 
Meta-analysis and decision analysis have in common that they synthesized knowledge.9  Each 
method takes parts of the medical literature or clinical experience and, based on this information, 
attempts to create a whole answer to a defined problem.  In addition, they are quantitative, using 
statistical and numerical analysis, aims to resolve uncertainty and facilitate decision making.  
Each plays a prominent role in the formulation of clinical and public policy in health care.9 
Meta-analysis is a qualitative and quantitative approach for systematically assessing and 
combining the results of previous studies in order to draw conclusions about the body of 
research.9  Studies of a topic are first systematically identified, and inclusion and exclusion 
criteria are defined.  In traditional meta-analysis, data from the eligible studies are abstracted or 
collected from the investigators of the study.  The data are then analyzed and the heterogeneity 
of the results is tested.  If the results are homogenous, a summary estimate of the size of the 
effect of treatment is estimated.  If the results are heterogeneous clinically or statistically, the 
heterogeneity needs to be further explored.70,71  Ideally, meta-analysis is applied most 
appropriately to RCTs and provides most powerful evidence.  When in cases of RCTs are 
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impossible, meta-analysis of observational studies is useful to explore dose-response 
relationship, to understand reasons for discrepancies among the results of difference studies, and 
to assess the possibility of differences in the effects of the drug exposure in subgroups.70  
Another type of meta-analysis, pooled analysis, obtains and analyzes the “individual” data from 
participants in a systematically ascertained group of studies.  Pool analysis of individual level 
data has the same concept and aim as traditional meta-analysis.9  When systematic review and 
meta-analysis are used to compare alternative treatments from the standpoint of real-world health 
care decision, they are considered as secondary comparative effectiveness studies.66   
The use of meta-analysis has been growing since 1987, the advantages of meta-analysis 
include increasing sample size and power to detect benefits and harms of a drug or treatment, 
good source for evidence-based clinical decision making, ability to assess subgroups effects and 
rare events, ability of indirect comparison and simultaneous evaluation of treatment therapies 
available for special conditions, and saving time, resources and money.72  In addition, cumulative 
meta-analysis could be as a tool to detect safety signal earlier. The disadvantages of meta-
analysis include susceptibility of the original studies to bias (garbage in and garbage out), 
publication and dissemination bias, practical difficulties of combining results from different 
studies (i.e., variations in study designs, subject characteristics, drug exposures, and outcomes), 
paradoxical results due to combining different studies, potential biased results from manipulation 
of study selection and analytic strategies, and challenges of including advanced study designs 
(e.g., case-crossover, clustered randomized trials).72 
For example, Maher et al. performed a systematic review and meta-analysis on the 
effectiveness and safety of atypical antipsychotic medications for off-label uses in adults.24  The 
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authors found that benefits and harms vary among atypical antipsychotic medications for off-
label use.  For global behavioral symptom scores associated with dementia in elderly patients, 
small but statistically significant benefits for global behavioral symptom scores associated with 
dementia in elderly patients were observed for aripiprazole, olanzapine, and risperidone. 
Quetiapine was associated with benefits in the treatment of generalized anxiety disorder, and 
risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; 
however, adverse events were common. 
 Decision analysis is a quantitative approach that assesses the relative value of different 
decision options.9  It is a method of probabilistic reasoning and decision-making under 
conditions of uncertainty.73  In other words, when some uncertainty about the appropriate clinical 
strategy for patients with a given health state and there is a meaningful tradeoff in the problem, it 
is appropriate to conduct a decision analysis.74  Decision analysis always requires comparison of 
at least two clinical strategies with advantages and countervailing disadvantages.74 The results 
from decision analysis are used to decide how to manage an individual patient and to formulate 
policy recommendations about a group of similar patients. Briefly, performing a decision 
analysis involves (1) defining a specific question, (2) creating a model (usually a decision tree or 
MarKov model) to frame the question, (3) assessing utilities or values to outcomes in the model, 
(4) assigning probabilities to chance events in the model based on direct assessment, literature or 
expert opinion, (5) identifying the best strategy within the model, (6) sensitivity analysis (to 
determine the robustness of the results), and (7) model refinement based on the internal, external, 
between-model consistency and predictive validity of the model.9,74   
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When an economic perspective is assumed, values of the outcome are assigned in terms 
of their monetary cost.  Economic decision analysis research is increasingly used to inform 
funding decisions for new therapies (e.g., incorporation as part of phase III trials), and deliver 
high-quality care within the constraints of limited budgets or reduced fee schedules.75  Types of 
economic decision analyses in pharmacoeconomic research considering both costs and utilities 
of outcome include cost-minimization, cost-effectiveness, cost-utility, and cost-benefit 
analyses (Table 2).73,75  Cost-minimization analysis (or cost-identification analysis) assumes 
that alternative treatment result in the same outcome, and value or decision is assigned entirely 
based on the lowest cost.  It is appropriate only if treatment outcomes or benefits are equivalent 
among the therapies being evaluated.75  Cost-benefit analysis remains a less common used 
technique in economic assessments of health care in the US, because it is difficult to translate all 
outcomes into monetary measures.9  Cost-effectiveness analysis assumes that cost and the 
effectiveness of interventions vary, and uses natural units as outcome measures.  Consequently, 
value is assigned by the cost per unit improvement of a health status, such as dollars per years of 
life saved.  Cost-utility analysis, a type of cost-effectiveness analysis, often presents the 
outcome as cost per quality-adjusted life-year.  The advantage of cost-utility analysis is that the 
utility assignment can be generalized to all health states.  
For example, Pignone et al. performed a cost-utility analysis of the effects of aspirin 
therapy, statin therapy, combination therapy with both drugs, and no pharmacotherapy for the 
primary prevention of CHD events in middle-aged men.25  Compared with no treatment, aspirin 
is less costly and more effective for preventing CHD events in middle-aged men with a 10-year 
risk for CHD ≥ 7.5%.  The addition of a statin to aspirin therapy becomes more cost-effective (an 
 34 
 
incremental cost-utility ratio of 42,500 dollars per quality-adjusted life-year gained) in men with  
a 10-year CHD risk ≥ 10% at baseline. 
 The main advantage of decision analysis is that it assists health care professionals having 
a better understanding the risk-benefit trade-off of different treatment options.  Another 
advantage is that decision analysis incorporates patients’ values into decision when utilities are 
obtained from patient populations (e.g., visual analog, stand gambling, or time trade-off 
methods).76  The decision analysis has inherent limitations.  Oftentimes, the tree may need to be 
simplified to show only major choices and outcomes rather than all choices and chance 
occurrences.77  For example, treatments vary among physicians and that heterogeneity may not 
be easily represented.  In addition, the decision tree is limited that in that patients cannot 
experience multiple outcomes at the same.77  Furthermore, many decision tree analyses require 
that some chance events occur for a set and limited amount of time.  Eliciting utilities can be 
challenging, even using the most reliable methods such as time trade-off and standard gamble 
methods.73  Lastly, using the assumptions made from the diverse and imprecise data in the 
decision analysis may heavily influence the quality and conclusions of the results.  
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Table 2. Overview of Types of Decision Analyses in Pharmacoeconomic Research 
Type of 
Analysis 
Measurement 
of Costs 
Measurement 
of Outcome  
Common 
Presentation for 
the Results 
Characteristics and 
Other Comments 
Example 
Cost-
minimization 
(or cost-
identification) 
Monetary 
units 
None  Cost per unit or 
service provide 
• Outcome is 
assumed to be the 
same  
• Not often used due 
to outcomes are 
usually different 
• Appropriate only if 
treatment outcomes 
or benefits are 
equivalent among 
the therapies being 
evaluated 
Evaluation of 
brand-name vs. 
generic drugs 
(with same 
outcome or 
indication) 
Cost-benefit Monetary 
units 
Monetary units  Net benefits or 
cost-benefit 
ratios 
• More commonly 
used in economics 
and policy than in 
health care (due to 
difficulties in 
assigning a cost to 
many outcomes) 
Pharmacist-
managed clinic 
for a disease vs. 
cardiac 
rehabilitation 
program 
Cost-
effectiveness 
Monetary 
units 
Natural units 
(e.g., life-years 
gained, 
disability-days 
saved, reduction 
of blood 
pressures)  
ICER is 
presented (e.g., 
$100,000 dollars 
per life saved) 
• Same outcome 
measured for the 
drugs/services 
being compared 
• Can be challenging 
to compare 
different outcome 
measures across 
different studies 
Cost/mmHg 
decrease in 
blood pressure 
treatment 
Cost-utility Monetary 
units 
Utility or 
healthy years 
(typically 
measured as  
QALY) 
ICUR is 
presented (e.g., 
$100,000 dollars 
per QALY 
gained) 
• Combine quantity 
and quality of life 
• A type of cost-
effectiveness 
analysis 
Cost/QALY 
gained for 
aspirin, statins, 
or both drugs for 
the primary 
prevention of 
coronary heart 
disease events in 
men 
Abbreviations: ICER: incremental cost-effectiveness ratio; ICUR: incremental cost-utility ratio; QALY: quality-adjusted life-year;
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1.2.10 Summary 
Each study design described above can be applied in pharmacoepidemiology research.  In 
general, science proceeds from the case reports toward RCTs.  Case reports and case series are 
useful for suggesting an association, while analyses of trends and case-control studies are useful 
for exploring these associations.  Observational study designs are important approaches to 
identify and evaluate of drug effects that would not be ethical to conduct in experimental studies.  
Observational studies also allow one to examine drug effects in more diverse or special 
populations (e.g., elders or children),  assess drug effects that are uncommon or latent, or that are 
the result from drug over-dose or off-label use.34   Case-crossover, case-time-control, and self-
controlled case series methods are increasingly used in pharmacoepidemiology, particularly in 
vaccine safety studies.  These methods are typically used to evaluate the association between a 
transient exposure and acute event.  Decision analysis provides a way to quantify preferences, 
and when it is evaluated in conjunction with cost data, this analytic tool may provide additional 
evidence for clinical decision making.  In summary, traditional study designs can generally 
optimize the conduct of research in pharmacoepidemiology, and further enhancements of novel 
approaches or tools have been developed specifically to solve challenges in 
pharmacoepidemiology.  The common aim of using an appropriate study design in 
pharmacoepidemiology is to investigate the optimal use of therapeutic agents and contribute to 
evidence-based decision-making in clinic settings and for overall public health.
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1.3 SOURCES OF DATA TO ASSESS SAFETY/BENEFIT OF DRUGS 
While premarketing studies identify many aspects of drug safety, the full safety and benefit 
profiles can only be identified when the drug is used in large numbers of patients in “real world” 
settings.  The major sources of data to assess safety or benefit of drugs include automated health 
data systems, field studies (or ad-hoc studies), and other special ad-hoc studies (e.g., case-control 
surveillance, prescription-event monitoring, and registries).  Main medication use sources will be 
reviewed in this section.  The details of each source/database are beyond the scope in this 
section.  Table 3 summarizes the characteristics, advantages, disadvantages and examples of 
these medication data sources.  The US National Cancer Institute also provides some available 
pharmacoepidemiology sources (see http://riskfactor.cancer.gov/tools/pharmaco/epi/). 
38 
 
Table 3. Overview of Sources of Data to Access Safety/Benefit of Drugs 
Sources Characteristics Advantages Limitations / Biases Examples 
Automated Data Systems: Often considered as the gold standard for medication data 
Administrative 
claims databases 
(claims databases) 
• Arises from a person’s use of health 
care system and the submission of 
claims to insurance companies for 
payment (health insurer databases) 
• Uncommon outcomes can often be 
studied 
• Can study drugs and devices as used 
in real-world clinical practices 
• Include membership data, physician 
services, outpatient pharmacy 
claims, hospital services, laboratory 
services  
• Large sample, quicker, less 
expensive  
• Very high-quality data on drug 
exposure 
• Minimize recall/interview bias 
• Usually have standard formats 
• Uncertain validity on diagnosis 
data (especially outpatient) 
• Unavailable confounders 
• Limited medication coverage 
• Lack of information on clinical 
data, patient history, OTC drugs, 
outside of the insurance’s plan, 
or uninsured population, 
patient’s adherence 
• Instability of the population 
(e.g., job changes) 
• US: HMO, Medicare, 
Medicaid, State blue 
cross/blue shield 
plans, commercial 
insurance (e.g., 
HealthCore, 
UnitedHealth group, 
Ingenix Research 
database) 
• Canada: Canadian 
provincial databases 
(e.g., BCLHD) 
Electronic health 
records (EHRs), or 
Electronic medical 
records (EMRs) 
• Used by healthcare professionals  in 
the delivery of care to patients 
• Uncommon outcomes can often be 
studied 
• Can study drugs and devices as used 
in real-world clinical practices 
• Include patient data, activity, 
prescription, clinical/lab 
observations, orders (diagnosis and 
procedure codes) 
• Large sample, quicker, less 
expensive  
• Better quality on diagnoses 
• Minimize recall/interview bias 
• Able to extract data from clinical 
text (e.g., through natural 
language processing method) 
• Require data manipulation 
• Uncertain completeness of data 
from other physicians/sites 
• Unavailable confounders 
• Lack of information on clinical 
data, OTC drugs, patient’s 
adherence 
• Complex and costly of computer 
hardware and software 
• US: HMORN, VA 
data, PPD, Cerner’s 
Health Facts Database 
• UK: GPRD, THIN 
• The Netherlands: 
PHARMO 
• Denmark: OPED, 
AUHD 
• Other: IMS Disease 
Analyzer 
Ad-Hoc Studies 
De Novo: Field 
study 
• Epidemiologic studies in which data 
are collected in the field for 
evaluating specific hypothesis 
• At least partially enroll the subjects 
and collect data 
• Mostly, self-reported data about 
medication use (recall or brown bag 
medication inventory)  
• More rigorous defined outcomes 
• Feasible to enroll subjects with 
very rare conditions 
• Feasible to obtain  
information/confounders  not 
collected in the pre-existing 
databases 
• Capture actual medication use 
(prescription, OTC medications 
and dietary/herbal supplements) 
• Time-consuming 
• Relatively expensive 
• Logistic challenges 
• Completeness of ascertainment 
of drug exposure varies from 
different study designs: e.g., 
recall accuracy on drug exposure 
in case-control study 
• Potential biases influencing 
study validity 
Studies in the elderly: 
CHS, EPESE, Health 
ABC, NSHAP, MrOS, 
SOF, WHAS, WHI 
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Table 3 (Continued) 
Sources Characteristics Advantages Limitations / Biases Examples 
Special Types of Ad-Hoc Studies 
Case-control 
surveillance (CCS) 
• Started in 1976 at collaborating 
hospitals in Boston, Baltimore, New 
York and Pennsylvania, U.S, A 
• Multiple case-control studies are 
conducted simultaneously 
• Relies on self-reported of regular or 
long-term medication and dietary 
supplement use for 43 indications or 
medication categories 
• Large sample size 
• Including OTC and dietary 
supplement 
• Ability to access the effect of 
a drug use that occurred in the 
distant past or long duration of 
exposure 
• Accurate outcome data from 
hospital discharge summary 
and pathology reports 
• Selection bias due to hospital-
based case-control studies 
• Difficulties in validating self-
reported OTC medication and 
dietary supplements 
• Potential misclassification of 
drug use 
• Dose of drugs was not collected 
Slone Survey 
Prescription-event 
monitoring (PEM) 
• Also called yellow-card system 
• Since 1981, PEM systematically 
monitors the safety of targeted 
medications in cohorts of 10,000-
15,000 patients in England 
• Questionnaires are sent to general 
practitioners to request information 
on specific drug use and events 
• Single-cohort design 
• Large sample size 
• Representativeness of patients 
treated in real-world clinical 
practices 
• Ability to examine adherence 
to prescribing guidelines 
• Examine drug utilization and 
safety in special populations 
• Medication exposures derived 
from dispensed prescriptions 
with validations from 
prescribers 
• Complete collections of 
outcome events 
• Absence of data on an unexposed 
comparator 
• Selection bias from preferential 
prescribing 
• Unpredicted patterns of adoption 
of a new drug 
• Non-response questionnaires 
• Possible under-reporting of 
serious/fatal adverse events 
• Misclassification bias depend on 
patient’s adherence, accuracy in 
physicians’ diagnosis 
• Inability to control/adjust all the 
confounders  
• Cannot study drugs used in 
hospitals 
Specifically refer to PEM 
in England 
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Table 3 (Continued) 
Sources Characteristics Advantages Limitations / Biases Examples 
Registry • An organized system that uses 
observational study methods to 
collect uniform data to evaluate 
specified outcome of a population 
defined by a particular disease, 
condition or exposure 
• Used for monitoring public health 
intervention and systematic 
collections of data on people with 
shared characteristics 
• Uses extended to patient support 
effectiveness/safety evaluations, 
characterization of clinical 
presentation of diseases 
• Ability to simultaneously 
collect detail clinical, 
administrative information 
• Flexibility to adapt over time 
to accommodate new research 
questions and purposes 
• Better representing the 
situations in real-world 
practices 
• Ability to follow patients over 
long periods of time 
• Lack of pre-specified hypotheses 
if registries are designed to 
provide an adaptive framework 
for evaluating treatment 
• Difficulties in explaining the 
observed effects if lack of 
comparison groups 
• Selection bias if recruiting 
subjects preferentially 
• Discouraging reporting rate if 
data collection systems are hard-
to-use 
The Surveillance, 
Epidemiology, and End 
Results (SEER) program of 
the National Cancer 
Institute in the US 
Abbreviations: AUHD: Arhus University Prescription Database; BCLHD: British Columbia Linked Health Database; CHS: Cardiovascular Health Study, EPESE: Established Population for Epidemiological Studies of the 
Elderly, FDA: US Food and Drug Administration; GPRD: General Practice Research Database; Health ABC: Healthy, Aging and Body Composition Study, HMORN: Health Maintenance Organization Research Network; IMS: 
Intercontinental Marketing Services; NSHAP: National Social Life, Health and Aging Project, MrOS: Osteoporotic Fractures in Men, OPED: Odense University Phamacoepidemiological Database; OTC: over-the-counter; 
PHARMO: PHARmacoMOrbidity Linkage System Database; PPD: Premier ProspectiveTM Database; SOF: Study of Osteoporosis Fractures, THIN: The Health Improvement Network; VA: Department of Veterans Affairs Heath 
Care System; WHAS: Women’s Health and Aging Study, WHI: Women’s Health Initiative; WHO: World Health Organization 
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1.3.1 Automated Data Systems (or Computerized Healthcare Data) 
Since 1980, automated databases (or computerized healthcare data) containing medical care data 
became an excellent source of data for pharmacoepidemiologic studies, especially for very rare 
adverse events (incidence rate <1 in 10,000).78  Databases that contain health information can be 
generally divided into two categories: administrative/claims database and electronic health 
records (EHR, or electronic medical records [EMR]). Claims data arise from a person’s use 
of the health care system (pharmacy, hospital, physician) and the submission of claims to 
insurance companies for payment.78  EHRs are used by clinicians in the delivery of care to 
patients.  They consist of pharmacy, primary care and hospital databases including information 
such as clinical observations, lab test results, and prescriptions.78  Since claims data arise from a 
system not designed for research or clinical care, linking to EHRs improves the range of data for 
research purposes.  A research study may link de-identified claims data from a population of 
patients diagnosed with a particular condition such as hypertension, with de-identified clinical 
data on everything from a patient’s body mass index, blood pressure, symptoms and more, while 
maintaining patient privacy and full compliance with HIPAA standards.  This linkage enables 
researchers to assess the effectiveness of medical treatments, prescription adherence, and disease 
management based on extensive clinical and administrative data including hospitalizations, 
ambulatory visits, filled prescription, cost, and reimbursements.  The existing automated 
databases in the US available for pharmacoepidemiologic research include Health Maintenance 
Organization Research Network (HMORN), Kaiser Permanente Medical Care Program (KP-
MCP), Group Health Cooperative (GHC), US government claims databases (e.g., Medicaid, 
Medicare), other commercial insurances (e.g., HealthCore, UnitedHealth group, Ingenix 
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Research database), and in-hospital databases (e.g., Pediatric Health Information System and 
Premier ProspectiveTM Database).78-82  The General Practice Research Database (GPRD), the 
Health Improvement Network (THIN) in UK, the Department of Veterans Affairs (VA) Heath 
Care System in the US, and the Intercontinental Marketing Services (IMS) Disease Analyzer are 
the most well-known and widely used examples of EHRs.83  Moreover, pharmacy-based medical 
record linkage systems, which integrate multiple autonomous databases with a primary 
pharmacy-based dispensing database into a single system, have been established in the Nordic 
countries (e.g., Danish Odense University Pharmacoepidemiologic Database [OPED] and Arhus 
University Prescription Database [AUHD]] and the Netherlands (PHARmacoMorbidity linkage 
system [PHARMO]).84  The International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) provides a useful electronic index (digest) of 327 databases worldwide (119 
in the US; available at http://www.ispor.org/DigestOfIntDB/CountryList.aspx).  The Digest 
consists of key attributes of each health care database. It is grouped by country and allows both 
key word searches and searches by type of database.85   
In general, automated databases are quite accurate representations of drug prescribing and 
are often considered the “gold standard” among medication data sources.86,87  The major 
advantages of automated databases are their ability to provide very large sample sizes, relatively 
inexpensive, minimization of recall and interviewer biases, and ability to calculate incidence 
rates (mainly for claim database; some EHRs can only obtain prevalence).88-90  Automated 
databases can also be used to assess clinician and patient adherence to evidence-based 
pharmacotherapy.91  Grymonpre et al. showed the high concordance between the rates of 
prescription refills from and pill counts.92  In addition, one may extract valuable, research-quality 
data from clinical texts in EHRs through developing methods (e.g., natural language processing 
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methods).83  Several limitations of the automated databases include the uncertain validity of 
diagnosis data (especially for the claims databases and outpatient data), lack of information on 
some potential confounding variables (e.g., alcohol consumption, diet, physical activity), lack of 
information on non-prescription medications (e.g., non-steroidal anti-inflammatory drugs) or 
outside of the particular insurance carrier’s prescription plan, instability of the population due to 
job changes or employment status (for claim-based data), restricted generalizability to certain 
population (e.g., patients without coverage or with insufficient insurance not included), expense 
or difficulty in obtaining permission to use the data, and lack of information on actual use by 
patients and adherence to treatments.88-90   Although the size of most individual automated 
databases is quite large, a study using these might still be underpowered to detect very rare 
outcomes or outcomes that only occur a long time after drug exposure.  The power can further be 
increased by combining data from different region- or country-specific databases into one 
analysis set through the unique linkage system.  This is relatively new development within the 
field of pharmacoepidemiologic research. For example, this principle of database linkage is 
being used in studies of the potential teratogenic effects of a drug where a prescription database 
is linked to a pharmacy database and a birth registry.93   
Research based on automated data plays an important role in pharmacoepidemiology.  
Automated data systems will become even more evaluable as larger, more effective records 
linkage systems are implemented.  The ideal automated database would include records from 
both in- and outpatient care, emergency care, mental care, clinical measurements (laboratory, 
radiological, pathology tests), medication data (prescription, over-the-counter [OTC] 
medications, dietary/herbal supplements), and other potential confounders (e.g., smoking status, 
alcohol use, body mass index, disease severity marker, physical activity).  Other requirements of 
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an ideal database are population-based, that all parts are easily linked by means of a patient’s 
unique identifier, that the records are updated regularly, verifiable/traceable, and reliable.78,89   
1.3.2 Field Study (or Ad Hoc Studies) 
Epidemiologic studies in which data are collected in the field for the purpose of evaluating a 
specific hypothesis are known as “field” or “ad hoc” studies.94  In contrast with studies using 
pre-existing data, field studies enroll the subjects and collect data (at least partially) to answer a 
specific research question.  Several special types of ongoing field studies such as case-control 
surveillance, prescription event monitoring, and registries will be described in the next section.   
The completeness of ascertainment of drug exposure varies across different study designs 
depending on how the participant is questioned and the specificity of the questions asked.  In 
case-control studies, questions on medication use can range from open-ended (e.g., did you take 
any drugs in the last month?), to ask about the use of specific medications of interest by name, 
and to even showing the participants cards with specific drug names on them.94  Mitchell et al. 
found that 0-45% of the use of a number of drugs was identified by asking an open-ended 
question, 35-81% by asking a structured list of selected indications, and 19-48% by asking a 
specific name.95  A diary of life events is commonly used as a memory aid for obtaining drug 
exposure information.  For obtaining recent medication use, requesting subjects to check the 
medication packages or using product photographs seems to be helpful.96  However, case-
controls studies may be more likely to have recall bias (e.g., cases are more likely to remember 
drug use than controls).   
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In cohort studies, a “brown bag” medication inventory through in-person interviews or 
phone surveys is used to collect actual medication use.97,98  Typically, for prescription 
medications, interviewers will either read or ask the participant to read the name, strength, 
frequency of the medication and the direction for use of the labels from the original prescription 
bottle.  Asking participants how many units or tablets/capsules they took over the previous day, 
week or month is helpful to assess consistency with the prescribed directions.99  A similar 
technique is repeated for over-the-counter medications and dietary/herbal supplements, except 
that strength and directions for use are not usually queried because many of these drugs are taken 
as needed and having multiple ingredients.  The correct coding and identification of dietary 
supplements can be difficult since many pharmacotherapy sources do not have complete 
information regarding these agents.99  A common approach is for interviewers to ask the 
participants to identify the supplement’s manufacturer so a further search may be conducted.  
Several studies show that the validity of self-reported medication use by older adults is 
reliable.100-102  The recall accuracy for past medication use leads most surveys of older adults to 
limit the recall period to the recent past (e.g., 1-4 weeks).99 
Compared to studies using information from pre-existing databases, the strengths of field 
studies include more rigorously defined outcomes (not only replying on diagnosis codes), 
increased feasibility of enrolling subjects with very rare conditions (unless using a large 
government databases or linking multiple databases for other sources), and increased feasibility 
of obtaining more comprehensive information (e.g., OTC drugs, herbals and other supplements, 
alcohol and tobacco consumption, and patient-reported quality of life).94   The limitations of field 
studies include being time-consuming, relatively expensive, having logistical challenges in 
enrollment and data collections, and potential biases that can influence study validity.  In 
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addition, many questions in pharmacoepidemiology are urgent in nature, especially if driven by 
regulatory concerns; thus, the long lead-time required to conduct field studies can be a 
significant barrier that must be balanced against the requirement for information that cannot be 
obtained by other approaches.94 
1.3.3 Case-Control Surveillance, Prescription-Event Monitoring, and Registry 
Case-Control Surveillance (CCS) was begun in 1976 and the data collection took place at 
collaborating hospitals in Boston, Baltimore, New York and Pennsylvania until 2009.103  In CCS, 
multiple case-control studies are conducted simultaneously in order to monitor the effects of 
prescription and OTC medications and dietary/herbal supplements on the risk of various 
diseases, particularly cancers.  CCS relies on self-report of regular or long-term medication and 
dietary supplement use (name, timing, frequency and duration) for 43 indications or medication 
categories (e.g., headache, cholesterol-lowering).  CCS collects many factors that may confound 
or modify drug-disease association.  The strengths of CCS include its large sample size and high 
statistical power, systematically assessing OTC medications and dietary/herbal supplements in 
addition to prescription medications, ability to assess the effect of drug use that occurred in the 
distant past or use with long duration of exposure, ability to control for potential confounders, 
and accurate outcome data (confirmed from the hospital discharge summary and pathology 
report).  Several limitations of CCS include potential selection bias due to hospital-based case-
control studies, difficulty in validating self-reported OTC medications and dietary/herbal 
supplement use, potential misclassification of drug use, and lack of dosage information.32,103   
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Since 1981, Prescription-Event Monitoring (PEM, or yellow-card system) 
systematically monitors the safety of targeted new medicines in cohorts of 10,000-15,000 
patients in England.  PEM is complementary to spontaneous reporting of suspected ADRs.104  
PEM selects new medicinal products which are expected to be widely used in general practice, or 
established products with a new indication or extending usage to a new population, and sends 
questionnaires to general practitioners to request information on specific medications use and 
medical events.   PEM offers opportunities for better quantification of ADRs and identifies and 
characterizes some ADRs which were unrecognized during premarketing development and are 
not possible to quantify through spontaneous reporting.104   The strengths of PEM include: (1) 
large sample size, (2) representativeness of patients treated in “real-world” clinical practices, (3) 
ability to examine adherence to prescribing guidelines and drug utilization and safety in special 
populations (e.g., children, elderly, pregnant women and with off-label use), (4) opportunities for 
following up subgroups of patients of interest and generating or strengthening signals of ADRs 
or diseases, (5) more accurate medication exposure data derived from dispensed prescriptions 
with validation from prescribers, and (6) complete collections of outcome events (regardless of 
recognized ADRs or unrecognized syndromes).   Several limitations of PEM include: (1) absence 
of data on an unexposed comparator due to the single-group cohort design, (2) potential selection 
bias from preferential prescribing, (3) unpredicted patterns of adoption of a new drug, (4) non-
response to questionnaires, (5) possible under-reporting of serious and fatal adverse event, and 
(6) misclassification bias depending on patients’ adherence and the accuracy and thoroughness of 
the general practitioners in diagnosis.  Furthermore, there is an inability to collect and control for 
all potential confounders, a restricted statistical power and sample size to detect very rare ADR, 
and an inability to study drugs used in the hospital.104,105  
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A registry is an organized system that uses observational study methods to collect 
uniform data to evaluate specified outcomes for a population defined by a particular disease, 
condition, or exposure and serves a predetermined scientific, clinical or policy purpose.106  
Traditionally, registries were either population-based tools for monitoring public health 
interventions (e.g., records of receipt of childhood vaccines), collections of data on people with 
shared characteristics (e.g., disease registries, birth defects, HIV) or other systematic programs 
for case ascertainment and recruitment.  Recently, registry methods extend to a variety of 
purposes such as patient support activities, evaluating safety and effectiveness of marketed 
products, health interventions, and characterizing clinical presentation and progression of 
diseases.  The strengths of registries include: (1) the ability to simultaneously collect detailed 
information (e.g., clinical and medical data, paper/electronic health records, and administrative 
data), (2) flexibility to adapt over time to accommodate new research questions and purposes, (3) 
better at reflecting the safety and effectiveness of medical interventions in real-world practice 
than clinical trials, and (4) ability to follow patients over long periods of time.  The limitations of 
registries include: (1) a lack of pre-specified hypotheses of registries that are designed provide an 
adaptive framework for evaluating new treatment, (2) having difficulties in explaining whether 
the observed effects are due to the intervention or are merely a characteristic of the type of 
people if lack of comparison groups, (3) selection bias if recruiting subjects non-randomly or 
preferentially, and (4) discouraging reporting rate if data collection systems are hard-to-use.107   
For example, the Surveillance, Epidemiology, and End Results (SEER) program of the National 
Cancer Institute in the US provides statistics for monitoring of cancer disease burden since 1973, 
drawing on 18 cancer registries in 14 states that collectively represent 28% the US population.108  
In pharmacoepidemiology studies, with approval, researchers may be granted access to the 
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SEER-Medicare linked data files to obtain medication use information prior to, during, and 
following cancer diagnosis and treatment in the elderly.109            
1.3.4 Summary 
It is important to tailor the choice of pharmacoepidemiology data sources to the research 
question to be addressed.   More than one data collection strategy or sources, in parallel or 
combination may be used.  By considering the characteristics of pharmacoepidemiology 
resources available, as well as the characteristics of the research question to be addressed, 
choices of data resources that are best suited to addressing the question at hand can be made.
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1.4 AVAILABLE DRUG CODING SCHEMES AND CLASSIFICATION SYSTEMS 
Appropriate coding and classification of medications can make a major contribution to efficient 
data management and analyses.  However, little is published reviewing and comparing different 
drug coding schemes and classification systems.  In this section, major available drug coding 
schemes including the National Drug Code (NDC),110 WHO Drug Dictionary (WHO-DD),111 
Iowa Drug Information System (IDIS)112, the Slone Drug Dictionary,113,114 Medi-Span®, Lexi-
DataTM (or Cerner Multum’s  Lexicon),90 First DataBank,115 Veteran Health Administration 
(VA) National Drug File Reference Terminology (NDF-RT) and  RxNorm/RxNav116 will be 
described.  Table 4 summarizes the characteristics of each coding scheme and its classification 
system.   These drug coding schemes integrated with the classification systems facilitate the 
identification and grouping of agents with similar pharmacologic properties and therapeutic uses.  
Two systems, the Anatomical Therapeutic Chemical (ATC) Classification System and American 
Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification®, are commonly 
used in pharmacoepidemiologic studies.  While no single classification system is comprehensive 
for all medications, both are well suited for coding most drugs used in Europe and the U.S, 
respectively and are proven practical useful.112   
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Table 4. Overview of Available Drug Coding Schemes 
Coding Schemes 
(Abbreviations) 
Characteristics Coding Example 
(Simvastatin) 
Example(s) Using 
the Coding Scheme 
National Drug Code 
(NDC)110 
• Maintain by the U.S Food and Drug Administration 
• Designed for inventory management and reimbursement 
• 10 digits (3 segment code):distributor/manufacturer/re-packager, 
product, and package size  
• Do not provide unique codes for drug ingredients 
0006-0740-31  
Manufacturer: Merck, Sharp & Dohme;  
Product: Zocor® 20mg/tablet;  
Package size: 30 tablets/bottle  
Community and 
nursing home 
pharmacies 
WHO Drug 
Dictionary (WHO-
DD)111 
• ATC classification system conjunction with the DDD method 
• ATC system: 5 hierarchical levels: a main anatomical group; 2 
therapeutic subgroups, a chemical –therapeutic subgroup, and a 
chemical substance subgroup 
• Contains primarily European drug names and their ingredients 
• Contains an herbal dictionary based on the Herbal ATC system 
• Yearly updated 
C10AA01 
C: cardiovascular system;  
C10: Lipid modifying agents;  
C10A: Lipid modifying agents, plain; 
C10AA: HMG CoA reductase inhibitors 
Italian group of 
pharmacosurveillance 
in the elderly study 
(Gruppo Italiano di 
Farmacovigilanza 
nell’ Anziano GIFA) 
study112 
Iowa Drug 
Information System 
(IDIS)112 
• Modified version of AHFS Pharmacologic Therapeutic Classification 
• 4 hierarchical levels: 3 levels of therapeutic categories and one level 
of chemical ingredient category 
• Mostly US prescription drug names linked to their therapeutic class 
24060205 
24: Cardiovascular agents 
2406: Antilipemic agents 
240602: Antilipemic agents-HMG-CoA 
reducatase Inhibitors 
Health ABC,117 
EPESE112 
Slone Drug 
Dictionary114 
• Use AHFS Pharmacologic Therapeutic Classification 
• Contains US and non-US drugs, and supplements and other non-
prescription products 
• Multi-component products are cross-linked with their individual 
ingredients 
• Have “Coalitions”, epidemiologist-defined groups 
560622: Simvastatin, single component 
drug, under AHFS classification code 
24:06:08:00 
(cardiovascular/antilipemic/HMG-CoA 
reductase inhibitors), under coalition 
790106 (HMG-CoA reductase inhibitors) 
Studies using data 
from Slone 
Survey96,118 
Medispan®119 • Use the Generic Product Identifier (GPI) system 
• Modified AHFS Pharmacologic Therapeutic Classification 
• Includes drug information, clinical decision support and disease suite 
modules, and application programming surface 
• Includes NDC, Universal product codes 
• Cross reference to RxNorm, uniform system of classification  
GPI (14 digits): 394000750003XX 
39 (drug group): cardiovascular agents;  
3940 (drug class): HMG-CoA reductase 
inhibitors;  
394000 (drug subclass): none; 
39400075 (drug name): simvastatin; 
3940007500 (drug name extension): none; 
394000750003 (dosage form): Tablet 
39400075000330 (strength):  20 mg 
CHS98 
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Table 4 (Continued) 
Coding Schemes 
(Abbreviations) 
Characteristics Coding Example 
(Simvastatin) 
Example(s) Using 
the Coding Scheme 
Lexi-DataTM (or 
Multum®)120 
• Use Multum’s Therapeutic Categorizations that are organized into 
a 3-level hierarchy permitting classification at the therapeutic, 
pharmacological and drug category levels. 
• Modified AHFS Pharmacologic Therapeutic Classification 
• Monthly update the new drug availability and other drug 
information from FDA and pharmaceutical manufacturer 
announcements and publications to research findings 
• Can cross-link to NDC and therapeutic drug classes 
• Simvastatin 20mg oral table:  
Multum Mediasource Lexicon (MMSL) 
numeric code: 3083; or MMSL with 
term type: CD3083, CD indicates as 
clinical drug; 
• Linked to 3-levels: level 1=358 
(metabolic agents), level 2=019 (anti-
hyperlipidemic agents), level 3=173 
(HMG-CoA reductase inhibitors) 
NHANES,121 
MEPS,122,123 
NSHAP120, NAMCS 
and NHAMCS124 
First DataBank (FDB)115 • Use FDB Enhanced Therapeutic Classification system, an 8-
character numeric identifier (ETC_ID) 
• Aggregates drug information on indications, drug-disease 
contraindications, side effects, drug/drug and drug/food 
interaction, allergy 
ETC_ID level 1: cardiovascular therapy 
agents: 00002553 (or 2553), ETC_ID level 
2: antihyperlipidemic agents: 00000263 (or 
263), and ETC_ID level 3: HMG-CoA 
reductase inhibitors: 00002747 (or 2747). 
A data book of 
Medicare Part D 
Program from the 
MedPAC 125 
Veterans Health 
Administration (VA) 
National Drug File-
Reference Terminology 
(NDF-RT)126 
• Non-proprietary drug terminology system 
• NDF-RT includes drug knowledge (e.g., disease-based 
interactions) and classifies drugs, most notably by mechanism of 
action, physiologic effect, and therapeutic categories 
• Use five-character alpha-numeric codes for classify a drug 
Simvastatin under drug class CV350 
CV350: Antilipemic drugs; 
CV: Cardiovascular medication 
Studies using VA 
medication data 
RxNorm/ RxNav116   • Non-proprietary drug terminology system 
• NLM repository of standard names (active ingredient, strength, 
dose form) for clinical drugs and assign a concept unique identifier 
(CUI) 
• Generic and branded normalized forms are related to each other 
and to the names of their individual components by a well-defined 
set of named relationships  
• Link to First DataBank National Drug Data File Plus, 
Micromedex, Medi-Span®, Gold Standard, Multum, and VA 
NDF-RT 
• Does not include drug knowledge 
Simvastatin 20 mg oral tablet [Zocor®] 
RXCUI: 104491 
 
TEDDY127 
Abbreviations: AHFS: American Hospital Formulary Service; ATC: Anatomic Therapeutic Chemical; CHS: Cardiovascular Health  Study; DDD: defined daily dose; EPESE: Epidemiologic Studies of 
the Elderly survey; Health ABC: Healthy Aging and Body Composition Study; MedPAC: Medicare Payment Advisory Commission; MEPS: Medical Expenditure Panel Survey; NAMCS: National 
Ambulatory Medical Care Survey; NHAMCS: National Hospital Ambulatory Medical Care Survey; NHANES: National Health and Nutrition Examination Survey; NLM: National Library of 
Medicine; NSHAP: National Social Life, Health and Aging Project; TEDDY: The Environmental Determinants of Type 1 Diabetes in the Young; WHO: World Health Organization
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1.4.1 National Drug Code (NDC) in the US 
Most pharmacies in the U.S use computer systems that automatically convert alphabetically 
entered drug product names into corresponding NDC numbers.  The NDC was designed for 
inventory management and reimbursement.  The NDC is 10-digit-code consisting of three parts 
delimited by dashes: a manufacturer code, a product code and a package size code (e.g., 0006-
0740-31: Merck Sharp & Dohme, Zocor® 20mg/tablet, 30 tablets/bottle).110  It does not provide 
unique codes for drug ingredients.  For example, any one drug product (e.g., simvastatin 20 mg 
tablet) can be represented by numerous codes since there may be various manufacturers (brand 
and generic) and package sizes (e.g., 100-count bottles, unit-dose packages).  To avoid problems 
associated with numerous NDC codes for each drug, other drug coding schemes with 
hierarchical levels (e.g., WHO-DD or IDIS) can be combined with NDC codes to facilitate 
analytical process.    
1.4.2 The Anatomical Therapeutic Chemical (ATC) Classification System and WHO 
Drug Dictionary (WHO-DD) 
The WHO-DD includes drug names linked to the ATC Classification System, which is generally 
used in conjunction with the defined daily dose (DDD) method to standardize doses.128  The 
WHO-DD contains primarily European drug names and their ingredients, and an herbal 
dictionary based on the Herbal ATC system (HATC) as well.129  This is a five-level hierarchical 
system including a main anatomical group, two therapeutic subgroups, a chemical/therapeutic 
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subgroup, and a chemical ingredient (e.g., simvastatin: C10AA01).  Products are classified 
according to the main therapeutic indication for the principal active ingredient.  Most products 
are assigned only one ATC code.  However, some active ingredients may have more than one 
ATC code, if the drug has different uses at different strengths (e.g., aspirin as a platelet 
aggregation inhibitor and as an analgesic–antipyretic), dosage forms (e.g., timolol to treat 
hypertension and to treat glaucoma) or both (e.g., medroxyprogesterone for cancer therapy and 
as a sex hormone).130  Prednisolone is an example of a drug that has six different codes.  Fixed 
dose combination products pose classification difficulties.  For example, a combination product 
that contains and analgesic and a tranquilizer is classified as an analgesic, even though it also 
contains a psychotropic substance.130  In addition, the ATC does not distinguish chemicals by 
dose-form or strength and assigns classes based on main therapeutic indication, so less common 
uses may be omitted.131 
1.4.3 The American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic 
Classification® and Related Coding Schemes 
The AHFS Pharmacologic-Therapeutic Classification® was developed and is maintained by the 
American Society of Health-System Pharmacists (ASHP).  The AHFS Pharmacologic-
Therapeutic classification® allows the grouping of drugs with similar pharmacologic, 
therapeutic, and/or chemical characteristics in a 4-tier hierarchy.  There are 31 classifications in 
the first tier, 185 in the second tier, 256 in the third tier, and 94 in the fourth tier.132  For example, 
the AHFS classification number for aspirin is 28:08.08.24 (Central Nervous System Agents: 
28:00; Analgesics and Antipyretics: 28:08; Nonsteroidal Anti-inflammatory Agents: 28:08.04; 
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Salicylates: 28:08.04.24).133  A drug may have multiple classes (due to its indication, mechanism 
of action, or route of administration) and all classes for a drug are considered equally valid.  For 
example, labetalol has AHFS classification numbers: 24:24 (β-Adrenergic Blocking Agents),   
24:04.04.16 (Class II Antiarrhythmics), 24:08.04 (α-Adrenergic Blocking Agents), and 24:08.08 
(β-Adrenergic Blocking Agents).  In addition, combination products inherit all of the 
classifications of the individual active ingredients since the AHFS classification is assigned to 
the active ingredient.132  In the next few paragraphs, coding schemes based on the modifications 
of AHFS Pharmacologic-Therapeutic Classification® will be briefly described. 
The IDIS scheme represents a modification of the AHFS Pharmacologic Therapeutic 
Classification.133  The IDIS scheme includes most of the US prescription drug names linked to 
their therapeutic class.  The IDIS code has eight numeric digits, two digits per level.  The first six 
digits of the drug code identify the hierarchical therapeutic class to which the drug term was 
assigned (e.g., simvastatin: 24060205).112  The seventh and eighth digits are assigned by the IDIS 
and had no hierarchical meaning.  The main difference between WHO-DD and IDIS scheme is 
that WHO-DD has specific codes for combinations of ingredients, while IDIS codes each 
ingredient separately.112  The advantage of IDIS over the NDC and other coding systems is that it 
provides codes for OTC medications and dietary supplements. 
The Slone dictionary developed and maintained by the Slone Epidemiology Center, is a 
computerized linkage system composed of single medication components and multi-component 
products.  The Slone dictionary contains US and non-US prescription drugs, and in addition it 
includes OTC products, vitamins and dietary supplements.113,134  Each product is assigned a 
unique number and links to its active ingredients; each active ingredient is classified by AHFS 
Pharmacologic Therapeutic Classification; the Dictionary includes “coalitions”, which are 
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epidemiologist-defined groupings of drugs and drug products that can be used in various 
analyses.113  The Slone Survey was used in many pharmacoepidemiologic studies and the Slone 
Epidemiology Data Center published three annual reports (2004-2006) on medication use in the 
U.S.135 
Other drug coding schemes use principles similar to those of AHFS and ATC 
classification systems and provide tables for mapping NDCs to their clinical drug codes, which 
offers increased flexibility or specificity for an individual drug product.  These commercial 
coding schemes usually integrate with drug information or knowledge databases (e.g., pricing, 
adverse effects, dosing, and cross-references to NDC, RxNorm or other coding systems or 
schemes), clinical decision support and disease suite modules and other applications or 
programs.  Other systems used in commercial drug coding schemes such as the Generic Product 
Identifier (GPI) system from Medi-Span® (Wolters-Kluwer Health, Inc., Conshohocken, PA),119 
Multum’s Therapeutic Categorization in the Lexi-DataTM (Cerner Multum, Inc. Denver, CO),90 
and First DataBank Enhanced Therapeutic ClassificationTM System (First DataBank, Inc., San 
Bruno, CA)®.115   
Medi-Span® incorporates the AHFS Pharmacologic-Therapeutic System and groups 
drugs with comparable compounds in the same therapeutic class through the GPI. 119  The GPI, a 
hierarchical classification scheme, is a 14-digit field consisting of seven subsets, each providing 
increasingly more specific information about the drug (i.e., drug group, class, sub-class, name, 
name extension, dosage form, and strength). 136  For example, the GPI for simvastatin tablet 20 
mg is 39400075000330 (39: cardiovascular agents; 3940: HMG-CoA reductase inhibitors; 
394000: no sub class; 39400075: simvastatin; 3940007503: tablet (PO); 394000750330: 20 mg).  
Products having the same 14-digit GPI are identical with respect to active ingredient(s), dosage 
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form, route of administration and strength or concentration.136  The same drug may be classified 
in multiple therapeutic classes.   
Lexi-DataTM incorporates four distinct therapeutic/chemical classification systems 
including Multum’s Therapeutic Categorization, Lexi-Comp’s Pharmacologic Category, 
Therapeutic Duplication Categorization, and Allergic Cross-Reactivity Categorization, to support 
different types of use.137  In general, Multum’s therapeutic categorizations are based on the 
AHFS therapeutic categories and are organized into a 3-level hierarchy permitting classification 
at the therapeutic level, pharmacological level and drug category level.120   For example, for 
simvastatin: the broadest category is metabolic agents [level 1=358]; the more detailed category 
is antihyperlipidemic agents [level 2=019]; and the most detailed category is HMG-CoA 
reductase inhibitors [level 3=713]).   Not all drugs have three classification levels; some may 
only have two [e.g. for digoxin: cardiovascular agents [level 1]; inotropic agents [level 2]), 
others only have one.124  Beginning with 2006, multiple-ingredient drugs are assigned a single 
generic drug code encompassing all of a drug's ingredients, rather than being assigned generic 
drug codes for each ingredient.124     
The First DataBank Enhanced Therapeutic Classification System is an advanced drug 
classification system with virtually unlimited levels of specificity, for easy formulary 
maintenance and drug selection.  It allows drugs to reside in multiple therapeutic classes, with 
links to drug concepts at any level of the hierarchy.115  The First DataBank Enhanced 
Therapeutic Classification identifier (ETC_ID) is an eight-character numeric column that 
identifies a unique therapeutic classification. This number is a stable identifier permanently 
associated with the ETC description.  For example, simvastatin has three levels of ETC_ID:  
ETC_ID level 1: cardiovascular therapy: 00002553 (or 2553), ETC_ID level 2: 
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antihyperlipidemic agents: 00000263 (or 263), and ETC_ID level 3: HMG-CoA reductase 
inhibitors: 00002747 (or 2747).115  In addition, multi-ingredient formulations are represented 
with a single class description (for example, ACE inhibitor and calcium channel blocker 
combination). 
1.4.4 US National Drug File Reference Terminology (NDF-RT) and Veterans Health 
Administration (VA) Drug Class Index 
The VA NDF-RT is a non-proprietary drug reference terminology that includes drug knowledge 
and classifies drugs, most notably by mechanism of action, physiologic effect and therapeutic 
category.126  The VA drug classes (approximately 400) are similar to the categories and classes 
in the other classification systems.  NDF-RT along with RxNorm (see the section 1.4.5) has been 
accepted by a federal standards-setting body, as recommended standards.  The VA drug 
classification system uses five-character alpha-numeric code specifies a broad classification and 
a specific type of product.  The first two characters are letters and form the mnemonic for the 
major classification.  Character 3 through 5 are numbers and form the basis for sub-
classificaiton.  For example, simvastatin is assigned to CV350 (CV: cardiovascular agents, 
CV350: Antilipemic drugs).  NDF-RT supports multiple indications and can identify specific 
characteristics of each drug, which is a crucial capability of a classification system.  The NDF-
RT contains a novel reference hierarchy to describe physiologic effects of drugs.126  The 
physiologic effects reference hierarchy contains 1699 concepts arranged into two broad 
categories organ specific and generalized systemic effects.126     
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1.4.5 RxNorm by US National Library of Medicine (NLM) 
The lack of interoperability of among the terminologies used in the commercial coding schemes 
was the primary motivation for the US National Library of Medician (NLM) to develop a public-
use coding scheme, RxNorm.116  RxNorm contains the names of prescription and many OTC 
formulations that exist in the United States.  A drug is assigned to a concept unique identifier 
(CUI).  Drugs whose names map to the same CUI are taken to be the same drug (i.e., identical as 
to active ingredient, strength and dosage form).  For example, the CUI for Simvastatin 20 mg 
oral tablet [Zocor®] is 104491.  RxNorm also provides normalized names for clinical drugs and 
links drug names to other drug coding schemes including National Drug Data File Plus, 
Micromedex, Medi-Span®, Gold Standard, and Multum.  RxNorm also includes the NDF-RT 
from the VA.  The goal of the RxNorm is to allow various systems using different drug 
nomenclatures to share data efficiently at the appropriate level of abstraction.   The RxNorm 
Navigator (RxNav) allows you to query the RxNorm database by any of its components.138   
1.4.6 Summary 
The coding system to be utilized depends on the objective of the study.  Analyses of focusing on 
beneficial or adverse effects of medications must consider drug ingredient.  Therefore, the 
coding system must allow for easy identification of the ingredients or combinations of 
ingredients contained in the drug products.112  Drug coding schemes with hierarchical codes for 
drug ingredients also make analysis easier and save time on programming.  In other potential 
studies involving the costs of drugs, it is essential to identify with a unique code the 
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manufacturer and the dosage form of each single drug product.  However, various drug coding 
schemes, while working well on their own, present a barrier when medical information systems 
containing these varying names and codes need to be cross-linked or reconciled.139  An 
international standardized nomenclature of drug names, codes and classification system will be 
an ultimate solution to conducting global pharmacoepidemiologic studies and exchanging and 
comparing health information and research outcome in public health.         
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1.5 BIAS AND CONFOUNDING IN PHARMACOEPIDEMIOLOGY 
In order to obtain accurate and valid results derived from observational studies in 
pharmacoepidemiology, several factors that must be considered including appropriate study 
designs, inclusion/exclusion criteria, drug exposure and outcome measurements, the changing 
phenomenon of drug exposure, potential biases, confounding factors (e.g., indications for 
prescribing), medical adherence, and the natural course of the disease.140,141  In this section, the 
importance of biases, sources of confounding and available solutions specifically for  
pharmacoepidemiologic studies will be discussed and summarized in Table 5.   
1.5.1 Bias and Available Solutions 
In general, common threats to internal validity in pharmacoepidmeiology include selection bias 
and information or misclassification bias.  Bias must be prevented through attention to the proper 
design and conduct of a study and cannot be routinely addressed at the analysis stage.142   
Conceptually, bias can be introduced by factors related to who is included in the study (selection 
bias), and errors of assessment and measurement (differential misclassification bias). 
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Table 5. Common Biases and Potential Solutions in Pharmacoepidemiology 
Bias Definition/Characteristics Example Potential Solutions 
Selection Bias  (the selection into the study groups of subjects who differ in characteristics from those in the target population) 
Referral • Occurs when drug exposure is associated with 
the likelihood of referral into the institution 
where the study takes place (e.g., hospitals) 
• Typically in hospital-based case-control studies 
• Frequently when a known/suspected association 
of the drug with the outcome 
• Usually occurs when an outcome presents in a 
manner such that an accurate diagnosis is not 
always obtained immediately 
• From a perspective of medical surveillance, 
referral bias can be regarded as a type of 
detection bias  
• Patients taking NSAIDs and presenting 
with mild abdominal pain may be more 
likely to be suspected as having a gastric 
ulcer and sent for further tests than 
patients with similar pain but without 
taking (results would be biased upward) 
• Women exposed to oral contraceptives 
may be more likely to be subjected to 
diagnostic tests for deep venous 
thrombosis compared to women not 
exposed 
• Restrict the participants to 
more serious cases of the 
disease 
• Identify cases and controls 
from the same screening 
program 
Self-selection • When study participants themselves decide to 
participate or leave a study based on drug 
exposure or change in health status 
• Those who did not join the study might belong 
to a special disease-exposure category 
• Particularly in case-control and retrospective 
cohort studies  
• Mothers of children with birth defects 
who also have something to report (e.g., 
medications) may be more likely to 
participate (biased towards an increased 
risk) 
• Systematically identify and 
recruit all eligible cases 
(e.g., select from 
population-based registries 
and prescription drug 
databases) 
Prevalence  • When prevalent cases rather than new (incident) 
cases are selected, usually in case-control 
studies 
• Patients who stay on treatment for a longer time 
may be less susceptible to the event of interest 
• Reflect an association with a prognostic factor 
rather than with incidence 
• Observational studies “failed” to show 
initial harmful effect of hormone 
replacement therapy (biased towards 
null) due to combination of prevalent 
users who tolerate therapy (survivor 
cohort effect) 
• Limit study recruitment 
incident cases with a clearly 
documented calendar time 
of diagnosis 
Protopathic • Occur when the initiation, discontinuation, or 
modification of a drug occurs in response to a 
symptom of the outcome (at this point 
undiagnosed) 
• Reflect a reversal association between outcome 
and drug exposure 
• Usually in retrospective studies 
• Estrogen was prescribed for uterine 
bleeding (before the diagnosis of 
endometrial cancer).  This biased the 
result to increased risk of endometrial 
cancer with estrogen use. 
• Have a full-understanding 
of the pathophysiologic 
mechanism of disease 
development 
• Using “lag-time” (or an 
index date) to define drug 
exposure periods 
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Table 5 (Continued) 
Bias Definition/Characteristics Example Potential Solutions 
Misclassification Bias (An error occurs when each time participants in a study are classified with regard to their drug exposure and disease status) 
Recall • A differential misclassification bias  
• Systematic differences in how exposure groups 
or disease groups remember certain information 
• More likely happen in retrospective studies, 
particularly case-control studies 
• Mothers with children having birth 
defects may give more valid and 
complete report of their drug exposures 
during the pregnancy 
• Select controls who are 
likely to have the same 
cognitive processes 
affecting memory of past 
drug exposures (e.g., 
alternative birth defects) 
Detection  • A differential misclassification bias  
• Can affect either cohort or case-control studies 
• Occurs when a presumably drug exposure leads 
to a closer surveillance that may result in a 
higher probability of detection of subclinical 
outcomes in exposed individuals 
• In case-control studies, if cases are more likely 
to be identified (or selected into the study) due 
to the exposure to a drug, detection bias can be 
regarded as a type of selection bias (i.e., referral 
bias)  
• In a cohort study, women taking 
postmenopausal hormonal supplements 
are more likely to see their doctors and 
be detected cancer at early stages than 
other women.  This differential follow-
up may lead to an excess number of 
diagnosed diseases in the treated group 
and falsely elevated risk, or to more 
complete preventive care leading to 
decreased risk. 
• In case-control studies, it occurs when 
the procedures for obtaining drug 
exposures are not similar in cases and 
controls (e.g., drug assessment is more 
thorough among cases) 
• Blinding of relevant study 
personnel  
• Standardization of the 
measurement process (e.g., 
specific training of 
interviewers) 
• For the analytic purpose to 
detect the possibility of 
detection bias, information 
should be obtained on the 
frequency of access to 
medical care and health 
awareness by participants.  
Stratification by disease 
severity helps too.  
Immortal-time • A differential misclassification bias 
• The exposed subjects will have a major survival 
advantage over their exposed counterparts 
because they are guaranteed to survive or to be 
event-free at least until their drug was dispensed. 
• Results of improper exposure definitions and 
analyses that cause serious misclassification 
• More likely to occur in cohort studies 
• Definition of exposed to inhaled 
corticosteroid: subjects who received 
their first prescription for an inhaled 
corticosteroid 90 days after cohort entry 
(90 days immortal time period) 
• Time-dependent methods 
for analyzing risks may be 
used to account for complex 
changes in drug exposure 
and confounders over time 
(e.g., Cox proportional 
hazard models with time-
dependent exposures) 
• Nested case-control design 
• Active comparative groups 
Abbreviations: NSAIDs: non-steroidal anti-inflammatory drugs
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1.5.1.1 Selection Bias 
Selection bias is a distortion of an estimated effect due to the selection into the study groups of 
subjects who differ in characteristics from those in the target population.141  In 
pharmacoepidemiology, four types of selection bias seem particularly important: referral bias, 
self-selection bias, prevalence study bias and protopathic bias.140   
Referral bias (or referral filter bias or Berkson’s bias or admission rate bias) can 
occur when drug exposure is associated with the likelihood of referral into the institution where 
the study takes place (often a hospital).143  Referral bias typically occurs in hospital-based case-
control studies and leads to a higher exposure rate among the hospital cases than the hospital 
controls.144,145  This is frequently in the case when there is already a known or suspected 
association of the drug with the outcome of interest, so referral to an institution where the 
diagnosis is made is more likely for patients taking this drug.143   In addition, it usually occurs 
when an illness or outcome presents in a manner such that an accurate diagnosis is not always 
obtained immediately.140  From a perspective of medical surveillance, referral bias can be 
regarded as a type of detection bias.144   An example of referral bias is a study of gastric ulcer in 
which cases and controls are identified in the same referral hospital.  Because a patient taking a 
non-steroidal anti-inflammatory drug (NSAID) and presenting with mild abdominal pain may be 
more likely to be suspected as having a gastric ulcer and sent for further tests than a patient with 
similar pain but who is not taking a NSAID.  This may bias the results towards increased risk 
between NSAIDs use and mild non-bleeding gastric ulcer.  Another example, knowledge of a 
well-established association between deep venous thrombosis (DVT) and oral contraceptives 
may make women exposed to oral contraceptives more likely to be subjected to diagnostic tests 
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for DVT compared to women not exposed.  A general solution for addressing referral bias is to 
restrict the study participants to more serious cases of the disease.  The reason for this is that it 
can be expected that for most diseases, regardless of previous drug exposure, all serious cases 
will eventually be diagnosed correctly.140  Identifying cases and controls from the same 
screening program can be another solution.144   
Self-selection bias may occur when study participants themselves decide to participate or 
leave a study based on both drug exposure and change in health status.140  Self-selection bias 
may particularly occur in case-control or retrospective cohort studies because both outcome and 
exposure are already manifested when study subjects are recruited.  For example, mothers of 
children with birth defects who also have something to report (e.g., medications) may be more 
(or less) likely to participate.  Also, those who are lost to follow-up in cohort studies might 
belong to a special disease-exposure category.  This can be controlled for by systematically 
identifying and recruiting all eligible cases.  Relying on population-based registries for case and 
prescription drug ascertainment is an excellent way to minimize the occurrence of selection 
bias.140   
Prevalence bias may occur when prevalent cases rather than new (incident) cases are 
selected for a study, which may occur in case-control studies.  An association between drug use 
and prevalent cases could thus reflect an association with a prognostic factor rather than with 
incidence.  In addition, patients who stay on treatment for a longer time (i.e., prevalent to drug 
exposure) may be less susceptible to the event of interest.  Limiting study recruitment to newly 
diagnosed or incident cases with a clearly documented calendar time of diagnosis favors the 
ascertainment of drug exposures that are relevant to disease incidence.140   
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Protopathic bias (or reverse causality bias) occurs when the initiation, discontinuation, 
or modification of a drug occurs in response to a symptom of the outcome (at this point 
undiagnosed).143  Protopathic bias reflects a reversal association between outcome and drug 
exposure.   It may particularly occur in case-control studies.  For example, analgesics were used 
in response to the pain caused by an undiagnosed tumor.146  Another example is that patients 
could stop taking aspirin because of the presence of bloody stools.  If the presence of blood was 
the first expression of colon cancer, we would subsequently find a negative association between 
current aspirin use and colon cancer.  This scenario may particularly occur in 
pharmacoepidemiology because diseases are often identified after their first clinical expression 
and because exposure to drugs may change from day to day, frequently with changes in actual or 
perceived health status.  Therefore, it is critically important to have a full-understanding of the 
pathophysiologic mechanism of disease development when designing pharmacoepidemiology 
studies.140  A general solution to prevent protopathic bias is the use of “lag-time” (or an index 
date) to define drug exposure periods.   Using this approach, a specific time period before the 
date of diagnosis with the disease under study would be excluded from the exposure assessment.  
Tamim et al showed that the ORs stabilized at lag-time around 6 months using two methods.147     
The goal to prevent selection bias is to recruit a study population that accurately 
represents the target population concerning the drug exposure and outcome association.  
Remedial strategies include random sampling from the source population, systematically 
recruiting a series of consecutive subjects, implementing a tracking procedure for those who drop 
out (e.g., document the reason and their health status), restricting to incident cases, and 
minimizing the number of lost to follow-up (e.g., select adherent patients). 
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1.5.1.2 Misclassification Bias 
Misclassification bias refers to the possibility of error when participants are classified with 
regard to their drug exposure and disease status.   There are two types of misclassification bias: 
non-differential (or random) misclassification and differential misclassification (also called 
information bias).  Non-differential misclassification occurs when the degree of 
misclassification is random or similar for all patients and independent of both drug exposure and 
outcome status.  It usually biases the results toward the null value, but may reverse the measure 
of effect in some extreme circumstances.  Differential or systematic misclassification can occur 
when misclassification is related to drug exposure-outcome association.  Differential 
misclassification can bias results toward or away from the null hypothesis based on the 
situations.141  In pharmacoepidemiology, common differential misclassification biases include 
recall bias, detection bias, and immortal time bias.   
Recall bias occurs if individual’s memories of exposure or outcome systematically differ 
based on exposure or outcome status.142  It is more likely to happen in retrospective studies, 
particularly case-control studies.  For example, mothers with children having birth defects may 
give more valid and complete report of their drug exposures during the pregnancy compared to 
mothers with children without birth defects.  In order to minimize this type bias, it is important to 
select controls who are likely to have the same cognitive processes affecting memory of past 
drug exposures (e.g., alternative birth defects). 140   
Detection bias (or medical surveillance bias) can occur in cohort studies or case-control 
studies.  It occurs when a presumably drug exposure leads to a closer surveillance that may result 
in a higher probability of detection of subclinical outcomes in exposed individuals (i.e., when 
identification of the outcome is not independent of the knowledge of exposure).144,148  In cohort 
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studies, it is particularly likely when an exposure of a drug or therapy leads to frequent and 
thorough checkups, and the outcome is a disease that characterized by a high proportion of 
subclinical cases.141  For example, women taking postmenopausal hormonal supplements are 
more likely to see their doctors and be detected cancer at early stages than other women.   This 
differential follow-up may lead to an excess number of diagnosed diseases in the treated group 
and falsely elevated risk, or to more complete preventive care leading to decreased risk.140  In 
case-control studies, it occurs when the procedures for obtaining drug exposures are not similar 
in cases and controls (e.g., drug assessment is more thorough among cases).   If cases are more 
likely to be identified (or selected into the study) due to the exposure to a drug, detection bias 
can be regarded as a type of selection bias (i.e., referral bias, see more details in the previous 
discussion of referral bias).144  The potential solutions include blinding of relevant study 
personnel and systematic standardization of the measurement process (e.g., specific training of 
interviewers).140   If these strategies are not feasible (especially in case-control studies), to 
examine the occurrence of this bias in the analysis stage, information should be obtained on the 
frequency and quality of medical care received by the study participants, and variables that 
indicate awareness of health problems.144  Finally, when detection bias occurs, the proportion of 
less advanced disease in a cohort study is higher in the exposed group.  In a case-control study, 
the association is found to be stronger or present for less advanced cases.  Therefore, 
stratification by disease severity at diagnosis is an additional strategy to examine and take into 
consideration the possibility of detection bias.144 
In addition, immortal time bias (or immortal person-time) is increasingly common in 
cohort studies of drug effects because drug exposure often changes over time (i.e., time-varying).  
Immortal time usually arises when the determination of an individual’s treatment status involves 
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a delay or wait period during which follow-up time is accrued.  This wait period is considered 
immortal because individuals who end up in the treated group have to survive until treatment 
definition is fulfilled.149 It is particularly problematic because it necessarily biases the results in 
favor of the treatment under study by defining an artificial survival advantage to the treatment 
group.  Several criteria can be used to identify immortal time bias: (1) Was treatment status 
determined after the start of follow up or defined using follow-up time? (2) Was the start of 
follow-up different for the treated and untreated group relative to the date of diagnosis? (3) Were 
the treatment groups identified hierarchically (one before the other)? (4) Were subjects excluded 
on the basis of treatment identified during follow-up? (5) Was a time fixed analysis used?149 For 
example, Sin et al. suggested inhaled corticosteroids given after hospital discharge were 
associated with a 29% reduction in the rate of all-cause mortality among elderly patients 
hospitalized for chronic obstructive pulmonary disease.150 The results may be biased due to the 
immortal time bias.  The exposed subjects who received their first prescription for an inhaled 
corticosteroid 80 days after cohort entry had to be alive on day 90.  Thus, the drug exposed 
subjects will have a major survival advantage over their exposed counterparts because they are 
guaranteed to survive or to be event-free (e.g., immortal time period: 90 days) at least until their 
drug was dispensed.  Time-dependent methods (e.g., Cox proportional hazard models with time-
dependent exposures) or nested case-control designs are recommended to use to account for 
complex changes in drug exposure and confounders over time.51,151 
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1.5.2 Confounding  
The biggest challenge in pharmacoepidemiology is to identify the appropriate designs, measures, 
and analytic techniques to avoid or control confounding.  Confounding occurs when the 
estimates of a measure of association between drug exposure and the outcome(s) of interest is 
masked by the effect of one or several extraneous variables that are also associated with drug 
exposure and the outcome of interest (but not part of the causal pathway).140,152  Failing to 
control for confounders can lead to spurious results. 
Confounding by indication is probably the most important and challenging confounder 
in pharmacoepidemiology.  It is also widely referred to as indication bias, channeling, 
confounding by severity, or contraindication bias.60,140,153  In general, confounding by 
indication occurs when an observed association between a drug and an outcome is due to the 
underlying diagnosis or other clinical features and not to any effect of the drug.  Confounding by 
indication describes the various factors related to an individual’s condition that determine the 
initiation and choice of a specific drug (e.g., statins for patients with high cholesterol), and thus 
comparisons of drug users to nonusers usually have to be made for patients sharing similar 
indications or conditions, as the condition itself is commonly one of the most important risk 
factors for the outcome of interest.143,154  The term broadly covers the more subtle considerations 
affecting the choice of a specific drug among patients with similar indications (sometimes 
referred to as channeling), relating to disease severity (confounding by severity), comorbid 
conditions, contraindications, patient demographics, the drug’s adverse-effect profile, and 
subjective impressions of the prescribing physician.143  For example, Laporte et al. reported that 
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upper gastrointestinal (GI) bleeding was associated with the use of selective COX-2 inhibitors.155  
These results were confounded by the fact that the patients who were treated with COX-2 
inhibitors were at higher risk of developing a GI hemorrhage independent of the COX-2 inhibitor 
use.  A possible solution in this scenario would be to select patients without any history of GI 
bleeding and new users of NSAIDs.   
However, Salas et al. suggested applying the term “confounding by severity” specifically 
to the situation in which the severity of disease acts a confounder.156 Confounding by severity 
should be considered a special form of confounding by indication, in which not only the disease 
that forms the indication but also its severity (and complications) is a potential confounder.  If 
one controls for the disease (or indication) but not for its severity, the possibility of residual 
confounding remains.  Moreover, in the product information of registered medicines, the 
indications for treatment pertain to diagnoses itself rather than to the severity of the 
manifestation of their clinical patterns.  Thus, when drug treatments are compared, controlling 
for these indications does not preclude confounding by severity.156  In patients with type 2 
diabetes, for instance, oral hypoglycemic agents are used early in the course of the disease, and 
insulin is reserved for patients who have more severe disease or who have not responded to oral 
agents.  Because treatment type is correlated with disease severity and duration, it is difficult to 
design a convincing observational study that compares oral agents with insulin for outcomes that 
are related to disease duration or severity.  Confounding by severity in observational studies 
usually makes the therapy appears to be less effective it appeared in the experimental studies 
(RCT can balance the severity distribution of the compared group).157  However, confounding by 
severity can be useful for other purposes.  For example, although a positive association between 
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β-agonists and asthma death was suspected to be confounded by disease severity, it can be 
informative because the amount of β-agonist used can be a proxy of prognosis.158   
Confounding by indication usually is not a problem or concern when a study is focusing 
on unexpected drug effects or side effects (because the indication is usually not related to the 
outcome), or the decision about whether to treat is not based on a formal indication (usually in 
primary prevention such as routine measles vaccination in healthy infants).154  Ideally, under the 
assumption of the choice between alternative treatments is effectively random, confounding by 
indication may seem less of a problem when doing comparisons among multiple alternative 
treatments.  In practice, it is challenging to control for confounding by indication because 
“indication” is a complex and multi-factorial phenomenon involving the physician’s knowledge, 
the longitudinal nature of disease and other factors which may not be entirely evident and which 
may act in different directions.140  If confounding by indication cannot be ruled out, RCTs are 
preferred over non-experimental studies.  If RCTs cannot be used, non-experimental study 
designs can be used to qualitatively demonstrate some degree of beneficial effect. Specifically, if 
confounding by indication is such that treated patients would have a worse clinical outcome than 
untreated patients, yet the outcome observed in treated patients is better than that observed in 
untreated patients, some degree of confidence that the drug has a beneficial effect can be built.154   
Moreover, some potential solutions to prevent or control confounding by indication should be 
considered (see section 1.5.3 for potential solutions) in non-experimental studies.     
Moreover, when effect modification (or interaction) exists, the stratum-specific effect 
provides more information than the overall adjusted results.  Effect modification indicates a 
variation in the drug effect, according to different levels of a third variable.  Consequences of 
this may lead to changes in prescribing practice or a better understanding of mechanisms.140  For 
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example, different dosage and potency are likely to have different effects that should be 
presented in the analysis.  Reducing the information related to drug exposure into an exposed 
versus non-exposed group increases the possibility of misclassification, biasing the results 
towards the null.  It is important in pharmacoepidemiology to consider differences in drug dose 
and potency in studying drug effects. 
1.5.3 Available Solutions to the Confounding 
The solutions available to minimize confounding in pharmacoepidemiologic can be broadly 
categorized into: (1) approaches that collect more information on potential confounders and 
apply efficient sampling designs to reduce the time and resources it takes to complete the study, 
and (2) analytic approaches that try to make better use of the existing data with the goal of 
improved control of confounding.49  Strategies to adjust confounding (at the design and/or 
analysis levels) in non-experimental studies vary depending on several aspects, especially on 
whether the potential confounders can be measured in a given study.158  At the design stage, 
matching and restriction can be used to control for measured confounders, and crossover design 
and active comparative group can be used to control for unmeasured confounders.  Several 
“analytic” methods can be used to overcome the confounding including standardization, 
stratification, multivariate analysis, propensity scores,  marginal structural models, two-stage 
sampling, external adjustment, sensitivity analysis, and instrumental variable approach.159 Each 
of them will be described briefly and subsequently.  
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1.5.3.1 Control for Measured Confounders at the Design Stage 
Restriction and matching have in common that they can only adjust factors that are measured and 
are then used either to restrict the study population or to identify strata of patients that are 
homogeneous with regard to the risk of study outcome.  Briefly, restriction allows the 
investigators to examine one stratum of the confounding variable, which effectively removes the 
effect of the confounder on the outcome.  For example, if age is a confounder, then investigators 
can restrict the study population to older adults.  Similarly, matching removes the effects of the 
confounder by forcing its distribution to be identical between groups of comparison.160  
Matching is commonly used in case-control studies.  Common matching factors are age, race, 
sex, socioeconomic status and occupation.  Matching may be of two types: (1) group match (or 
frequency matching) and (2) individual matching.  Group matching consists of selecting the 
controls in a manner that the proportion of controls with a certain characteristics is identical to 
the proportion of cases with the same characteristic (e.g., 25% married).  This type of matching 
generally requires that all of the cases be selected first.  For individual matching, for each case 
selected, a control is selected who is similar to the case in terms of specific variable(s).44  It 
limits the generalizability to other populations if one chooses many variables to restrict study 
participants.  Similarly, the more variables that one chooses to match, the more difficult it will be 
to find a suitable control.  Once restriction or matching is used, one cannot study that 
characteristic.44   
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1.5.3.2 Control for Measured Confounders at the Analysis Stage 
Under the assumptions of no unmeasured confounding, usual strategies for controlling 
confounding can be applied at the analysis stage including standardization, stratification, 
multivariate modeling and marginal structural models.     
Standardization is often used for comparing vital statistics from populations that have 
different age or sex distribution.  A standardized rate is a weighted average of stratum-specific 
rates.  There are two methods of standardization: direct and indirect.  The factors that can be 
managed by standardization are limited (two to three at most).  Use of standardization in 
pharmacoepidemiology is limited since pharmacoepidemiologic research usually requires the 
manipulation more than three factors.140    
Stratification uses confounding factors to identify strata of patients that are homogenous 
with regard to the risk for the outcome.  The limitation of stratification is that each time a new 
factor is added, stratum-specific cell sizes become smaller, and the probability of having people 
not exposed or not sick in each stratum becomes larger.  The stratum specific estimate of the 
measure of association cannot then be computed or provide any statistical information due to a 
lack of power.140   
Multivariate modeling allows many factors to be adjusted at the same time in a 
mathematical model and is the most common technique used to adjust for confounding.  The 
estimate represents the individual contribution of each factor for the risk of the outcome, 
adjusted for all other factors.  In order to maintain reasonably stable estimates of parameters,  
there are general rules of thumb for ensuring an optimal sample size: approximately 10 
observations are required per factor in a multiple regression model where the outcome is 
continuous, and approximately 10 events per factor for logistic regression models where the 
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outcome is binary.161  In addition, the most frequently applied empirical assessment of 
confounding includes comparing changes in the estimate of the drug-outcome association as a 
function of increasing adjustment until the incremental change in estimate becomes small (i.e., a 
change of less than 10% was suggested as a cut-off point).162  Hence, while multivariate analysis 
provides a more efficient tool of controlling for several confounders simultaneously, the 
adequacy of the data in meeting these requirement and assumptions required for each model 
must be examined. 
The above methods, however, are constrained to a limited number of covariates (or 
limited number of covariates per outcome).  In an effort to overcome this limitation, the 
exposure propensity score (or propensity score, PS) analyses, developed by Rosenbaum and 
Rubin, have become a widespread tool to combine information from various confounding factors 
into a single variable in many research fields.107,108  This approach is useful when many 
confounders or rare outcomes exist in pharmacoepidemiologic studies (especially in automated 
databases).  A PS is the probability (or propensity) that an individual would be treated given their 
individual measured covariates.  It can be estimated by using multivariate logistic regression 
model where the dependent variable is drug exposure, and the independent variables are 
covariates related to drug exposure.  
Each participant is assigned an estimated probability of drug exposure ranging from 0 to 
1 that reflects the probability of being prescribed a given drug, given all measured confounders.  
The probability of being prescribed a drug or assigned a treatment is dependent only on the PS 
covariates otherwise treatment assignment is random.  The 3 techniques most commonly used to 
control for confounding based on the PS are: (1) as a matching factor prior to analysis (e.g., 
Greedy matching technique),163 (2) stratification on the PS during analysis (e.g., use quintiles of 
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the PS of the entire study population),164 or (3) as a covariate in multivariate analyses.165  The 
use of propensity score-based weighting (e.g., inverse-probability-of-treatment weighted 
estimator or standardized mortality/morbidity ratio weight) has also been proposed.166,167  Figure 
2 summarizes the methodological approach to building the propensity score.  All methods have 
advantages and disadvantages and also involve different underlying assumptions that have to be 
considered.  The PS method has extended uses in estimating treatment effects conditional on 
pretreatment variables in a way that treatment can be continuous, ordinal or discrete, and in case-
cohort studies as well.168  The PS method’s advantages including the ability to deal with many 
covariates, frequent exposures, or rare outcomes (to avoid the risk of over-fitting in the model) in 
the automated databases, and offer increased feasibility compared to RCTs in situations where  
ethical or cost concerns are relevant.169  By using the PS method, the effects of all of the 
prognostic covariates used in estimating the treatment effect are removed from the estimation of 
treatment effect, thus reducing the bias.  However, the analysis of drug exposure-outcome 
association may lack transparency because a number of covariates are bundled into one 
propensity score.   It also has been postulated that, if a variable is more of a risk factor for an 
outcome than it is a predictor of treatment, confounding might be better controlled by inclusion 
of the variable as an individual confounder of the outcome rather than in the PS model.170  
Further, PS methods only have advantages when there are seven or fewer outcome events per 
confounder. When there are eight or more outcome events per confounder, logistic regression 
represents a preferable approach.171  Another limitation of using a PS approach is that residual 
confounding cannot be excluded when unmeasured or imperfectly measured confounders exist in 
the databases.  
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Figure 2. Approach to Build the Propensity Score 
 
 
The techniques discussed above may be inadequate in longitudinal observational studies 
when more complex biases are present, such as when exposure is time-dependent and time-
varying confounders are present.  A time-varying confounder is a variable affected by prior 
exposure that predicts both subsequent outcome and subsequent exposure.  One solution to this 
problem is to employ a more complex analytical approach that incorporates prediction of 
treatment as well as censoring in specific time intervals.  Robins et al.  developed a new model 
called marginal structural models.166  Marginal structural models use inverse-probability of 
exposure weights to create an artificial population in which covariate imbalances are removed 
and causal effects can be accurately estimated.172  With respect to the PS approach, the marginal 
structural model is an extension of the inverse-probability of treatment weighted estimator.  
Stabilized inverse-probability weights and the mean of the stabilized inverse-probability close to 
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one can be used to evaluate whether the marginal structural model performs appropriately.172   
Stabilized inverse-probability weights with a mean far from one may indicate a violation of some 
of the hypotheses of the model (e.g., a misspecification of the weight model or a violation of the 
positivity assumption).172,173 Compared with the standard errors in the conventional models, 
marginal structural models increase the median standard error of the estimates nearly 20% while 
controlling for time-varying confounding.172 This increase in standard error is a trade-off 
between bias and precision. 173  Marginal structural models can be used in observational studies 
with time-varying confounding, as well as in RCTs if the study is randomized at baseline but 
post-baseline changes in treatment are not randomized.172       
1.5.3.3 Unmeasured Confounders that Can be Measured in A Validation Study 
If confounders that are unmeasurable in the main study but measurable in validation sub-studies, 
two-stage sampling or external adjustment may be considered.  Two-stage sampling designs 
rely on an internal validation study to collect information on covariates that were not measured 
in the main study.140  In stage one, information is collected on drug exposure and disease 
outcomes for the entire cohort (main study) such as a large automated database.  To use the 
resource optimally, in stage two, a subgroup of the main study will be sampled and contacted, 
and detailed information will then be obtained.  Regression coefficients and standard errors will 
then be weighted for multivariate analysis according to the specific sampling fraction.174  The 
balanced design, wherein an equal number of individuals in each cell of the second stage’s 2×2 
table, is usually the most efficient strategy compared to random and disease- or drug-exposure-
based sampling.175  This strategy decreases the occurrence of small cells (which are responsible 
for large variance) by forcing an over-representation of individuals who belong to small groups 
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in the drug-disease cross classification.140  Interaction can also be evaluated in the two-stage 
sampling.  Two-stage sampling designs can be valuable tools to adjust for unmeasured 
confounders if access to individual patients is possible in the automated databases in 
pharmacoepidemiology.158  However, two-stage sampling can be time-consuming to identify a 
subgroup and can lead to additional data collection.   
If internal validation studies are not feasible or too costly, external adjustment (i.e., 
using external data sources) can be used under certain assumptions (e.g., similar characteristics 
of participants in the main and external datasets).  For example, the Medicare Current 
Beneficiary Survey studies a representative sample of Medicare beneficiaries to measure a wide 
variety of characteristics (e.g., limitations of daily living activities, cognitive impairment) that 
are not captured in Medicare claims data.  Traditionally, these external variables can be further 
added as additional confounders in the model. A new technique of propensity score calibration 
was developed to apply in external adjustments.  The error component of the PS in the validation 
study is then quantified and can be used to correct the PS in the main study, using established 
regression calibration techniques.176  The advantage of PS calibration is that it implicitly takes 
into account the joint effect of unmeasured confounders, as well as the relation between 
measured and unmeasured confounders.158   
1.5.3.4 Control for Unmeasured Confounders at the Design Stage 
If residual confounding by unmeasured factors is suspected and unmeasured confounders are 
truly unmeasured because of technical difficulties or factors were unknown to the investigators, 
strategies to adjust unmeasured confounding including application of an active comparison 
group and/or crossover study designs (see section 1.2.7 for details) at the design stage.   
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Active (or competing) comparator design can be seen as a special type of restriction 
because the choice of a comparator group is restricted to patients with similar indications.  When 
comparing the effects of two active therapies that are prescribed under the assumption of similar 
effectiveness and safety, it is less likely that predictors of the outcome are imbalanced and will 
cause confounding.158  For example, two similar selective COX-2 inhibitors, rofecoxib and 
celecoxib, were likely to be equally prescribed to patients at risk for cardiovascular events, so 
that an increased risk of myocardial infarction associated with one compared with the other is 
unlikely to be attributable to confounding by indication.177  The measurement of association 
while using active comparative group design is “relative excess risk” as a comparative relative 
risk adjusted for the baseline risk, or “absolute excess risks”.158,178    
1.5.3.5 Control for Unmeasured Confounders at the Analysis Stage 
Proxy adjustment, instrumental variable and/or sensitivity analysis can be used to control for 
unmeasured confounders at the analysis stage.  Proxy adjustment refers to adjusting for a 
surrogate of an unmeasured factor is equivalent to adjusting for the factor itself.  For example, 
older age serves as a proxy for many factors, including co-morbidity, frailty, and cognitive 
decline.  Further, having regular annual check-ups is indicative of a health-seeking lifestyle and 
is likely to be a proxy for increased overall treatment adherence.49 The number of prescription 
drugs dispensed, the number of physician visits, and hospitalizations before the index drug 
exposure are frequently used proxies in pharmacoepidemiology.  If many proxies are identified, 
they can then be adjusted for in a large PS model.  Collinearity may likely occur but is irrelevant, 
as the individual parameters estimated in the large PS regression will not be interpreted but only 
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used for predicting treatment.179  However, it is challenging empirically to know with enough 
certainty whether a variable is a proxy confounder or an instrument. 
 By adjusting for an instrument variable, the indication for treatment may be controlled 
for under the following assumptions that an instrumental variable is: (1) causally related to the 
treatment, (2) weakly associated or not associated with any potential confounder, and (3) not 
associated with the outcome other than through the treatment.154  Thus, an instrument is an 
external factor that influences an outcome only through its effect on treatment.  However, it is 
extremely challenging to find good instruments for studying the effectiveness and safety of drugs.  
In addition, instruments used in healthcare services research are often only weakly associated 
with the actual treatment, which leads to imprecise estimates and requires large sample sizes.  
Adjusting for an instrumental variable is useful when the choice of medication used is influenced 
more by prescriber preference than patient risk factors (i.e., there is exposure variation between 
providers).  This can be further adjusted for measured patient or physician characteristics.158  
Some instruments used in pharmacoepidemiology include regulatory or coverage interventions 
and provider treatment preference (e.g., distance to specialist provider, physician prescribing 
preference, regional treatment preference, hospital formulary, surgeon treatment preference, 
medication co-payment level, and dialysis preference level).49  For example, strong prescriber 
preference was observed among patients starting NSAID therapy either with non-selective 
NSAIDs or COX-2 inhibitors.  An instrumental variable can be used such as grouping physicians 
into those who always initially prescribed non-selective NSAIDs (instrumental variable=0) and 
those who always started with prescribing COX-2 –selective NSAIDs (instrumental 
variable=1).180 
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 Sensitivity analysis, defined as a quantitative analysis of the potential for systematic 
error, is a more formal approach used to communicate this uncertainty with respect to the 
validity of findings (i.e., how robust study findings are to implicit and explicit assumptions).140  
In other words, sensitivity analyses make informed assumptions about potential residual 
confounding and calculate its effect on the risk estimate of the drug-outcome association. 
Existing approaches include an array approach which is helpful to explore the effect of residual 
confounding over a wide range of parameter constellations,181 and a rule-out approach to assess 
how much confounding would have to be present to fully explain the observed findings (i.e., 
observed point estimate would move to the null).182  The details and calculations of these two 
approaches are beyond the scope of this review, however, we can easily perform these sensitivity 
analyses using a spreadsheet program available at http://www.drugepi.org/dope-downloads/.181   
Sensitivity analysis not only brings to the forefront the important issues related to the validity of 
results but it is also provides a means for presenting objective evidence that may be used by 
readers to evaluate the magnitude of the threat to validity and give them a sense of confidence in 
the study results.  In addition, it can provide direction for future research by serving in a 
hypothesis-generating manner.  Sensitivity analysis is limited to one binary confounder, which 
may not be helpful if several confounders are unmeasured and the joint effect of such 
confounders is unknown. 
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1.5.4 Healthy-User Effect and Related Confounding and Biases in Observational Studies 
of Preventive Interventions 
Because numerous high-profile observational studies of the effect of prevention on health 
outcomes reported exaggerated relationships that were later contradicted by RCTs recently, a 
growing body of research identifies sources of bias and confounding in observational studies that 
are related to patient behaviors or underlying patient characteristics, known as the healthy user 
effect, the healthy adherer effect, confounding by functional status or cognitive impairment, 
and confounding by selective prescribing.183  These special confounding and biases resulting 
from patient-level tendencies to engage in healthy behaviors or physician’s perceptions of the 
health of patients, and potential solutions will be described specifically and briefly in this section. 
The healthy user effect is described as patients who receive preventive therapies or tests 
are more likely to seek other preventive service or partake in other healthy behavior (e.g., healthy 
diet, exercise, or avoid tobacco).184  An observational study evaluating the effect of a preventive 
therapy (e.g., hormone replacement therapy) on a related outcome (e.g., cardiovascular disease) 
without adjusting for other related preventive behaviors will tend to overstate the effect of the 
preventive therapy under study.   Similarly, the healthy adherer effect arises when patients who 
adhere to preventive tests or therapies are more likely to pursue health-seeking behaviors than 
their non-adherent counterparts.183  For example, in a study of elderly patients initiating statins, 
patients who filled ≥ 2 statin prescriptions during a 1-year ascertainment period were more likely 
than patients who filled only one prescription to receive prostate-specific antigen tests, fecal 
occult blood tests, screening mammograms, influenza vaccinations, and pneumococcal 
vaccinations during follow-up.185  In addition, confounding by functional status or cognitive 
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impairment refers to poor functional or cognitive status limits some patients’ interest in, or 
ability to visit, their physician.183  Studies do not account for functional status or cognitive 
impairment will overstate the effect of a preventive therapy.  For example, Jackson LA et al. 
found that elderly women with higher levels of functional impairment had significantly lower 
rates of breast and cervical cancer screening.186  Confounding by selective prescribing refers to 
physicians are less likely to prescribe preventive treatments patients who are frail, have terminal, 
or acute illness (both in the inpatient and outpatient settings).187 For example, patients with 
terminal cancer or end-stage renal disease, may be less likely to receive or more likely to 
discontinue a preventive therapy.  Failing to account for selective prescribing that correlate with 
the health of patients will lead to overestimation of the benefits of a preventive therapy.   
Several approaches can be used to minimize these bias and confounders, and affirm the 
validity of the results in pharmacoepidemiology.  The approaches include: (1) using new user 
designs; (2) restricting the study population to subjects who are similar in having similar patterns 
of the use of preventive tests or therapies; (3) using an intention-to-treat analysis; (4) using an 
active comparator (i.e., another preventive therapy); (5) adjusting for functional status, cognitive 
impairment, frailty, or disease severity; (6) identifying proxies for further adjustment (e.g., 
vaccines, mammography, colonoscopy, or medications for dementia); (7) adjusting for 
unmeasured confounders using propensity score or instrumental variables;  and (8) conducting 
sensitivity or secondary analyses (e.g., evaluating negative control outcomes events that should 
not be affected by the treatment under study, but may confound or bias the results).183  
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1.5.5 Summary  
A thorough understanding of the potential sources of bias and confounding in non-experimental 
studies is important to designing studies that minimize their influence on results.  Several 
strategies can be used to avoid major bias in pharmacoepidemiology including: (1) restricting the 
design to new (or incident) users, those without contraindications, and those who are adherent to 
prevent prevalent bias; (2) systematically identify and recruit all eligible cases to prevent self-
selection bias ; (3) applying “lag-time” (or an index date) to define drug exposure periods to 
prevent protopathic bias; (4) restricting the outcome of interest to more serious cases (instead of 
mild or subclinical diagnosis) to prevent referral bias; (5) selecting controls who are likely to 
have the same cognitive processes affecting memory of past drug exposures to prevent recall 
bias; (6) to prevent detection bias, blinding relevant study personnel, standardizing the 
measurement process, and/or obtaining information on the frequency of  access to medical care 
and health awareness by participants; (7) to prevent immortal-time bias, using nested case-
control or active comparative design, and time-dependent statistical methods to account for 
complex changes in drug exposure and time-varying confounders. 
Strategies used to control confounding in non-experimental studies in 
pharmacoepidemiology vary from whether confounders can be measured or not.  For measurable 
confounders, one can use restriction and/or matching (including matching by PS) at the design 
stage, or apply standardization, stratification, multivariate analysis (including PS adjustment), or 
marginal structural model at the analysis stage.  For confounders cannot be measured in the main 
study, but can be measured in a validation study, two –stage sampling or external adjustment can 
be used to control these confounders.  For confounders that are truly unmeasured, crossover 
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design or active comparative group can be used at the design stage.  Crossover design is usually 
used to evaluate the association between a transient exposure and acute event (e.g., vaccine 
safety).  In addition, proxy adjustment, instrumental variables, and/or sensitivity analysis may be 
potential approaches to control for unmeasured confounders at the analysis stage.  Beyond the 
above strategies and under a distinctive set of challenges and unique set of resources, 
pharmacoepidemiologists are developing and implementing innovative study designs and new 
analytic approaches in order to maximize the validity of results from non-experimental studies.   
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2.0  OBJECTIVES AND SPECIFIC AIMS 
The burdens of chronic diseases and functional disability increase with age.  Chronic diseases are 
costly health conditions which negatively affect quality of life, contributing to declines in 
functioning and the inability to remain in the community.188   Hypertension, cardiovascular 
disease (CVD), stroke, chronic lower respiratory disease, cancer, diabetes, arthritis, dementia, 
depression, and some infectious diseases are common health threats in the US population.188  The 
prevalence of multi-morbidity, referring to co-occurrence of several medical conditions within an 
individual, also increases with age.  CVD and cancer are the top two leading causes of death 
among all people age ≥ 65 years, irrespective of sex, race, or Hispanic origin.188  Prevention and 
control of hypertension, dyslipidemia, diabetes, cancer, and disability, are key strategies to 
promote health and well-being at all ages.   
While clinical risks associated with chronic disease are well-known, the use of 
medication and therapeutic risk-benefit balance are often under recognized.  Improved 
methodology in pharmacoepidemiologic research may extend new understanding of the 
medication use and enable one to evaluate the influence of the policy and evidence-based studies 
(e.g., guidelines), and the effectiveness or therapeutic risk-benefit balance of the treatments in 
“real-world” practices.  There is also growing interest in potential agents or medications to 
prevent or slow cancer development or progression.  The overall aim of this dissertation is to 
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apply pharmacoepidemiologic methodology to examine medication utilization, therapeutic risk-
benefit balance in older adults and evaluate potential chemopreventive agents for ovarian cancer 
prevention. 
Specific Aims: 
Aim 1: The aim of the first study is to examine whether utilization patterns of cholesterol-
lowering medications in community-dwelling older adults changed following the release of the 
National Cholesterol Education Program Adult Treatment Panel III guidelines and results from 
the Prospective Study of Pravastatin in the Elderly at Risk in 2002, using the data from Health, 
Aging and Body Composition (Health ABC) study.  
Aim 2: The aim of the second study is to examine whether the use of statins is associated with a 
decreased risk of gait speed declines of 0.05 m/s or more and 0.1 m/s or more per year in 
community-dwelling older adults in the Health ABC study.   
Aim 3: The aim of the third study is to evaluate the associations of aspirin, NA-NSAIDs, or 
acetaminophen use with the risk of incident ovarian cancer, using the data from Hormones and 
Ovarian Cancer Prediction (HOPE) study, the second-largest population-based case-control 
study on ovarian cancer in the US. 
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3.1 ABSTRACT 
Background: The impact of evidence-based guidelines and controlled trial data on use of 
cholesterol-lowering medications in older adults is unclear.  
Objective:  To examine whether utilization patterns of cholesterol-lowering medications in 
community-dwelling older adults changed following the release of the National Cholesterol 
Education Program Adult Treatment Panel III guidelines and results from the Prospective Study 
of Pravastatin in the Elderly at Risk in 2002.    
Methods: Community dwelling older adults who were enrolled in the Health, Aging and Body 
Composition Study in 1997-1998 were followed for up to 11 years.  An interrupted time-series 
analysis with multivariable generalized estimating equations (GEE) was used to examine level 
and trend changes in cholesterol-lowering medication use before and after 2002, adjusting for 
sociodemographics, health-related behaviors and health status. 
Results:  Cholesterol-lowering medication use increased nearly 3-fold from 14.9% in 1997-1998 
to 42.6% in 2007-2008, with statins representing the most common class used (87%-94%).  
Multivariable GEE results revealed no difference in the level of cholesterol-lowering medication 
use after 2002 (adjusted odds ratio: 0.95, 95% confidence interval [CI] 0.89-1.02).  Multivariable 
GEE results revealed trends changes in the rate of increase in cholesterol-lowering medication 
declined after 2002 (adjusted ratio of odds ratios 0.92, 95% CI 0.89-0.95). 
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Conclusions:  The use of cholesterol-lowering medication increased substantially over a decade 
in community dwelling elders, but was not related to a change in level or trend following the 
release of the guidelines and evidence-based data. 
                                                        3.2 INTRODUCTION 
3.2.1 Epidemiology of Cardiovascular Disease and Dyslipidemia in the Elderly 
Cardiovascular disease remains the leading cause of death and disability among the elderly in the 
US, with the average age of first myocardial infarction being 65 years for men and 70 years for 
women.1  Approximately 60% of hospital admissions for acute myocardial infarction and 81% of 
coronary heart disease (CHD) mortality are in people aged ≥ 65 years.1, 2   Although 
cardiovascular disease remains the leading cause of death and disability among the elderly in the 
US, the incidence of coronary heart disease (CHD) and associated mortality actually declined by 
approximately 25% from 1997 to 2007.1-3   This decline may be due to improved medical care 
and use of evidence-based preventive medications, including cholesterol-lowering therapy.3, 4  
With regard to further reducing the burden of CHD morbidity and mortality, the emphasis 
is on the treatment of acute events and secondary or primary prevention through treatment and 
control of risk factors.  A meta-analysis of individual data from 61 prospective studies reaffirmed 
that higher total cholesterol, non-high-density lipoprotein cholesterol (non-HDL-C) and lower 
high-density lipoprotein cholesterol (HDL-C) are associated with higher risk of CHD mortality 
in both men and women in different age groups.5  Although the relative risk for CHD mortality 
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associated with high total cholesterol or low HDL-C decreases with advancing age, this lower 
relative risk is offset by the greater absolute and attributable risk for CHD in the elderly.6 
From the National Health and Nutrition Examination Survey (NHANES) years 1999 – 
2004 (n=3,810 aged ≥ 65 years),7 women had a higher prevalence of hypertension than men 
(77% vs. 63%, p ≤ 0.001), a similar rate (76%) of awareness of hypertension, and a lower rate of 
control on treatment (43% vs. 58%, p ≤ 0.001).  Diabetes affected approximately 22% of older 
males and females.  Women had a higher rate of awareness of diabetes than men (79% vs. 64%, 
p ≤ 0.01).  About 50% prevalent diabetic older males and females were treated 
pharmacologically and goal attainment among those treated with diabetes was 50%.  Overall, 
dyslipidemia prevalence was 60% (men: 62% vs. women: 59%).  Men were less likely to be 
aware of their dyslipidemia than women (59% vs. 71%, p ≤ 0.001), although both genders were 
equally likely to be treated (41% vs. 45%).  Compared to those aged of 65-74 years, those aged ≥ 
85 years had a lower prevalence of dyslipidemia (64% vs. 46%, p ≤ 0.001), a lower rate of 
awareness of dyslipidemia (68% vs. 39%, p ≤ 0.001), had a lower treatment rate (45% vs. 24%, p 
≤ 0.001).  Sixty-five percent of the older male and female medically treated for dyslipidemia 
reached their LDL cholesterol goal.   Age of 85 years and above was negatively associated with 
awareness and treatment of dyslipidemia.  Low annual household income (< $15,000 in 2002 
dollars) was negatively associated with awareness and controlled on treatment of dyslipidemia.  
Female, higher education, and more doctor visits in the past year were positively and strongly 
associated with awareness, treatment of dyslipidemia. 
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3.2.2 Drugs for Lipid Lowering Therapy 
The treatment of dyslipidemia may require two approaches, therapeutic lifestyle changes and 
medications.  In the cases that cholesterol levels cannot reduced effectively by dietary 
modification and increased physical activity, or for persons with other risk factors of CHD, the 
use of cholesterol-lowering medications is recommended.8  There are several classes of 
cholesterol-lowering drugs, but statins (or HMG-CoA reductase inhibitors) are the drug class of 
choice because of their demonstrated safety and efficacy in lowering LDL-C and reduction in 
cardiovascular mortality.  Other available cholesterol-lowering medications including bile acid 
sequestrants (colesevelam, colestipol, cholestyramine), cholesterol absorption inhibitor 
(ezetimibe), fibrates (gemfibrozil, fenofibrate, fenofibric acid), niacin, and fish oil capsules, may 
be required in patients who are statin-intolerant, have mixed dyslipidemia, or in whom standard 
doses of statins may not be sufficient to achieve LDL-C goals.9 
3.2.3 Statin Therapy for Secondary Prevention of Cardiovascular Disease in the Elderly 
Recommendations for the detection and control of hypercholesterolemia for adults have been 
offered since 1988 (Table 6), by the National Cholesterol Education Program (NCEP) Adult 
Treatment Panel (ATP).8, 10-12  Results from several meta-analyses13-15 and subgroup analyses of 
randomized clinical trials (RCTs)16-26 show that statins have benefits of lowering the risk of all-
cause mortality and CHD mortality, reduce cardiovascular events, stroke, and the need for 
revascularization among patients (aged 60-82) with established CHD.  In a meta-analysis of data 
from 90,056 patients in 14 RCTs (47% of patients had pre-existing CHD), statins reduced the 
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risk of major coronary events similarly among those aged < 65 years and ≥ 65 years (22% vs. 
19%).13  In another meta-analysis of 18 RCTs (n=51,351) conducted by Robert et al,14 62% of 
the participants were aged ≥ 60 and 12% were aged ≥ 70 years.  Statins reduced risk of all-cause 
mortality and CHD mortality by 15% for those aged ≥ 60 and 23% for those aged ≥ 70 years, 
respectively.  Afilalo et al. conducted a meta-analysis from the individual data of nine RCTs 
(four were unpublished data), in which 19,569 participants were aged 65 to 82.15  Statins reduced 
risks of all-cause mortality by 22%, CHD mortality by 30%, nonfatal MI by 26%, need for 
revascularization by 30% and stroke by 25%. 
Table 6. NCEP ATP Guidelines Recommended Drug Therapy According to LDL-C Levels 
NCEP 
Guidelines (first 
published year) 
Risk groups LDL-C levels 
(mg/dL) to 
initiate drug 
therapy 
Minimal Goals 
of LDL-C levels 
(mg/dL) if under 
drug treatment 
ATP I (1988)11 With CHD or ≥ 2 risk factora ≥ 160 < 130 
Without CHD and with < 2 risk factorsa ≥ 190  < 160 
ATP II (1993)12 With CHD ≥ 130 < 100 
Without CHD and ≥ 2 risk factorsb ≥ 160 < 130 
Without CHD and with < 2 risk 
factorsb 
≥ 190 < 160 
ATP III (2002)9 High risk: with CHD or CHD risk 
equivalentc (10-year risk > 20%) 
≥ 100 < 100 (optimal 
<70) 
Moderate-high risk: ≥ 2 risk factorsd 
(10-year risk of 10-20%) 
≥ 130 < 130 
Moderate risk: < 2 risk factorsd  
(10-year risk < 10%) 
≥ 160 <130 
Low risk: 0-1 risk factor d ≥ 190 < 160 
Abbreviations: CHD: coronary heart disease; HDL-C: high-density lipoprotein cholesterol ; LDL-C: low-density lipoprotein cholesterol; NCEP 
ATP: National Cholesterol Education Panel Adult Treatment Panel 
a: Risk factors include male sex, family history of premature CHD, cigarette smoking, hypertension, low levels of HDL cholesterol (<35 mg/dL), 
diabetes, definite cerebrovascular or peripheral vascular disease, or severe obesity; 
b: Positive Risk factors include age (men ≥ 45 years and women ≥ 55 years), family history of premature CHD, current cigarette smoking, 
hypertension, low levels of HDL-C (<35 mg/dL), diabetes.  Negative risk factors include high HDL-C (≥ 60 mg/dL). 
c: CHD risk equivalents include clinical manifestations of non-coronary forms of atherosclerotic disease (peripheral arterial disease, abdominal 
aortic aneurysm, and carotid artery disease, transient ischemic attacks or stroke of carotid origin or >50% obstruction of a carotid artery), diabetes, 
and 2+risk factors with 10-year risk for hard CHD 20%. 
d: Risk factors include cigarette smoking, hypertension, low HDL cholesterol (<40 mg/dL), family history of premature CHD (CHD in male first-
degree relative <55 years of age; CHD in female first-degree relative <65 years of age), and age (men ≥ 45 years; women ≥ 55 years). 
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3.2.4 Statin Therapy for Primary Prevention of Cardiovascular Disease in the Elderly 
Limited data are available for elderly patients without CHD.27  Other subgroup analysis from the 
RCTs suggested that statins reduced the incidence of major cardiovascular events in both those 
aged < 65 and ≥ 65 years, without known CHD, regardless their baseline cholesterol levels.20, 28-
33  This shifted primary prevention toward an emphasis on the consideration of the patient’s 
global risk for CHD rather than focusing only on lipid levels when determining those who would 
benefit from primary prevention.  
3.2.5 Lipid-Lowering with Non-Statin Drugs in the Elderly 
Except fibrates, little evidence shows that other lipid-lowering medications have benefits to 
reduce CHD risk in older adults.  Only three RCTs of non-statin drugs were for primary 
prevention of CHD,34-36  but none of them enrolled participants aged > 75 years.  The studies of 
other lipid-lowering medications mainly focused on the efficacy and safety in lowering 
cholesterols in older adults.  No differences in safety and efficacy of colesevelam, ezetimibe, and 
niacin were observed between those aged < 65 years and ≥ 65 years.37-39  
The results from the RCTs of fibrates in older adults are mixed in reducing the risk of 
cardiovascular disease.  Of 2,531 men with CHD, HDL-C ≤ 40 mg/dL and LDL-C ≤ 140 mg/dL 
in Veterans Affairs High Density Lipoprotein Intervention Trial (VA-HIT),40 the mean age of 
participants was 64 years (50% were aged ≥ 66 years).  After one-year treatment, Gemfibrozil 
significantly reduced the risk of the composite outcomes (CHD death, nonfatal myocardial 
infarction, or stroke) by 24%, compared to placebos.   Risk reductions were similar between 
98 
 
those aged < 66 years (26%) and those aged ≥ 66 years (22%).  The Fenofibrates Intervention 
and Event Lowering in Diabetes  (FIELD) study did not show an overall decrease in CHD events 
with fenofibrate in diabetic patients aged 50–75 years (with or without CHD), but did reduce 
total cardiovascular events (the composite of CVD death, myocardial infarction, stroke and 
coronary and carotid revascularization).35  However, a subgroup analysis by age showed a 
significant decrease in total cardiovascular events in those aged < 65 years, but not in patients 
aged ≥ 65 years.  
3.2.6 Significance of Current Study 
In 2002, NCEP ATP III guidelines were published and for the first time strongly recommended 
the use of statins for older persons with established CHD or at high risk for developing CHD 
(e.g., diabetes mellitus).8  These recommendations were based in part upon the results from the 
subgroup analysis of several previous trials with statins,15-18, 20 and the 2002 Prospective Study of 
Pravastatin in the Elderly at Risk (PROSPER).19  Conclusively extrapolating the results from 
subgroup analysis to all older adults was controversial, in part because most of these trials had 
defined an upper age limit (70-75 years of age) that favored the inclusion of only “younger” 
older adults.16-18  The 2002 Medical Research Council/British Heart Foundation Heart Protection 
Study (HPS) included an appropriate proportion (28%) of participants aged ≥ 70 years.20  Among 
1,263 individuals aged 75 to 80 years at baseline, the rate of major coronary events was 
significantly lower in the statin group than placebo group.20  The PROSPER is the only trial 
focused on an exclusively elderly cohort involving 5804 older men and women (aged 70 to 82 
years).19  They found that that the risk of CHD death, or non-fatal myocardial infarction was 
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significantly reduced in those with established CHD, but not in those receiving the drug for 
primary prevention (e.g., diabetes mellitus).19   
There is limited information about the use of cholesterol-lowering medications before 
and after 2002 in older adults aged ≥ 75 years.  From the National Health and Nutrition 
Examination Survey 1999-2002 to 2003-2006, cholesterol-lowering medication use significantly 
increased in older adults aged ≥ 60 years (46% vs. 57%), but no information was reported in 
those aged ≥ 60 years with CHD and/or with diabetes.41  Physician prescribing inertia despite 
clinical practice guidelines or evidence-based data may be due to lack of familiarity of the 
benefits of specific pharmacotherapy, or difficulty in balancing the impact on quality of life with 
patient’s comorbidities, functional status, life expectancy and preferences.42  In addition, these 
publications are somewhat inconsistent regarding the need for cholesterol-lowering medications 
in the elderly (e.g., those with diabetes but without CHD).8, 19, 43-46  To date, no formal 
assessment of the impact of these publications on use of cholesterol-lowering medications in the 
elderly has been undertaken.  Therefore this study compares the utilization patterns of 
cholesterol-lowering medications in community-dwelling older adults before and after the 
release of the NCEP ATP III guidelines and results from the PROSPER in 2002.  The Health, 
Aging and Body Composition Study, a cohort study enrolled the well-functioning elders aged ≥ 
70 years, provided a great opportunity to examine our research question. 
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                                                             3.3 METHODS 
3.3.1 Study Design, Sample, and Source of Data 
An interrupted time-series analysis was used to examine yearly level and slope (trend) changes in 
the utilization of cholesterol-lowering medications.47  A random sample of 3075 black and white 
men and women, aged 70-79, were recruited from Medicare beneficiaries residing in Pittsburgh, 
PA and Memphis, TN.48, 49  The baseline visit of the Health Aging and Body Composition Study 
occurred in 1997/1998 at which time  participants were aged 70 to 79 and reported no difficulty 
walking one-quarter of a mile (400 m), climbing 10 steps without resting, performing basic 
activities of daily living; no use of a cane, walker, crutches or other special equipment to 
ambulate. 48, 49  Twenty baseline participants were excluded because of missing medication 
information.   The study was approved by the Institutional Review Boards of the Universities of 
Pittsburgh and Tennessee, and written informed consent was obtained from each participant.  
3.3.2 Data Collection and Data Management 
The information collected annually during in-person visits by trained interviewers included 
blood samples, a battery of detailed physiological measurements and questionnaire material 
regarding sociodemographic characteristics, multiple aspects of health status, and medication 
use.48, 49  From the collected fasting blood samples obtained in 1997-1998, 2002-2003, 2004-
2005, 2007-2008, serum cholesterol, HDL-C and triglyceride values were determined by a 
colorimetric technique on a Vitros 950 analyzer (Johnson & Johnson, New Brunswick, NJ).  
101 
 
LDL-C was calculated using the Friedewald equation.50, 51  Both health and behavior factor and 
medication use data were used to define specific conditions of interest in this study (i.e., diabetes 
mellitus and hypertension).  Hypertension was defined by self-reported diagnosis of hypertension 
and use of anti-hypertensive medications.52  Diabetes was defined by self-reported diagnosis of 
diabetes or use of anti-diabetic medications.53  Several comorbidities examined in the current 
study (i.e., CHD, stroke, or peripheral artery disease [PAD]) were centrally adjudicated by a post 
hoc committee based on conclusive evidence from hospitalization or death records.48, 49  
For medications, at baseline (1997-1998), and annually for 10 years (except years 2000-
2001, 2003-2004, and 2005-2006), participants were asked to bring all prescription medications 
taken in the previous month.  Trained interviewers transcribed information from the medication 
containers on medication name, dosage form, and whether the medication was taken as needed.  
The medication data were coded using the Iowa Drug Information System and then entered into 
a computerized database.54  These methods of medication data collection are considered highly 
accurate and concordant with information contained in pharmacy claims data.55 
3.3.3 Outcome Variable: Cholesterol-Lowering Medication Use 
The dichotomous outcome variable was use of any cholesterol-lowering medication from any of 
two discrete classes: 1) statins, and 2) others (i.e., fibrates, bile acid binding resin agents, 
probucol, niacin, and cholesterol absorption inhibitors (i.e., ezetimibe)).  These two classes 
correspond to IDIS codes 24060009-24060404 and 88080004.54 
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3.3.4 Primary Independent Variable 
The independent variable for these analyses was time (i.e., baseline [1997-1998] and each 
follow-up year).  The year 2002 was the year in which the NCEP ATP III guidelines and the 
results of the PROSPER were released.  Therefore, two non-overlapping time segments were 
defined for the time series: 1997-2002 and 2003-2008. 
3.3.5 Covariates 
Several characteristics that could potentially confound or modify cholesterol-lowering 
medication use were adjusted for in the analysis, and were grouped into three domains: 1) 
sociodemographic, and 2) health-related behaviors and 3) health status.56-59  Sociodemographic 
factors that were characterized as categorical variables included race (black, white), sex, study 
site, education (postsecondary education, high school graduate, and less than high school 
graduate), and living status (alone, not alone).  Age was considered as a continuous variable.  A 
dichotomous time-varying variable for prescription drug coverage was also included to account 
for patients on and off insurance over the study period. 
Health-related behaviors were characterized as categorical variables for smoking status 
and alcohol use (current, past, or never).  Health status factors were characterized as 
dichotomous measures (present vs. absent) for self-reported health conditions, including 
congestive heart failure, kidney disease, pulmonary disease, and cancer.  A time-varying 
dichotomous variable was created for self-rated health (excellent/good vs. not excellent/good).  
A categorical variable for body mass index (BMI- underweight or normal [<25.0 kg/m2], 
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overweight [25.0–29.9 kg/m2], or obese [≥30.0 kg/m2] was created.60  The number of overall 
prescription medications (excluding cholesterol-lowering drugs) was included as a time-varying 
continuous variable as a proxy for comorbidity.61  Dichotomous variables were created for 
cognitive impairment (3MS < 80) and high depressive symptoms (Center for Epidemiologic 
Studies Depression Scale score >15).62, 63  Interviewers were trained with the standard manual of 
operation and certificated for all the clinical assessments (e.g., 3MS test).64 
3.3.6 Main Statistical Analyses 
All analyses were performed using SAS® version 9.3 (SAS Institute Inc. Cary, NC).  
Appropriate descriptive statistics (mean, standard deviation, frequency and percentage) were 
employed to summarize participant characteristics and main analytic variables.  For descriptive 
purposes, we also reported the prevalence of fibrate and ezetimibe use separately from other non-
statin agents because fibrates were the second commonly used cholesterol lowering medications 
and ezetimibe was introduced to the market in 2002.41  We conducted a multivariable interrupted 
time-series analysis (using generalized estimating equations [GEE]) to estimate changes in the 
level and the slope (trend) of the outcome rates after 2002.47, 65  This analysis used the SAS® 
GENMOD procedure with an autoregressive working correlation structure to account for 
potential multiple years of data from the same participants and the resulting stochastic non-
independence of observations.47, 65  Specifically, level changes were calculated by comparing the 
predicted prevalence use in the year 2002-2003, which was extrapolated from the slope of the 
time series 1997-2002, with the observed prevalence use in the year 2002-2003.  The level 
changes were calculated as an adjusted odds ratio (OR) and 95 percent confidence interval (95% 
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CI).  An odds ratio greater than one for level changes would indicate that the 2002 publications 
did have an immediate impact on cholesterol-lowering medication use.  Slope or trend changes 
were calculated as the ratio of adjusted odds ratios and 95% CI.  This approach estimates the 
change in cholesterol-lowering medication use following 2002 publications controlling historical 
year-to-year changes prior to 2002 as well sociodemographic, health-related behaviors and health 
status factors.66  A ratio of adjusted odds ratios for slope or trend changes greater than one would 
indicate that the guidelines had an impact on yearly rate of increase in cholesterol-lowering 
medication use.  Both sociodemographic, health-related behaviors and health status factors were 
controlled for in these multivariable analyses.  
3.3.7 Sensitivity Analysis and Stratified Analysis 
A series of sensitivity analyses were conducted to better understand and assure the robustness of 
the main findings.  First, changes in utilization patterns of cholesterol-lowering medications were 
evaluated among four mutually exclusive subgroups using the definitions of risk factors based on 
the 2002 NCEP ATP III guidelines.8  The four subgroups were: 1) any CHD (including 
myocardial infarction, angina pectoris, surgical or percutaneous revascularization); 2) no CHD, 
diabetes only (CHD risk equivalent); 3) no CHD or diabetes, but either with PAD, stroke, or ≥ 2 
CHD risk factors (hypertension, current smoking, or low-levels of HDL-C [i.e., < 35 mg/dL]), 
and 4) no CHD or diabetes or PAD or stroke, and < 2 CHD risk factors.  Those with PAD (n=83) 
or stroke only (n=86) were considered into group 3 because of insufficient sample sizes for 
examining the impact of these conditions separately, and many of these elders had multiple 
comorbidities/risk factors.  The composition of each risk group changed over time as it gained 
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(or lost) participants who developed or acquired some risk factors (or died).  However, once 
participants were considered to have the comorbidities including CHD, diabetes, hypertension, 
PAD, and stroke, these conditions were considered permanently.  For the second sensitivity 
analyses, we replaced missing covariate values with those generated using the multiple 
imputation.67  Most demographic and health behavior/status covariates had complete 
information, and none had more than 5% with missing information.  The third sensitivity 
analysis was performed by restricting the analysis to only those with data for the entire 10 year 
time period.  The final sensitivity analyses used 2004-2005 as the index year to separate the pre- 
and post-guideline periods and allow for a potential lag effect from dissemination and physician 
awareness of the guidelines.  A year lag effect was selected because it may take at least 1 to 1.5 
years for physicians being informed about these publications through different sources.68, 69  
Finally, stratification analyses by sex, age and race were conducted to examine any differences in 
utilization patterns. 
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3.4 RESULTS 
The baseline characteristics are shown in Table 7 according to all participants.   Among 3055 
participants, mean age was 74 years, 52% were female, 41% were black, 30% lived alone, 62% 
had prescription medications coverage, 5% had severe depressive symptoms, and 10% had 
cognitive impairment.  Table 8 shows the prevalence of cholesterol-lowering medication use in 
the elderly from 1997-2008.  Overall, 14.9% of the elders took cholesterol-lowering drugs at 
baseline (1997-1998) with statins accounting for 87% of the overall rate.  The overall rate of 
cholesterol-lowering drugs use increased to 26.7% in 2001-2002 and to 42.6% by 2007/2008.  In 
particular, statin use increased to 24.9% in 2001-2002 and to 39.1% in 2007-2008.  The use of 
fibrates slightly increased from 1% in 1997-1998 to 2% in 2007-2008, and the use of bile acid 
sequestrants, probucol, and niacin remained the same over that 10 year time period (about 1.5%).  
The use of ezetimibe increased from 0.1% in 2002 when introduced to the market to 5% in 2007-
2008.   
Table 9 shows the results of the multivariable interrupted time-series analysis estimating 
changes in the level and the slope (trend) of cholesterol lower drug use rates after 2002.  There 
was no level change of any cholesterol-lowering medication use the year before compared with 
the year after 2002 (adjusted OR 0.95, 95% CI 0.89 to 1.02).  The multivariable results also 
revealed a decline in trend changes for the rate of increase in cholesterol-lowering medication 
after 2002 (adjusted ratio of odds ratios 0.92, 95% CI 0.89 to 0.95).  Similar results for lack of 
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change in level but changes in trend were seen for statin and other cholesterol lowering 
medications (Table 9).  
Sensitivity and Stratification Analyses 
At baseline, 18% had any history of CHD, 11% had diabetes only, 27% were in the group 
that had PAD, stroke or 2 or more risk factors, and 43% were in the group of less than 2 risk 
factors (Table 7).  The prevalence of cholesterol-lowering medication use in 1997-1998 was 
30.6% among those with any history of CHD; 11.8% among those with diabetes only; 14.0% for 
those who had PAD, stroke, or 2 or more risk factors; and 9.7% for those with no CHD, DM, 
PAD or stroke and less than 2 risk factors  (Figure 3).  For these same groups, the percentage of 
elderly patients who took cholesterol-lowering medications in 2001-2002 was 49.9%, 30.1%, 
24.0% and 14.6%, respectively, and 68.8%, 46.1%, 35.4%, and 26.6%, respectively took 
cholesterol-lowering medications in 2007-2008.  A similar pattern was seen with statins for each 
of the four groups.  Similar findings were also seen for level and trend changes as noted for the 
overall sample (data not shown).  None of the additional sensitivity analyses appreciably 
changed our main findings (data not shown).  Females were less likely than males to take any 
cholesterol-lowering medications (females vs. males: 15.1% vs. 14.8% in 1997-1998; 24.5% vs. 
29.2% in 2001-2002; and 37.4% vs. 48.9% in 2007-2008, respectively).  Older adults aged ≥ 75 
years were less likely than those aged < 75 years to take any cholesterol-lowering medications 
(aged ≥ 75 vs. age < 75 years: 13.7% vs. 15.8% in 1997-1998; 24.6% vs. 27.9% in 2001-2002; 
and 41.2% vs. 43.3% in 2007-2008, respectively).  Blacks were less likely than whites to take 
any cholesterol-lowering medications (whites vs. blacks: 17.2% vs. 11.8% in 1997-1998; 30.2% 
vs. 21.2% in 2001-2002; and 45.7% vs. 36.8% in 2007-2008, respectively).  Similar findings 
were also seen by sex, age, and race for level and trend changes (data not shown). 
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3.5 DISCUSSION 
Our study found that the use of cholesterol-lowering medications in the elderly nearly tripled 
during the period of 1997-2008 (14.9% to 42.6%).  Moreover, as one might expect given their 
greater ability to reduce LDL-C, statins were the most common drug class used.  These findings 
are consistent with that reported by other studies.41, 59, 70-72  It was interesting to find that only half 
of those with known CHD and/or diabetes received any cholesterol lowering agent.  It is difficult 
to determine if this represents under use of an important medication for secondary prevention as 
shown in other studies,73-75 or rational omission since published data is only valid for those up to 
82 years of age,19, 76 and the mean age of Health ABC study participants in 2007-2008 was 82.4 
± 2.8 years.  It is also notable that use of cholesterol lowering agents for primary prevention (i.e., 
those without CHD equivalent risk factors) occurred in up to 26.6%  participants despite the lack 
of convincing efficacy evidence and the potential for greater adverse drug effects in older 
adults.27  Similar to the reports by other studies,41, 59, 70 despite the observed increase in 
cholesterol-lowering medication use in both racial groups, blacks remained less likely than 
whites to take cholesterol-lowering medications.  A possible explanation is that long-term 
persistence in statin use has been shown to be worse in older blacks than whites.77 
We hypothesized that after the release of the NCEP ATP III guidelines and the results 
from the PROSPER Study in 2002, that the use of cholesterol-lowering medication would 
increase immediately (i.e., change in level).  However, our study showed this new data in 2002 
had no immediate impact on cholesterol-lowering medication use.  One possible explanation for 
this finding is that the dissemination and implementation of clinical guidelines and evidence-
based results are complex and take years to overcome barriers in clinical practice.78,79  Additional 
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unique factors in the elderly that may further contribute to the lag in dissemination of evidenced-
based guidelines in to clinical practice for the elderly include difficulty in translating the results 
from highly selective trial populations to a heterogeneous community population, competing 
causes of morbidity and mortality (e.g., cancer), polypharmacy and drug interactions, short 
remaining life expectancy, reported poor adherence of statins, and patient economic concerns.77, 
80-82 
We also hypothesized that after 2002 that there would be an increase in yearly rate of 
cholesterol-lowering medication use (i.e., change in slope).  Instead, we saw that there was a 
decrease in the yearly rate of increase of cholesterol-lowering medication use.  Although the use 
of cholesterol-lowering medication in the elderly has increased substantially over time, the 
change in slope declined with advancing age is consistent with the findings from other studies.73-
75   
So what are the clinical implications of these study findings for clinical pharmacy 
practice?  The potential underuse of cholesterol lowering therapy in those elders aged ≥ 80 with 
CHD or risk equivalent that was observed in this study may be appropriate as summarized by a 
recent review.44  The authors concluded that there is insufficient evidence to support the 
initiation or continuation of cholesterol-lowering treatment in this patient group.44  Moreover, it 
may also be appropriate to not utilize cholesterol-lowering medications in those elders with CHD 
or risk equivalent that also have a limited life expectancy given that it takes 2 to 5 years of statin 
treatment to reduce the risk of cardiovascular events.15  Lack of secondary prevention with 
cholesterol-lowering medications in older adults may also be justified given that they are at 
higher risk to experience adverse effects (e.g., myalgia with statins).  This increase in the risk of 
cholesterol-lowering medication adverse effects may be due to a number of factors including: 1) 
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age-related decline in systemic clearance, 2) multiple comorbidities and medications, 3) drug 
interactions (e.g. macrolides inhibiting CYP3A4 hepatic enzyme metabolism of atorvastatin, 
lovastatin or simvastatin), and 4) medication adherence difficulties that can be seen especially in 
those with cognitive impairment.83, 84  Having said this, the use of these agents should not be 
considered as contraindicated for elders aged ≥ 80 years in good health since the potential benefit 
may be most pronounced in this patient group due to the known increased risk of coronary heart 
disease with increasing age.  It is important for health care professionals to discuss these 
potential benefits and risks with older patients with CHD or risk equivalent and take into account 
their informed preferences.82   
Some limitations should be taken into account when interpreting the results of this study.  
Inherent to most longitudinal studies examining a broad range of older adults, the potential for 
survivor bias should be considered.  However, the results from a sensitivity analysis, restricted to 
participants in the study from 1997-2008, yielded similar results.  It is also possible that any use 
of cholesterol-lowering medications may be underestimated as medication use was measured at 
multiple fixed annual time points.  We also cannot rule out potential confounding by such factors 
as family history of premature CHD, dietary therapy, and adherence to medications as 
information about these were not collected in the Health ABC study.  Lastly, the study sample 
was drawn from two US cities and may not be generalizable to all other populations. 
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3.6 CONCLUSION 
This study found that the use of cholesterol-lowering medication increased substantially over a 
decade in community dwelling elders, but was not related to a change in level or trend following 
the release of the guidelines and evidence-based data.  Further studies are warranted to better 
guide cholesterol-lowering therapy and investigate the potential benefits and barriers of 
treatment among the oldest old elders (≥85 years) with CHD or at high risk. 
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3.8 TABLES AND FIGURES 
Table 7. Baseline Characteristics of the Health ABC Cohort and Four Subgroups (N=3,055)a 
Sociodemographic 
Factors 
All 
(n=3,055) 
Any CHD 
(n=556) 
Diabetes 
only 
(n=349) 
PAD, or 
Stroke or 2+ 
risk factors 
(n=836) 
<2 risk 
factors 
(n=1314) 
Age, mean (SD) 73.6 (2.9) 74.0 (2.9) 73.5 (2.9) 73.4 (2.9) 73.6 (2.9) 
Female sex 1574 (51.5) 202 (36.3) 169 (48.4) 404 (48.3) 799 (60.8) 
Black race 1266 (41.4) 220 (39.6) 211 (60.5) 372 (44.5) 463 (35.2) 
Pittsburgh site 1516 (49.6) 305 (54.9) 164 (47.0) 401 (48.0) 646 (49.2) 
Education 
   Postsecondary 1285 (42.2) 227 (40.8) 117 (33.7) 355 (42.7) 586 (44.6) 
   High school 996 (32.7) 182 (32.7) 105 (30.3) 283 (34.1) 426 (32.4) 
   Less than high 
  school graduate 
766 (25.1) 147 (26.4) 125 (36.0) 193 (23.2) 301 (22.9) 
Living alone 920 (30.2) 146 (26.3) 111 (31.8) 257 (30.7) 406 (30.9) 
Prescription  drug 
coverage 
1883 (61.7) 383 (68.9) 213 (61.2) 499 (59.9) 788 (60.0) 
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Table 7 (Continued) 
Health-related 
behaviors  
All 
(n=3,055) 
Any CHD  
(n=556) 
Diabetes 
only 
(n=349) 
PAD, Stroke, 
or 2+ risk 
factors 
(n=836) 
< 2 risk 
factors 
(n=1314) 
Smoking status       
   Current 316 (10.4) 53 (9.6) 30 (8.7) 187 (22.4) 46 (3.5) 
   Past 1397 (45.8) 311 (56.0) 165 (47.6) 324 (38.8) 597 (45.5) 
   Never 1337 (43.8) 191 (34.4) 151 (43.80) 324 (38.8) 670 (51.0) 
Alcohol use      
   Current 1505 (49.5) 276 (49.8) 100 (28.7) 422 (50.8) 707 (54.0) 
   Past 677 (22.3) 141 (25.5) 134 (38.5) 192 (23.1) 210 (16.0) 
   Never 859 (28.3) 137 (24.7) 114 (32.8) 216 (26.0) 392 (30.0) 
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Table 7 (Continued) 
Health Status  
Factors 
All 
(n=3,055) 
Any CHD  
(n=556) 
Diabetes 
only 
(n=349) 
PAD, Stroke, 
or 2+ risk 
factors 
(n=836) 
< 2 risk 
factors 
(n=1314) 
Congestive heart    
    failure 
40 (1.3) 22 (4.2) 6 (1.7) 10 (1.2) 2 (0.2) 
Chronic kidney disease 45 (1.5) 11 (2.0) 5 (1.4) 12 (1.4) 17 (1.3) 
Pulmonary disease 127 (4.2) 26 (4.7) 20 (5.8) 26 (3.1) 55 (4.2) 
Cancer 577 (18.9) 112 (20.2) 57 (16.3) 164 (19.6) 244 (18.6) 
Excellent/good self-
rated health 
2558 (83.8) 418 (75.2) 261 (74.8) 691 (82.8) 1188 (90.4) 
Body mass index      
  Under/Normal 982 (32.1) 173 (31.1) 71 (20.3) 233 (27.9) 505 (38.4) 
  Overweight 1293 (42.3) 237 (42.6) 146 (41.8) 364 (43.5) 546 (41.6) 
  Obese 780 (25.5) 146 (26.3) 132 (37.8) 239 (28.6) 263 (20.0) 
Number of prescription 
drugs, mean (SD) 
2.9 (2.6) 4.4 (2.9) 4.0 (2.7) 2.9 (2.4) 2.1 (2.3) 
Severe depressive  
  symptoms (CES-D  
  > 15) 
144 (4.8) 31 (5.6) 15 (4.4) 41 (4.9) 57 (4.4) 
Cognitive impairment 
(3MS< 80) 
304 (10.0) 59 (10.7) 44 (12.7) 89 (10.7) 112 (8.6) 
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Table 7 (Continued) 
Lipid profiles All 
(n=3,055) 
Any CHD  
(n=556) 
Diabetes 
only 
(n=349) 
PAD, Stroke, 
or 2+ risk 
factors 
(n=836) 
< 2 Risk 
factors 
(n=1314) 
Total cholesterol 
(mg/dL), mean (SD) 
202.8 (38.7) 193.7 (39.5) 201.1 (39.4) 199.7 (40.0) 209.0 (36.3) 
LDL-C (mg/dL), 
mean (SD) 
121.7 (34.8) 115.5 (35.5) 122.3 (35.4) 122.7 (35.7) 123.4 (33.4) 
HDL-C (mg/dL), 
mean (SD) 
53.9 (17.0) 49.3 (16.4) 50.6 (15.6) 46.8 (12.4) 61.2 (17.2) 
Triglyceride  
(mg/dL), mean (SD) 
138.7 (82.9) 148.3 (87.1) 144.1 (91.7) 156.2 (102.6) 122.3 (58.3) 
a Data represented as N (%), unless otherwise stated;  
Abbreviations: CES-D: Center for Epidemiologic Studies-Depression scale; HDL-C: high-density lipoprotein 
cholesterol; LDL-C: low-density lipoprotein cholesterol, PAD: peripheral artery disease 
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Table 8. Prevalence of Cholesterol-Lowering Medication Use from 1997-2008 
 1997-
1998 
(n=3055)  
n (%) 
1998-
1999 
(n=2908)  
n (%) 
1999-
2000 
(n=2820)  
n (%) 
2001-
2002 
(n=2631)  
n (%) 
2002-
2003 
(n=2515)  
n (%) 
2004-
2005 
(n=1780)  
n (%) 
2006-
2007 
(n=1592)  
n (%) 
2007-
2008 
(n=1344)  
n (%) 
Any 
cholesterol 
lowering 
medications 
456 
(14.9) 
509 
(17.5) 
586 
(20.8) 
702 
(26.7) 
737 
(29.3) 
656 
(36.9) 
676 
(42.5) 
573 
(42.6) 
Any statins 395 
(12.9) 
461 
(15.9) 
542 
(19.2) 
654 
(24.9) 
695 
(27.6) 
615 
(34.6) 
620 
(38.9) 
525 
(39.1) 
Any fibrates 35 (1.2) 30 (1.0) 32 (1.1) 33 (1.3) 29 (1.2) 29 (1.6) 33 (2.0) 28 (2.1) 
Any bile acid  
 sequestrants,   
 probucol,  
 niacins 
43 (1.4) 33 (1.1) 33 (1.2) 35 (1.3) 40 (1.6) 21 (1.2) 21 (1.3) 21 (1.6) 
Any  
  ezetimibe 
0 (0) 0 (0) 0 (0) 0 (0) 2 (0.1) 38 (2.1) 77 (4.8) 69 (5.1) 
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Table 9. Effect of the Release of the NCEP ATP III Guidelines and Results from PROSPER Study in 2002 on Cholesterol-Lowering Medications Usea 
Drug Class 
Level Changes Slope (Trend) Changes 
Observed vs. 
Predicted (using 
pre-guideline trend) 
Difference in Use 
in year 2003 
(Adjusted OR, 95% 
CI) a 
P-
value 
Pre-
Guideline 
Trend per 
year 
(Adjusted 
OR and 95% 
CI) a 
Post- 
Guideline 
Trend per year 
(Adjusted OR 
and 95% CI) a 
Post- vs. Pre-
Guideline 
Difference in 
Trends Over 
Time per year 
(Adjusted ROR, 
95% CI) a 
p-
value 
Any Cholesterol Lowering  
  Medication Use 
0.95 (0.89, 1.02) 0.18 1.18 (1.15, 1.20) 1.09 (1.02, 1.15) 0.92 (0.89, 0.95) <0.0001 
Any Statin Use 0.95 (0.88, 1.01) 0.12 1.19 (1.16, 1.22) 1.07 (1.01, 1.13) 0.90 (0.87, 0.93) <0.0001 
Any Fibrate/Other Use  1.04 (0.83, 1.30) 0.74 1.02 (0.93, 1.08) 1.24 (1.01, 1.46) 1.22 (1.10, 1.35) 0.0003 
a Multivariate generalized estimating equations models adjusted for sociodemographics (race, age, sex, site, education, living status), health behavior (alcohol use), and health status (pulmonary disease, 
body mass index, polypharmacy, and prescription medications coverage).  Polypharmacy and prescription coverage are time-varying variables.   
Abbreviations: CI: confidence interval; OR: odds ratio; ROR: ratio of odds ratio
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Figure 3. Yearly Prevalence of Cholesterol-Lowering Medication Use by Four Groups from 1997-
2008 
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4.1 ABSTRACT 
Background: The evidence that statin use may impact physical function decline in older adults 
is mixed.  
Objective:  To examine whether the use of statins is associated with a lower risk of gait speed 
decline of 0.05 m/s or more and 0.1 m/s or more per year in community-dwelling older adults.    
Design: Longitudinal cohort study. 
Setting: Health, Aging and Body Composition study. 
Participants: 2405 participants with medication and gait speed data 1998-1999 and 1999-2000 
were included.     
Measurements: Any use, summated standardized daily doses (low, moderate, high) and duration 
(<2 years, ≥ 2 years) of statin use were computed.  The effect of lipophilic/hydrophilic statins on 
gait speed decline was also evaluated.  The primary outcomes were small, meaningful decline in 
usual gait speed (≥ 0.05 m/s), and substantial usual gait speed decline (≥ 0.1 m/s per year) during 
a 20-m walk annually over a four-year time period.  Multivariable generalized estimating 
equations (GEEs) were used, adjusting for demographic, health-related behaviors and health 
status factors. 
Results:  The use of statins increased from 16.2% in 1998-1999 to 25.6% in 2002-2003.  
Approximately 34% to 38% of participants had gait speed decline ≥ 0.05 m/s per year, and 23% 
of participants had decline ≥ 0.1 m/s per year.  Compared to non-users, any statin use was 
associated with a 16% risk reduction of gait speed decline ≥ 0.05 m/s per year (aOR = 0.84, 95% 
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CI = 0.74-0.96).  A similar finding was seen in low-dose, long-term, and hydrophilic statin users.  
However, only low-dose statin users had a 22% decrease in the risk of gait speed decline ≥ 0.1 
m/s per year (aOR = 0.78, 95% CI = 0.61-0.99).   
Conclusion:  Statin use may decrease the risk of gait speed decline, suggesting low-dose statin 
may be a treatment option for older adults.  
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4.2 INTRODUCTION 
4.2.1 Epidemiology of Impaired Physical Function and Disability in the Elderly 
The public health challenge of age-related disability and loss in physical function emerges an 
important topic in our rapidly aging population (1, 2).   Maintenance of physical function is 
important in the elderly because of its relationship to the ability to live independently and to 
overall quality of life (3).  The prevalence of physical limitations varies by age, sex, race, and 
education (2).  National Health Interview Survey 2001-2007 showed that the prevalence of one 
or more physical limitations increases with advancing age (age of 50-59: 16.5%; age of 60-69: 
22.9%; age of 70-79: 31.4%; age of 80 and over: 42.9%), as does the prevalence of having three 
or more physical limitations (age of 50-59: 8.1%; age of 60-69: 11.5%; age of 70-79: 16.2%; age 
of 80 and over: 26.7%) (2).  Non-Hispanic black adults aged ≥ 50 years have higher prevalence 
of physical limitations compared to non-Hispanic white (age of 50-59: 24.1% vs. 17.2%; age of 
60-69: 33.9% vs. 24.4%; age of 70-79: 43.9% vs. 35.2%; age of 80 and over: 58.4% vs. 52.1%) 
(2).  For both non-Hispanic white and black older adults aged ≥ 50 years, women are more likely 
than men of the same age to have one or more physical limitations (white: age of 50-59: 20.5% 
vs. 13.8%; age of 60-69: 28.2% vs. 20.3%; age of 70-79: 39.5% vs. 29.6%; age of 80 and over: 
55.4% vs. 46.3%; black: age of 50-59: 27.8% vs. 19.5%; age of 60-69: 39.8% vs. 26.7%; age of 
70-79: 50.4% vs. 33.8%; age of 80 and over: 63.5% vs. 48.2%)  (2).  For both non-Hispanic 
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white and black older adults aged ≥ 50 years with less than a high school education have higher a 
prevalence of physical limitations than those with at least a high school diploma (2).   
4.2.2 Gait Speed and Potential Factors that Influence Gait Speed 
The ability to walk underlies many basic and community functions necessary for independence 
(4).  The appearance of difficulties in walking marks a critical point such that assessment of gait 
speed has been described as the “sixth vital sign”(5), with the potential to serve as a core 
indicator of health and function in aging and disease (4).   
Judgment about how an individual’s gait speed compares with those of the population to 
which they belong requires the availability of reference values (6, 7).    Gait speed is determined 
by physical features such as age, sex, height, presence or absence of disease and physical fitness 
(8, 9).   Numerous large scale epidemiological studies have documented gait speed in healthy, 
community-dwelling older adults (10, 11), and normative values have been established specific 
to this group (6, 12).  The usual gait speed for healthy women aged between 70-79 years is 1.13 
m/s and for men 1.26 m/s (12).  For women and men aged 80-99, the values are 0.94 m/s and 
0.97 m/s, respectively (12).   For well-functioning older adults, the gait speed < 0.80 m/s is an 
indicator of prevalent mobility limitations, <1.0 m/s is associated with adverse health outcomes 
and mortality in well-functioning older adults, and <1.2 m/s is associated with difficulty in 
crossing streets in the community (11, 13-15).   A recent meta-analysis showed that the gait 
speed estimate for usual pace was 0.58 m/s (95% CI: 0.75-1.02) in older adults aged ≥ 70 years 
across the hospital settings, and 0.46 m/s (95% CI: 0.65-0.83) in acute care settings (16).  
Abellan et al. proposed a gait speed of 0.8 m/s as a predictor of poor clinical outcomes and 0.6 
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m/s as a threshold to predict further functional decline in those older adults already impaired 
(10).  
Slowing of movement with aging appears to be a universal biological phenomenon and is 
likely to reflect the integrated performance of numerous organ systems.  Factors that influence 
walking ability can be classified into six main physiological subsystems: central nervous system, 
perceptual system, peripheral nervous system, muscles, bone, and/or joints, and energy 
production and/or delivery (17).  Impaired physical function and subsequent disability can occur 
as a result of age-related losses of muscle mass and strength or an acute event (e.g., stroke or hip 
fracture), or as a consequence of chronic disease (e.g., osteoarthritis or congestive heart failure) 
(18).  Neurologic and musculoskeletal deficits linked with reductions in motor discharge rate, 
lower activation of muscle fibers, poor balance performance, physical fitness are other 
contributing factors (6, 9).   In addition, area with growing body of evidence suggests a 
relationship between chronic inflammation and age-related muscle and strength loss, risk of 
disability, frailty, and physical function decline (18-28).  Inflammatory cytokines have a 
catabolic effect on muscle (22, 29-31), and have been implicated in the pathogenesis of 
musculoskeletal disorders such as osteoarthritis (32).  Higher IL-6 levels were significantly 
associated with lower muscle mass (30), weaker grip strength (30) and lower gait speed (33).   A 
recent study showed that each doubling in CRP and IL-6 change over 9 years was associated 
with higher risk of physical or cognitive impairment (odds ratio for CRP: 1.29 [95% CI 1.15-
1.45] and odds ratio for IL-6: 1.45 [95% CI 1.20-1.76]) among 1051 participants in the 
Cardiovascular Health Study All Starts Study (34). 
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4.2.3 Potential Mechanisms that How Statins Affect Physical Function 
Multiple factors appear to be involved in frailty and age-related physical function decline (25, 
26, 35).  The Muscial effect of statins on physical performance may be explained by three 
mechanisms.  Firstly, statins might affect physical function by retarding the deleterious effects of 
atherosclerosis on blood vessels in skeletal muscle, ensuring better perfusion and therefore, 
preventing muscle wasting and reducing muscle weakness and/or fatigue (36, 37).  Indeed, 
statins increase the production of nitric oxide in the endothelium which has local vasodilator 
properties, in addition to antithrombogenic, antiproliferative and leukocyte adhesion inhibiting 
effects (36, 37).  Secondly, statins may elicit their effect by reducing the risk of incident of 
cardiovascular events, which are major determinants of physical performance in older adults 
(38).  The literatures suggest that statins may exert a beneficial effect on stroke (39) and 
dementia (40-42) prevention.  Recent studies show that statins improve endothelial function in 
peripheral arteries (43).  Finally, the most intriguing hypothesis is that statins may reduce chronic 
inflammation, which, in turn, is an important determinant of disability and impaired function 
(20).  Anti-inflammatory effects of statins may affect type II (fast-twitch) muscle fibers to a 
greater degree than type I (slow-twitch) muscle fibers.  Indeed, in older adults, higher levels of 
inflammatory markers are strong independent predictors of incident disability probably through 
an accelerated muscle catabolism leading to muscle wasting (23).  Several studies have 
demonstrated that statins reduce levels of CRP and other inflammatory markers independent of 
their effects on cholesterol (44-47).  Therefore, the evidence appears to provide a rationale for a 
direct effect of statins on physical function impairment or disability.  
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It is possible that the potential beneficial effect of statins may be counteracted by the 
muscle-related adverse events (e.g., myalgia, muscle weakness, cramps) (48-54).  The incidence 
of myopathy among statin users was as high as 5%-10% (55, 56).  A variety of different 
hypotheses have been suggested to account for the myotoxic effects of statins (57).  These 
included statin-induced interruption of glycoprotein synthesis in the muscle membrane (58), 
deficiency in chloride channel activation in the muscle membrane (59), and increased 
intracellular calcium concentrations leading to impaired membrane function (60), all of which 
may result in myocyte injury.  Decreased intracellular cholesterol which is associated with low 
plasma cholesterol from statin therapy may result in reduced membrane lipid content, which in 
turn may cause physical modification of membrane fluidity and a decrease in cell proliferation 
(61).  In addition, HMG-CoA reductase catalyses the formation of mevalonate from HMG-CoA.  
Mevalonate is an important precursor not only of cholesterol but also of ubiquinone (co-enzyme 
Q), dolichols and isopentenyl adenine.  All these products are involved in cell replication and 
dolichols is required for glycoprotein synthesis (62).  Deficits in these products may adversely 
affect myocyte duplication and cause disruption of the cell membrane, predisposing to myotoxic 
consequences.  Ubiquinone is utilized by mitochondria for electron transport, reduced synthesis 
of ubiquinone may result in defective mitochondrial myopathies (63) and defective ATP 
synthesis predisposing myocyte instability (64).  However, the precise mechanisms remain 
unclear and there is no clear consensus of opinion regarding which is more likely to be 
responsible. 
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4.2.4 Significance of the Current Study 
The preservation of physical function is critically important for prolonged, independent living 
and overall quality of life for older adults (3).  Hence, identifying modifiable factors to delay 
physical function decline in older adults is a significant priority of public health interest.   
Gait speed is a simple, but important indicator of functional status in older adults (10, 11, 65).  
Declines in gait speed consistently predict future physical disability, mortality, and major health-
related outcomes (e.g., hospitalizations, nursing home admissions, falls, cognitive 
decline/dementia and poor quality of life) in older adults (10, 11, 13, 66-68).  In older adults, 
every 0.1 m/s slower gait speed is associated with a 12% higher mortality (11).   Despite the 
importance of gait speed decline, a paucity of literature has identified risk or protective factors, 
other than physical exercise, for age-related gait speed decline, or the magnitude of important 
gait decline in gait speed associated with these factors (69).  
Evidence suggests that statins have anti-inflammatory effects, which is beyond their 
cholesterol-lowering and anti-atherosclerosis effect, and therefore may be candidates for 
preventing physical disability and related outcomes (10, 44-47, 70-76).  The evidence that exists 
shows mixed results.  Previous studies showed that statin use was associated with improved 
walking speed, walking distance, better physical performance, and improved physical activity in 
individuals with peripheral arterial disease (PAD) (77-81).  However, Gray SL et al. did not find 
that statin use, regardless of any use, dose- and duration-response, lower risk of mobility 
limitation or physical function decline in community-dwelling older adults aged 65-79 years at 
baseline (82, 83) over 6 years of follow-up.   
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To our knowledge, the association between statin use and gait-speed decline over a 20-m 
walk in community-dwelling older adults has not been previously explored.  The objective of 
this study was to examine whether the use of statins is associated with a decreased risk of 
clinically meaningful gait speed decline (i.e., 0.05 m/s or more and 0.1 m/s or more per year) in 
community-dwelling older adults.  We hypothesized that statin users when compared to non-
users had a decreased risk of gait speed decline.  Dose-response, duration-response, and 
lipophilicity/hydrophilicity of statin use were also examined.   We hypothesized that high-dose, 
long-term and hydrophilic statin use was associated with a decreased risk of gait speed decline 
compared to non-users. 
                                                            4.3 METHODS 
4.3.1 Study Design, Sample, and Source of Data 
Participants were from the Health, Aging and Body Composition (Health ABC) Study, which is 
a prospective cohort study of 3,075 initially well-functioning white and black adults aged 70-79 
years (84, 85).  Participants were recruited in 1997 and 1998 from a random sample of Medicare 
beneficiaries residing in Pittsburgh, Pennsylvania and Memphis, Tennessee.  Eligibility criteria 
included no self-reported difficulty in walking one-quarter of a mile (400 m), climbing 10 steps 
without resting, and performing basic activities of daily living.  In addition, eligible participants 
could not use a cane, walker, crutches or other special equipment to ambulate (84, 85).  The 
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study was approved by the Institutional Review Boards of the Universities of Pittsburgh and 
Tennessee, and written informed consent was obtained from each participant. 
4.3.2 Study Subsample 
The Year 2 (1998-1999) Health ABC visit was used as baseline since serial testing of 20-m gait 
speed began at this visit.   A total of 2,045 participants who had both medication information and 
gait speed data from the 1998-1999 and 1999-2000 clinic visits were included in the current 
analysis. 
4.3.3 Data Collection and Data Management 
The data collected during annual in-person visits included results from blood tests (e.g., serum 
creatinine), a battery of detailed physiological measurements using standardized methods and 
responses to questionnaires regarding sociodemographic characteristics, multiple aspects of 
health behavior and status, and medication use (84, 85).  Health behavior and health status 
factors, as well as medication use, were used to define a numbers of conditions of interest for this 
study (e.g., diabetes mellitus and hypertension) (86, 87).  Several comorbidities examined in the 
current study (i.e., coronary heart disease [CHD), congestive heart failure [CHF], stroke, or 
peripheral artery disease [PAD]) were centrally adjudicated by a post hoc committee based on 
conclusive evidence from hospitalization or death records (84, 85).     
At baseline (1998-1999) and annually for four years (except year 2000-2001), participants were 
asked to bring all prescription medications taken in the previous month.  Trained interviewers 
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transcribed information from the medication containers on medication name, dosage form, dose, 
and whether the medication was taken as needed.  The medication data were coded using the 
Iowa Drug Information Service (IDIS) and then entered into a computerized database (88).  
These methods of medication data collection are considered highly accurate and concordant with 
information contained in pharmacy claims data (89).  
 Gait speed was measured over a 20-m course in an unobstructed corridor at baseline 
(1998-1999) and continued annually for the next four years (90, 91).   A 20-m gait speed was 
summarized in meters per second (m/s).  Participants were instructed to walk at their usual pace 
from a starting point and walk past an orange cone indicating the end of the course.  Timing 
started with the first step after the starting line and ended after the first step over the finishing 
line.  Participants were allowed to use walking aids during the test, such as cane.  Gait speed has 
high test-retest reliability in older adults with intraclass correlation coefficients greater than 0.9 
(8). 
4.3.4 Independent Variables 
Statin use was determined from the coded prescription medication data, corresponding to IDIS 
codes 24060202-24060208.  The primary independent variable was use versus no use of statins 
at baseline and annually (as a dichotomous time-varying variable).  Statin exposure had to 
precede the ascertainment of gait speed measures in the subsequent year.  For example, statin use 
in 1998-1999 was a potential risk/protective factor for gait speed measure assessed in 1999-2000.  
Statin nonusers were always the reference group for all of the analyses.   
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Several operational definitions of statin use (i.e., dose, duration, and lipophilicity/ hydrophilicity) 
were used to examine the robustness of the findings.  A priori standardized daily dose (SDD) 
was used to test dose-response relationships between time-varying exposure of statin doses and 
gait speed measures (92).  For current users of each individual statin medication at baseline, 
1999-2000, and 2001-2002, we calculated the daily dose by multiplying the number of dosage 
forms taken the previous day by medication strength.  Little information is available regarding 
the comparative effect of statins on inflammatory markers.  Some studies suggest that effects on 
C-reactive protein (CRP), may be independent of degree of lipid lowering, but comparative 
metrics are not available for anti-inflammatory effects (75, 93).  To compare across statins, we 
converted the daily dose to units of equivalent dose reported to decrease LDL-C by 37% (94, 
95).  The following daily doses were considered to equal one unit of equivalent dose 
(atorvastatin 10mg, fluvastatin 80 mg, lovastatin 40 mg, pravastatin 40 mg, simvastatin 20 mg, 
rosuvastatin 5 mg) (94, 95).  The SDD were operationally defined based on the distribution of 
the data and clinical relevance into three categories: low-dose (<1.0 SDD), moderate-dose (1.0 
SDD), and high-dose (> 1.0 SDD) use.     
To examine the relationship between the duration of statin use and outcome measures, we 
operationally defined a time-varying independent categorical variable (i.e., short-term: use < 2 
years vs. long-term: use ≥ 2 years) for the duration of each statin use based on the data 
distribution.  For example, at baseline, duration of use of statin was operationally defined as 
either “long-term” (e.g., continuous use for previous 2 years) or “short-term” (use only at the 
baseline in-person medication review).  At follow-up, duration of use among current users was 
operationally defined as either long-term (use of any statin medications at most recent and 
138 
 
previous in-person medication reviews) or short-term (use at most recent in-person medication 
review only). 
In addition to this, some in vitro and in vivo experiments suggest that lipophilic statins 
(i.e., lovastatin, simvastatin, atorvastatin, fluvastatin) might be more likely to produce muscular 
adverse effects than relatively hydrophilic statins (i.e., pravastatin, rosuvastatin) (96).  Therefore, 
analyses were stratified by lipophilic versus hydrophilic of statins. 
4.3.5 Primary Outcome Measure: Gait Speed Decline per year 
Previous studies show that gait speed alone is strongly associated with morbidity and mortality in 
older adults (11, 13, 97).   The best initial estimates of small meaningful change for gait speed 
are near 0.05 m/s.  The best estimates of substantial change for clinical and research use are near 
0.10 m/s for gait speed (98).  The primary outcome variables were gait speed decline 1) by 0.05 
m/s or more, and 2) gait speed decline by 0.1 m/s or more per year (98). 
4.3.6 Covariates 
Several characteristics that could confound or modify the association between statin use and gait 
speed were adjusted for in the analysis, and were grouped into three domains: (1) 
sociodemographic factors, (2) health-related behaviors and (3) health status (99-102).  Age was 
considered as a continuous variable.  Other sociodemographic factors that were characterized as 
categorical variables included race (black or white), sex, study site, education (postsecondary 
education, high school graduate, or less than high school graduate), and living status (alone or 
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not alone).    A dichotomous time-varying variable for prescription drug coverage was also 
included to account for patients who were on and off insurance over the study period. 
Health-related behaviors were characterized as categorical variables for smoking status, 
alcohol use (current, past, or never), and exercise level (yes vs. no) which was based on self-
report of having high to moderate intensity exercise in the previous week.  Health status factors 
were characterized as time-varying dichotomous measures (present vs. absent) for comorbidities 
including hypertension, diabetes, CHD, CHF, stroke and PAD to control the confounding by 
indications.  Hypertension was defined by self-reported diagnosis of hypertension and use of 
anti-hypertensive medications (86).  Diabetes was defined by self-reported diagnosis of diabetes 
or use of anti-diabetic medications (87).  Chronic kidney disease (CKD) was defined as 
estimated glomerular filtration rate (eGFR) less than 60 ml/min, which was calculated using the 
four-variable version of the Modification of Diet in Renal Disease equation (103, 104).  
Dichotomous measures (present vs. absent) were used for self-reported pulmonary disease, 
osteoarthritis, and Parkinson disease at initial baseline for the Health ABC.  A time-varying 
dichotomous variable was created for self-rated health (excellent/good vs. not excellent/good).  
A categorical variable for body mass index (BMI: underweight or normal [<25.0 kg/m2], 
overweight [25.0–29.9 kg/m2], or obese [≥30.0 kg/m2]) was created (105).    Dichotomous 
variables were created for cognitive impairment (Modified Mini-Mental State [3MS] < 80) (106) 
and high depressive symptoms (Center for Epidemiologic Studies Depression Scale score >15) 
(107).  Two continuous variables were considered, leg muscle strength (i.e., average maximum 
torque [Nm]) and body composition (i.e., average total body lean mass [kg]) (52).  Time-varying 
variables (yes vs. no) of medications related to falls and mobility problems including 
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benzodiazepines, and anticholinergic medications were also controlled (92, 108-110).  In 
addition, three dichotomous time-varying variables (yes/no) for  other medications with anti-
inflammatory effects were created including (1) angiotensin converting enzyme inhibitors 
(ACEIs), (2) non-steroidal anti-inflammatory drugs (NSAIDs), and (3) other medications (i.e., 
systematic glucocorticoids, immunosuppressive medications, and some medications for 
rheumatoid arthritis, asthma, inflammatory bowel diseases, systemic lupus erythematosus and 
other systemic inflammatory diseases [Appendix]) (111-116).  The number of overall 
prescription medications (excluding statins, benzodiazepine, ACEIs, and anti-inflammatory 
drugs) was included as a time-varying continuous variable as a proxy for comorbidity (117). 
4.3.7 Main Statistical Analysis 
All analyses were performed using SAS® version 9.3 (SAS Institute Inc. Cary, NC).   
Appropriate descriptive statistics (mean, standard deviation, frequency and percentage) 
were used to summarize participant characteristics and main analytic variables.  For descriptive 
purposes, the prevalence of statin use and gait speed decline over time were reported.  For 
primary outcome (gait speed decline ≥ 0.1 m/s per year), multivariable generalized estimating 
equations [GEEs] models was conducted to examine the association between statin use and gait 
speed decline.   This analysis used the SAS® GENMOD procedure with an autoregressive 
working correlation structure to account for potential multiple years of data from the same 
participants and the resulting stochastic non-independence of observations (118).  A forward 
selection procedure was performed to determine the impact of each variable on the association of 
statin use and gait speed decline.  In the final multivariate models, odds ratios (ORs) and 95% 
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confidence intervals (CI) for statin use were computed adjusted for demographics, baseline gait 
speed measures and covariates with a p-value less than 0.15 from the forward selection 
procedure.  A similar approach adjusted for same covariates was conducted using other 
operational definitions of statin use as main predictors to test dose-response, duration-response, 
and lipophilicity or hydrophilicity of statin use. 
4.3.8 Sensitivity and Stratification Analyses 
A series of sensitivity analyses were conducted to better understand and assure the robustness of 
the main findings.  First, we assessed change in gait speed (m/s) per year as a continuous 
outcome variable, and examined the associations between statin use using a series of conditional 
linear mixed model implemented in SAS® MIXED procedure (119, 120).  The subject-specific 
random effect was used to accommodate the likely correlation between repeated measurements 
for the same participants.  The change in gait speed was the successive difference in the 
particular functional performance measure of interest (i.e., from baseline to 1999-2000, from 
1999-2000 to 2000-2001, from 2001-2002 to 2002-2003).   Similar to the main analyses, other 
operational definitions of statin use were evaluated based on dose-response, duration, and 
lipophilicity of statins, separately.  The second sensitivity analysis was performed by restricting 
the analysis to only those with data for the entire five year time period.  The last sensitivity 
analysis was to determine if the cut point for meaningful change in gait speed for a 20-m walk is 
the same as the one derived from 10 feet to 10-m walk in Perera S’s study (98).    Finally, a 
stratification analyses were conducted by race, sex, and baseline gait speed (<1.0 m/s, 1.0-1.22 
m/s and >1.22 m/s) due to the flooring and ceiling effects of gait speed decline.  Walking 1.22 
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m/s is a minimum speed needed to cross a street at a timed crosswalk (15), and walking less than 
1.0 m/s is a risk factor for mortality (13). 
4.4 RESULTS 
The baseline characteristics of the overall participants and according to statin use are shown in 
Table 10.   Of the 2,405 participants, the mean age was 74.6 years, 51% were female, 37% were 
black, and 63% had prescription medication coverage.  Among 2,405 participants, 390 (16.2%) 
participants used statins.  Compared with non-users, statin users were more likely than non-users 
to be younger, white, from Pittsburgh site, have prescription drug coverage, smoke previously, 
drink alcohol currently, have high- or moderate-intensity exercise, have more chronic 
comorbidities (i.e., hypertension, diabetes, CHD, CHF, stroke, PAD, and CKD).   Statin users 
were also more likely to be benzodiazepine and ACEI users and took more prescription drugs.    
Table 11 provides the information on statin use over the study period.  At baseline, 390 
(16.2%) older adults used a statin, with 48% using low doses, 71% had been taking a statin for 2 
years or longer, and 86% used lipophilic statins.  Statin use increased steadily over the course of 
the study, to 20.1% in 1999-2000 and 25.6% in 2001-2002.      
Table 12 describes the prevalence of gait speed decline for the overall participants and 
according to statin use over time.  Statin users had a faster gait speed at baseline (1.17 m/s vs. 
1.14 m/s, p=0.02), and this trend was seen during the follow-up years.  The overall gait speed 
decline of 0.1 m/s or more per year changed slightly from 22.2% in 1999-2000 to 23.9% in 2002-
2003.  Compared to non-users, statin users had less gait speed decline of 0.05 m/s or more  per 
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year (34.5% vs. 28.7% p =0.03) , and decline of 0.1 m/s or more per year (23.3% vs. 18%, p 
=0.03) in 1999-2000.  However, statin users had similar proportions of gait speed decline of 0.05 
m/s or more and 0.1 m/s or more per year as non-users in 2000-2002 and 2002-2003. 
Table 13 shows the univariate and multivariate associations between statin use and gait 
speed decline of 0.05 m/s or more per year.  There was a 16% risk reduction in gait speed decline 
of 0.05 m/s or more per year among any statin users compared to non-users (adjusted OR 0.84; 
95% CI 0.74-0.96).  A similar protective effect was seen in low- and high-dose, long-term and 
hydrophilic statin use. 
Table 14 shows the univariate and multivariate associations between statin use and gait 
speed decline of 0.1 m/s or more per year.  Compared with non-users, any statin use was likely to 
decrease the risk of gait speed decline of 0.1 m/s or more per year (adjusted OR 0.89; 95% CI 
0.76-1.05), but was not statistically significant.  A similar finding was seen in high-dose, long-
term and hydrophilic of statin use when individually compared to nonusers.  However, there was 
a 22% risk reduction in gait speed decline of 0.1 m/s or more per year among low-dose users 
compared to non-users of statins (adjusted OR 0.78; 95% CI 0.61-0.99). 
Sensitivity and Stratification Analyses 
None of the additional sensitivity analyses appreciably changed our main findings.  First, 
the results from the mixed models revealed that any statin users (0.011 m/s, 95% CI 0.002-
0.020), low-dose (0.021 m/s, 95% CI 0.008-0.034) and long-term (0.012 m/s, 95% CI 0.002-
0.022) statin use had a less mean gait speed decline per year compared to non-users.  Secondly, 
the restriction of the analysis to only those with data for the entire time period had similar 
findings (data not shown).  Thirdly, the results from testing different cut points showed that 
statins use had a decreased risk of gait speed decline between 0.04-0.06 m/s per year (data not 
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shown).    Lastly, the analysis stratified by sex yielded similar results.  However, any statin use 
reduced the risk of gait speed was more predominant in blacks (OR: 0.76, 95% CI: 0.58-1.01) 
than in whites (OR: 0.94, 95% CI: 0.78-1.08).  The stratification analysis only supported that any 
statin use reduced the risk of gait speed decline among those with baseline gait speed between 
1.0 to 1.22 m/s (OR: 0.73, 95% CI: 0.55-0.98) compared to non-users, but not among those with 
baseline gait speed less than 1.0 m/s (OR: 0.92, 95% CI: 0.63-1.36) or 1.22 m/s or greater (OR: 
1.05, 95% CI: 0.83-1.32). 
4.5 DISCUSSION 
Our study showed that statin use, compared to non-users, had a decreased risk of decline in gait 
speed of 0.05 m/s or more per year in community-dwelling older adults (98). In addition, low-
dose statin use had a decreased risk of gait speed decline of 0.1 m/s or more per year (98), which 
has been related to outcomes of self-reported motility and other health-related adverse events.  
These findings are consistent with the protective effects of statins in physical function decline 
from two small randomized trials (81, 121), and two longitudinal studies (77, 78) in individuals 
with PAD.  The overall protective association between any statin use and risk of small 
meaningful decline in gait speed is reassuring in the context of concerns of statin-related 
muscular adverse events in older adults.  Furthermore, the muscle-related adverse events of statin 
use are associated with dose and blood level (122, 123).  The statin-related muscular adverse 
events may occur in up to 10% of the adults receiving high-dose statins (56), however, the 
precise estimate is unknown for older frail adults.  Low-dose statin use may minimize muscle-
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related adverse effects in older adults, and therefore may be less likely to counteract beneficial 
effects on slower gait speed decline due to anti-inflammatory effect.   The beneficial effects of 
statins in gait speed decline may be due to better endothelial function resulting in enhanced 
lower extremity blood flow (77), besides a reduction in inflammation-mediated sarcopenia.  
Regression of arterial plaque may be responsible for these associations.  However, our study 
findings were in contrast of previous studies conducted in other community-dwelling 
populations, which were not restricted to a specific disease (i.e., PAD) (50, 82, 83, 124).  
Possible explanations of these discrepancies of the association with physical function decline 
include different populations (e.g., women only, younger baseline age), without testing for dose- 
and duration-response, and less precise outcome measure (e.g., self-reported outcomes vs. 
objectively assessed physical function measures).   
It is also notable that hydrophilic statins may have better beneficial effect in gait speed 
decline than lipophilic statins.   Hydrophilic statins are less capable of entering nonhepatic cells.  
This is one possible reason why statin-related muscular adverse events appear to be reported less 
frequently with the use of hydrophilic statins.  However, due to limited sample size of 
hydrophilic statin users, further studies will be required to elucidate how different statins with 
different lipophilic properties and safety profiles are associated with the risk of myotoxicity (125, 
126).    
Strengths of this study include the prospective design in a large sample of community-
dwelling older adults, well-collected medication information, the availability of serially obtained, 
standardized gait speed measures, and the ability to adjust for numerous potential confounders.  
However, some limitations should be considered when interpreting the results of this study.  
Inherent to most longitudinal studies examining older adults, the potential for survivor bias 
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should be considered.  This may lead to an underestimation of the association because 
individuals who missed follow-up assessments (e.g., due to health problems or death) were more 
likely to have gait speed decline than included participants.  However, the results from a 
sensitivity analysis, restricted to participants in the study from 1998-2003, yielded similar results 
(data not shown).  It is also possible that any use of statins may be underestimated as medication 
use was measured at multiple fixed annual time points.  We also cannot rule out potential 
confounding by such factors as adherence to medications and use of health care services because 
information about these was not collected in the Health ABC study.  Given the high rates of non-
adherence in statin users, it is possible that the protective effects of statins from gait speed 
decline were underestimated.  Despite employing several strategies, unmeasured confounding by 
indications cannot be ruled out completely (127).  Lastly, the study sample was drawn from two 
US cities and may not be generalizable to all other populations.    
4.6 CONCLUSION 
In conclusion, findings from this study suggest that statin use may benefit in a decreased risk of 
age-related gait speed decline.  Although our results do not suggest any negative effects on gait 
speed decline at higher dose, given that older adults are at higher risk to experience other adverse 
effects of statin use, low-dose statins are suggested for older adults to start with, and hydrophilic 
statins may be used for those with multiple comorbidities and medications.  Further studies and 
randomized clinical trials are needed to confirm the observed associations between statin use and 
declines in gait speed in other older adults populations. 
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4.8 TABLES 
Table 10.  Baseline Characteristics of the Health ABC Cohort and According to Statin Usea 
All cohort 
(N= 2405) 
Statin Users 
(N= 390) 
Statin Non-Users 
(N= 2015) 
Sociodemographics 
Age, mean (SD) ǂ 74.6 (2.8) 74.3 (2.7)* 74.7 (2.9) 
Female sex 1235 (51.4) 195 (50.0) 1040 (51.6) 
Black race 894 (37.2) 114 (29.2)*** 780 (38.7) 
Pittsburgh site 1257 (52.3) 239 (61.3)**** 1018 (50.5) 
Education 
    Postsecondary 1084 (45.2) 192 (49.4) 892 (44.4) 
    High school 793 (33.1) 129 (33.1) 664 (33.0) 
    Less than high school 
graduate 
522 (21.8) 68 (17.5) 454 (22.6) 
Living alone 697 (29.0) 105 (26.9) 592 (29.4) 
Prescription drug coverage 1521 (63.3) 282 (72.3)*** 1239 (61.6) 
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Table 10 (Continued) 
 All cohort  
(N= 2405) 
Statin Users  
(N= 390) 
Statin Non-Users  
(N= 2015) 
Health-related behaviors    
Smoking status    
    Current 206 (8.6) 22 (5.6)*** 184 (9.2) 
    Past 1119 (46.6) 219 (56.2) 900 (44.7) 
    Never 1077 (44.8) 149 (38.2) 928 (46.1) 
Alcohol use    
    Current 1226 (51.2) 223 (57.2)* 1003 (50.0) 
    Past 507 (21.2) 79 (20.3) 428 (21.3) 
    Never 663 (27.7) 88 (22.5) 575 (28.7) 
Having high or moderate- 
intensity exercise in the 
past 7 days 
690 (28.7) 141 (36.2)*** 549 (27.3) 
Health Status Factors    
Hypertensionǂ 1104 (45.9) 220 (56.4)**** 884 (43.9)  
Diabetes mellitusǂ 363 (15.1) 75 (19.2)* 288 (14.3) 
Coronary artery diseaseǂ 450 (18.7) 165 (42.3)**** 285 (14.1) 
Congestive heart failureǂ 103 (4.3) 28 (7.2)** 75 (3.7) 
Strokeǂ 133 (5.5) 33 (8.5)** 100 (5.0) 
Peripheral artery diseaseǂ 151 (6.3) 48 (12.3)**** 103 (5.1) 
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Table 10 (Continued) 
 All cohort  
(N= 2405) 
Statin Users  
(N= 390) 
Statin Non-Users  
(N= 2015) 
Health Status Factors    
Chronic kidney disease 484 (20.3) 108 (27.8)**** 376 (18.8) 
Pulmonary disease 99 (4.1) 10 (2.6) 89 (4.4) 
Osteoarthritis 1345 (55.9) 219 (56.2) 1126 (55.9) 
Parkinson disease 15 (0.6) 0 (0) 15 (0.7) 
Excellent/good self-rated 
health 
2057 (85.5) 327 (83.9) 1730 (85.9) 
Body mass index    
    Under/Normal 798 (33.2) 110 (28.2)* 688 (34.1) 
    Overweight 1030 (42.8) 187 (48.0) 843 (41.8) 
    Obese 577 (24.0) 93 (23.8) 484 (24.0) 
Severe depression 
symptoms (CES-D >15) 
102 (4.3) 16 (4.1) 86 (4.3) 
Cognitive impairment 
(3MS < 80) 
187 (7.8) 22 (5.6) 165 (8.2) 
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Table 10 (Continued) 
 All cohort  
(N= 2405) 
Statin Users  
(N= 390) 
Statin Non-Users  
(N= 2015) 
Leg muscle strength: 
Average maximum torque 
(Nm), Mean (SD) 
104.6 (37.3)  
 
106.1 (38.5) 
 
104.4 (37.1) 
 
Body composition: Total 
body lean mass (Kg), Mean 
(SD) 
48.8 (10.3)  
 
48.6 (9.7) 
 
48.8 (10.4) 
 
Anticholinergic useǂ 345 (14.4) 52 (13.3) 293 (14.5) 
Benzodiazepinesǂ 146 (6.1) 33 (8.5)* 113 (5.6) 
ACEIǂ 402 (16.7) 90 (23.1)***  312 (15.5)  
NSAID usebǂ 513 (21.3)  71 (18.2)  442 (21.9)  
Other drugs with anti-   
     inflammatory effect use cǂ 
96 (4.0) 17 (4.4)  79 (3.9)  
Number of prescription 
drugs, mean (SD)dǂ 
2.7 (2.4)  3.4 (2.5)**** 2.6 (2.3)  
Abbreviations: ACEI: angiotensin converting enzyme inhibitors; CES-D: Center for Epidemiologic Studies-Depression scale; CNS: central 
nervous system; 3MS: Mini-Mental Status examination; NSAID:  non-steroidal anti-inflammatory drugs; SD: standard deviation 
a  Data represented as N (%), unless otherwise stated; Numbers of missing information: education (n=6), prescription drug coverage (n=4), 
smoking (n=4), alcohol drinking (n= 11), history of congestive heart failure (n=36), kidney disease (n=19), pulmonary disease (n=8), severe 
depression (n=19), and cognitive impairment (n=2).    
b   Including non-aspirin NSAIDs aspirin use ≥ 1200 mg/day, and prescription salicylates medications.   
c  Other drugs with anti-inflammtory effect include  systemic glucocorticoids, immunosuppressive agents, Alefacept , Anakinra, Antithymocyte 
globulin, Olsalazine, Efalizumab, Etanercept, Hydroxycholoroquine, Infliximab, Muromonab-CD3 (OKT3), Montelukast, Natalizumab, 
Omalizumab, Rituximab, Sulfasalazine, Thalidomide, Zafirlukast, Zileuton  
d numbers of total prescription drugs – numbers of prescription statin, anticholinergic, benzodiazepines ACEI, NSAID, and other drugs with anti-
inflammatory effect 
*: P <0.05, **: P < 0.01, ***: P<0.001, ****: P<0.0001 from chi-square or t-test between statin users and non-users. 
ǂ: time-varying variables 
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Table 11. Prevalence of Statin Use Over Timea 
 1998-1999 
(Year 2)  
(N= 2405), N% 
1999-2000 
(Year 3)  
(N= 2206), N% 
2001-2002 (Year 
5) 
(N= 1968), N% 
Statin Use: Any users 390 (16.2) 444 (20.1) 504 (25.6) 
    High-dose (>1 SDD) 59 (2.5) 76 (3.5) 137 (7.0) 
    Moderate-dose (1 SDD) 143 (6.0) 195 (8.8) 235 (11.9) 
    Low-dose (< 1 SDD) 188 (7.8) 173 (7.8) 132 (7.0) 
    Long-term (≥ 2 years) 278 (11.6) 321 (14.6) 338 (17.2) 
    Short-term (< 2 years) 112 (4.7) 123 (5.6) 166 (8.4) 
    Lipophilic statin useb 334 (13.9) 398 (18.0) 461 (23.4) 
    Hydrophilic statin useb 56 (2.3) 46 (2.1) 43 (2.2) 
Abbreviations: SDD: standardized daily dose;  
a  Detail medication information were only collected from Years 1, 2, 3, 5 and 6.  
b: Lipophilic statins include atorvastatin, lovastatin, fluvastatin and simvastatin, and hydrophilic statins include pravastatin and rosuvastatin 
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Table 12. Gait Speed and Change in Gait Speed According to Statin Use Over time 
Variables 1998-1999  
(Year 2)a  
(N=2405) 
1999-2000 
(Year 3)  
(N=2405) 
2000-2001 
(Year 4)  
(N=2206) 
2002-2003 
(Year 6)  
(N=1968) 
Gait speed in m/s (mean [SD]) 1.14 (0.23) 1.15 (0.22) 1.15 (0.22) 1.10 (0.22) 
    Statin users 1.17 (0.22)*  1.19 (0.20)**** 1.17 (0.22) 1.11 (0.20) 
    Statin non-users 1.14 (0.23) 1.14 (0.22) 1.15 (0.22) 1.10 (0.22) 
Gait speed decline ≥ 0.05 m/s per 
year, N (%) 
    
    Overall -- 807 (33.6) 805 (36.5) 754 (38.3) 
    Statin users -- 112 (28.7)* 166 (37.4) 185 (36.7) 
    Statin non-users -- 695 (34.5) 639 (36.3) 569 (38.9) 
Gait speed decline ≥ 0.1 m/s per 
year, N (%) 
    
    Overall -- 534 (22.2) 501 (22.7) 470 (23.9) 
    Statin users -- 70 (18.0)* 114 (25.7) 119 (23.6) 
    Statin non-users -- 464 (23.3) 387 (22.0) 351 (24.0) 
a: Year 1 (1997-1998) did not measure a 20-m gait speed; Year 4 (2000-2001) did not collect medication data. 
P values (statin users versus nonusers): * P <0.05, **: P < 0.01, ***: P<0.001, ****: P<0.0001 
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Table 13. Univariate and Multivariate Associations between Statin Use and Gait Speed Decline of 0.05 m/s or 
More Per Year  
 Gait speed decline 
≥ 0.05 m/s per year 
(yes/no),  
Crude OR (95% 
CI) 
P value Gait speed 
decline ≥ 0.05 
m/s per year 
(yes/no), 
Adjusted OR 
(95% CI)a 
P value 
Non-users Reference -- Reference -- 
Any users 0.93 (0.83, 1.05) 0.27 0.84 (0.74, 0.96) 0.01 
High-dose (>1 SDD) 0.87 (0.68, 1.13) 0.31 0.76 (0.58, 0.99) 0.05 
Moderate-dose (1 SDD) 1.01 (0.85, 1.20) 0.91 0.96 (0.79, 1.16) 0.67 
Low-dose (< 1 SDD) 0.88 (0.73, 1.07) 0.20 0.76 (0.62, 0.94) 0.009 
Long-term (≥ 2 years) 0.93 (0.82, 1.07) 0.34 0.83 (0.71, 0.96) 0.02 
Short-term (< 2 years) 0.93 (0.76, 1.15) 0.52 0.88 (0.70, 1.10) 0.25 
Lipophilic statin useb 0.97 (0.85, 1.10) 0.60 0.88 (0.76, 1.01) 0.06 
Hydrophilic statin useb 0.69 (0.47, 1.02) 0.06 0.60 (0.41, 0.87) 0.007 
Abbreviations: OR: odds ratio; SDD: standardized daily dose;  
a Separate multivariable Generalized Estimating Equation analysis were used to adjust for baseline demographics (race, sex, site).  Models 
included time-varying statin use, age, coronary heart disease, diabetes, stroke, peripheral artery disease, self-rated health, gait speed at previous 
year, anticholinergics, benzodiazepines, angiotensin converting enzyme inhibitors, nonsteroidal anti-inflammatory drugs, other anti-inflammatory 
drugs, and number of prescription drugs.    
b Lipophilic statins include atorvastatin, lovastatin, fluvastatin and simvastatin, and hydrophilic statins include pravastatin, and rosuvastatin. 
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Table 14. Univariate and Multivariate Associations between Statin Use and Gait Speed Decline of 0.1 m/s or 
More Per Year 
 Gait speed 
decline ≥ 0.1 m/s 
per year (yes/no),  
Crude OR (95% 
CI) 
P value Gait speed decline 
≥ 0.1 m/s per year 
(yes/no), 
Adjusted OR 
(95% CI)a 
P value 
Non-users Reference -- Reference -- 
Any users 0.99 (0.86, 1.14) 0.87 0.89 (0.76, 1.05) 0.17 
High-dose (>1 SDD) 1.00 (0.75, 1.34) 0.98 0.89 (0.66, 1.20) 0.45 
Moderate-dose (1 SDD) 1.06 (0.86, 1.30) 0.59 1.01 (0.81, 1.26) 0.91 
Low-dose  (< 1 SDD) 0.91 (0.73, 1.13) 0.40 0.78 (0.61, 0.99) 0.04 
Long-term (≥ 2 years) 0.96 (0.82, 1.13) 0.65 0.85 (0.71, 1.01) 0.07 
Short-term (< 2 years) 1.06 (0.84, 1.35) 0.61 1.02 (0.79, 1.31) 0.89 
Lipophilic statin useb 1.01 (0.87, 1.17) 0.88 0.92 (0.78, 1.08) 0.31 
Hydrophilic statin useb 0.83 (0.54, 1.27) 0.39 0.72 (0.47, 1.12) 0.15 
Abbreviations: OR: odds ratio; SDD: standardized daily dose;  
a Separate multivariable Generalized Estimating Equation analysis were used to adjust for baseline demographics (race, sex, site).  Models 
included time-varying statin use, age, coronary heart disease, diabetes, stroke, peripheral artery disease, self-rated health, gait speed at previous 
year, anticholinergics, benzodiazepines, angiotensin converting enzyme inhibitors, nonsteroidal anti-inflammatory drugs, other anti-inflammatory 
drugs, and number of prescription drugs.    
b Lipophilic statins include atorvastatin, lovastatin, fluvastatin and simvastatin, and hydrophilic statins include pravastatin, and rosuvastatin. 
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5.1 ABSTRACT 
Background: Aspirin, non-aspirin nonsteroidal anti-inflammatory drugs (NA-NSAIDs) and 
acetaminophen all have biological effects that might reduce the risk of ovarian cancer. However, 
epidemiologic data on this question are mixed.   
Methods: A population-based, case-control study in western Pennsylvania, eastern Ohio, and 
western New York State included 902 women with incident epithelial ovarian cancer who were 
diagnosed between February 2003 to November 2008 and 1,802 matched controls.  Regular use 
(at least 2 tablets per week for 6 months or more) of aspirin, NA-NSAIDs, and acetaminophen 
before the reference date (9 months before interview date) was assessed by in-person interview.  
We used logistic regression to calculate adjusted odds ratios (ORs) and 95% confidence intervals 
(CIs).   
Results:  The OR for aspirin use was 0.81 (95% CI= 0.63–1.03).  Decreased risks were found 
among women who used aspirin continuously (0.71 [0.54–0.94]) or at a low-standardized daily 
dose (0.72 [0.53–0.97]), who used aspirin for the prevention of cardiovascular disease (0.72 
[0.57–0.97]), who used aspirin more recently, or who used selective COX-2 inhibitors (0.60 
[0.39–0.94]).  No associations were observed among women using non-selective NA-NSAIDs or 
acetaminophen.   
Conclusions:   Risk reductions of ovarian cancer were observed with use of aspirin or selective 
COX-2 inhibitors.  However, the results should be interpreted with caution due to the inherent 
study limitations and biases. 
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5.2 INTRODUCTION 
Ovarian cancer is the second leading gynecologic cancer, following cancer of the uterine corpus, 
and causes more deaths per year than any other cancer of the female reproductive system.1  It 
afflicts about 1 in 70 women, and is the fifth leading cause of cancer death among women in the 
United States.1,2  Approximately 21,550 new cases of ovarian cancer are diagnosed annually, 
resulting in 14,600 deaths.1,2  Thus, strategies that focus on prevention may provide the most 
rational approach for meaningful reductions in incidence and deaths attributable to ovarian 
cancer.   
Ovarian cancer has a poorly understood etiology and natural history.  Two dominant 
hypotheses explain the genesis of the disease.3 The ovulation hypothesis relates ovarian cancer 
risk to incessant ovulation, while the pituitary gonadotropin hypothesis implicates elevations in 
gonadotropin/estrogen levels.  Epidemiologic and biologic observations do not entirely support 
either hypothesis.  Previous work has suggested that ovarian cancer may be related to chronic 
pelvic inflammation that acts in concert with ovulation.4  This theory could be an important 
consideration for prevention of ovarian cancer and is supported by the mechanism of action of 
non-steroidal anti-inflammatory drugs (NSAIDs).  NSAIDs, including aspirin and non-aspirin 
NSAIDs (NA-NSAIDs), act through non-competitive and irreversible inhibition of 
cycloxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes in the synthesis of 
prostaglandins to produce anti-inflammatory and anti-neoplastic effects.5  In addition, NSAIDs 
may suppress ovulation and affect cell proliferation, angiogenesis, and apoptosis of the 
epithelium in ovarian cancer cell lines.6   Acetaminophen, another commonly used analgesic and 
antipyretic drug, has weak anti-inflammatory activity and may have an anti-gonadotropic effect.7  
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Acetaminophen may also inhibit ovarian carcinogenesis through the depletion of glutathione 
leading to necrosis.8  Therefore, aspirin, NA-NSAIDs, or acetaminophen may be potential agents 
for the chemoprevention of ovarian cancer.  NSAIDs and acetaminophen are two of the most 
frequently used classes of medication in the United States.9,10  NSAIDs generated about $14 
billion in sales world-wide in 2008.11  Because of the widespread use of aspirin, NA-NSAIDs 
and acetaminophen, any association with an increased or decreased cancer risk may have 
important public health implications. 
Several studies have described associations between aspirin or NA-NSAIDs use and the 
risk of ovarian cancer, but the findings are contradictory and inconclusive.  Previous studies were 
relatively small and lacked information or statistical power to assess the effects of dose, duration, 
drug classes, or indications.  The purpose of this study was to describe the associations of 
aspirin, NA-NSAIDs, or acetaminophen use with ovarian cancer risk, using the data from 
Hormones and Ovarian Cancer Prediction (HOPE) study, the second-largest population-based 
case-control study on ovarian cancer.    
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5.3 METHODS 
5.3.1 The HOPE study 
Study population and recruitment details have been published previously.12  Briefly, this is a 
case-control study involving 902 women with incident ovarian cancer (cases) from a contiguous 
region comprising western Pennsylvania, eastern Ohio, and western New York State.  Cases 
were residents of this region with histologically confirmed, primary, epithelial ovarian, fallopian 
tube, or peritoneal cancer diagnosed between February 2003 and November 2008.  Both 
borderline/low-malignant potential and invasive tumors were included.  For brevity, the term 
“ovarian cancer” is used here to describe all cases.  Women were referred from comprehensive 
hospital tumor registries, clinical practices, or pathology databases and contacted with the 
permission of their gynecologists.  Age-adjusted incidence rates for 2003-2007 for the catchment 
counties in our study were similar to the rates based on the Surveillance and Epidemiology End 
Results (SEER) data (overall incidence rate in SEER was 14 vs. HOPE, 13 cases per 100,000).  
The ascertained cases were representative of the population from this region and considered as 
population-based.   Eligible women had to be at least 25 years of age and recruited within 9 
months of initial diagnosis.  We excluded a total of 1,608 women (ineligible on the basis of age 
and time since diagnosis, residence outside of the counties in which referral hospitals were 
located, prior diagnosis of ovarian cancer, being non-English-speaking, or dead). Of 1,270 
eligible cases, 902 completed the interview. 
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Controls were identified through random-digit-dialed phone numbers.  Controls consisted 
of women at least age 25 who lived in the same telephone exchanges as cases.   These women 
were further screened to ensure that they had no previous oophorectomy or diagnosis of ovarian 
cancer.  Controls were frequency matched to cases by 5-year age groups and telephone exchange 
in approximately a 2:1 ratio.  Overall, 1,802 eligible controls completed interviews (Figure).   
A standardized 2-hour interview (see eAppendix [http://links.lww.com] for 
questionnaire) was conducted by trained interviewers in the homes of participating women.   The 
questionnaire included a reproductive and gynecologic history, a contraceptive history, a medical 
history, a family history, and information on lifestyle practices.  A life-events calendar, which 
marked milestones such as marriages and births, was used to aid recall of reproductive history, 
infertility treatment, hormone use, and use of aspirin, over-the-counter (OTC) and prescription 
pain relievers until the reference date.  The reference date was calculated as 9 months before the 
interview (for both cases and controls) to ensure that exposures occurred before the ovarian 
cancer diagnosis in cases and within a similar time frame for cases and controls.   The study 
protocol was approved by the University of Pittsburgh Institutional Review Board and by the 
human subject committees at each hospital where cases were identified.  All study subjects gave 
informed consent.      
5.3.2 Assessment of aspirin, NA-NSAIDs and acetaminophen use  
Since most analgesic use is sporadic, regular use was defined as at least 2 tablets/week for 6 
months or more. This definition created an exposure group that was homogeneous in its 
consistency of usage, and thus maximized the likelihood of detecting an association with ovarian 
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cancer.  Women who used less than this minimal level were defined as non-users.  Participants 
were first asked if they took any aspirin, OTC pain relievers or NA-NSAIDs, or prescription 
medications for pain or inflammation on a regular basis before the reference date. Women who 
responded affirmatively were then asked the drug name, dose and frequency (numbers of pills 
taken per day, week, or month), the age at which they started, and duration (months or years) of 
use.  For each episode, the primary reason for using the drug was recorded. The conditions were 
grouped as arthritis/burstitis/rheumatism, gout, menstrual cramps, injury, surgical/dental pain, 
back pain, headache, muscle ache, heart disease prevention (only listed for aspirin), others, or 
unknown.  Aspirin products were defined as any product containing generic aspirin.  NA-
NSAIDs included celecoxib, diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, 
indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumatone, 
naproxen/naproxen sodium, rofecoxib, sulindac, valdecoxib, or other NA-NSAIDs.  
Acetaminophen products were defined as any product containing acetaminophen.    
5.3.3 Statistical Methods 
Student’s t test was used for continuous variables, and the Chi-square test for categorical 
variables to compare differences between cases and controls.  Unconditional logistic regression 
was used to calculate multivariable-adjusted odds ratios (ORs) as estimates of the relative risk 
and related 95% confidence intervals (95% CIs) for analgesics use.  Potential confounders fell 
into 2 groups: those variables that (1) a priori were thought to be related to the exposure and also 
were risk factors for ovarian cancer and (2) those variables that previously published studies 
considered confounders.  Confounders included the following: age (at reference year); interview 
170 
 
year; region of residence (western Pennsylvania, eastern Ohio, and western New York); 
education; race; religion; parity; breastfeeding; history of infertility; contraceptive use and 
duration; menstrual status (age at menarche, menopausal status and age at menopause); use of 
postmenopausal hormone and duration; indications for aspirin, NA-NSAIDs, or acetaminophen 
use; prior hysterectomy or tubal ligation; history of endometriosis; history of pelvic 
inflammatory disease; family history of breast cancer or ovarian cancer in first-degree relative; 
body mass index; cigarette smoking; alcohol consumption; comorbidities; and yearly household 
income.     
Data were analyzed initially by constructing frequency counts of cases and controls by 
exposure variables and calculating ORs adjusted for age, region of residence, and interview year 
(Table 1).  Second, confounders were forced into the models but were kept in the final regression 
model only if they changed the parameter estimates by at least 15%.  The final multivariate 
model included age, region of residence, interview year, race, education, breastfeeding, numbers 
of full-term births, duration of oral contraceptive use, body mass index, postmenopausal 
hormone use, prior tubal ligation, arthritis, and diabetes (Tables 2-4).  For the primary analyses 
of NSAIDs, women who had never used aspirin or NA-NSAIDs on a regular basis were the 
referent group.   Risk was assessed separately among the subgroups of women who had used 
aspirin only, NA-NSAIDs only, and any NSAIDs (aspirin plus NA-NSAIDs).  For the 
acetaminophen analyses, nonusers were considered as never having used acetaminophen 
regularly (but did not exclude aspirin or NA-NSAIDs use) before the reference date. 
Duration of use was defined by three indicators as follows: (1) continuous (had used for 
at least 1 year and until or beyond the reference date); (2) current (used only less than a year and 
used on the reference date); and (3) past (discontinued use at least 1 year before the reference 
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date).  To examine dose-response effects, the average daily dose was calculated by multiplying 
the number of dosage forms per day with the strength of the medication taken during the most 
recent period before the reference date.  For aspirin, the average daily dose was converted to a 
standardized daily dose by dividing it by 325 mg, assuming it was used as antithrombotic therapy 
for cardiovascular disease based on the dosage suggested by American College of Chest 
Physicians Evidence-Based Clinical Practice Guidelines.13   For NA-NSAIDs and 
acetaminophen, the average daily dose was then converted to a standardized daily dose by 
dividing it into minimal effective analgesic doses per day.14  The minimal effective analgesic 
doses per day for individual agents were as follows: acetaminophen (1500 mg), celecoxib (200 
mg), diclofenac (100 mg), etodolac (400 mg), fenoprofen (800 mg), flurbiprofen (150 mg), 
ibuprofen (1200 mg), indomethacin (75 mg), ketorolac (40 mg), ketoprofen (75 mg), 
mecolfenamate (150 mg), meloxicam (7.5 mg), nabumetone (1000 mg), naproxen (500 mg), 
piroxicam (20 mg), rofecoxib (25 mg), tolmetin (600 mg), sulindac (300 mg), and valdecoxib (10 
mg).15-17  Dosages were categorized into three clinically relevant categories: low-dose (≤ 0.5 
standardized daily dose), moderate-dose  (0.5-1 standardized dose) and high-dose (> 1 
standardized dose).14  Morever, the subgroup analyses were conducted by recency of use (e.g., 
age at first/last time use), self-reported indication and two types of NA-NSAIDs (i.e., non-
selective NA-NSAIDs and selective COX-2 inhibitors).   For the analysis on indications for 
analgesics, women who used different analgesics or the same analgesics but for different 
indications were considered separately.  Analyses were also conducted separately among women 
with borderline and invasive epithelial ovarian tumors, and various histologic subgroups (i.e., 
serous, mucinous, endometrioid, clear cell, mixed cell and other epithelial cells); age less than 55 
and 55 or more years; with and without arthritis; and with and without diabetes.  All analyses 
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were carried out using STATA, version 11.0, statistical package (StataCorp LP, College Station, 
Texas, USA). 
5.4 RESULTS 
Population characteristics are described in Table 15. Ninety-seven percent of the women were 
white; 61% of cases and 57% of controls were older than age 55.   Cases were more likely to be 
older, black, and nulliparous, and to have a body mass index of 30 kg/m2 or more. Controls were 
more likely to be educated beyond high school, to have breastfed, have used oral contraceptives 
or postmenopausal hormones, have a history of tubal ligation, and have cormobidities including 
arthritis and diabetes.  Overall, 489 cases and 1,015 controls reported having used aspirin, NA-
NSAIDs, or acetaminophen on a regular basis. 
 Table 16 describes the regular use of aspirin or NA-NSAIDs and risks of ovarian cancer. 
The adjusted OR for regular use (versus never-use) of aspirin was 0.81 (95% CI= 0.63–1.03).  
ORs were reduced among continuous users (0.71 [0.54–0.94]), women who had used aspirin at 
low-standardized daily dose (0.72 [0.53–0.97]), women who began using aspirin only after age 
45 (0.66 [0.50–0.88]), and women who stopped using after age 55 (0.70 [0.53–0.93]).  Of those 
in the low-standardized daily dose group, the OR for using aspirin at daily doses of ≤81 mg was 
0.66 (0.48–0.90). There were no associations between NA-NSAIDs or acetaminophen and 
ovarian cancer (Table 19). 
 In Table 17, the adjusted OR for regular use of aspirin for prevention of cardiovascular 
disease was 0.72 (0.57–0.97). Seventy-one percent of women had used aspirin 81 mg daily for 
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this purpose.  A decreased OR was more evident among women who used aspirin for 
cardiovascular prevention for at least 5 years (0.66 [0.48–0.92]).  Risk patterns remained 
essentially unchanged when stratified by indications for NA-NSAIDs use (Table 20). 
ORs were reduced among women who used selective COX-2 inhibitors (0.60 [0.39–0.94]), but 
not in users of non-selective NA-NSAIDs (Table 18).  The protective effects of selective COX-2 
inhibitors were found only in women who used celecoxib (0.46 [0.25–0.84]), with no evidence of 
association in women who used rofecoxib or valdecoxib. 
 Cases included 677 women with invasive epithelial ovarian tumors, 97 with borderline or 
low-malignant potential epithelial ovarian tumors, 75 with peritoneal tumors, 32 with fallopian 
tumors, and 21 with “other/missing” type.  Among the various histologic types of ovarian cancer, 
516 cases were diagnosed with serous, 66 with mucinous, 100 with endometrioid, 54 with clear 
cell, 77 with mixed cells and 89 with other epithelial tumors.  The results were similar for 
borderline or low-malignant potential and invasive tumors, and across categories of histologic 
types (Table 21).  Stratification by age (less than 55 and 55 or more), arthritis status, and 
diabetes status, did not reveal any important differences in the associations between aspirin, NA-
NSAIDs, or acetaminophen use and ovarian cancer. 
5.5 DISCUSSION 
Aspirin or selective COX-2 inhibitors were associated with reduced risk of ovarian cancer, 
especially among middle aged and older women who took aspirin at low doses (or for prevention 
of cardiovascular disease) continuously over a long period of time.  The results do not support 
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the regular use of non-selective NA-NSAIDs and acetaminophen in the chemoprevention of 
ovarian cancer.  We were able to evaluate dose-effects comprehensively among NSAIDs by 
using a standardized daily dose, and we had sufficient sample size to perform stratified analyses 
by indications of analgesic use and types of NA-NSAIDs.   
Our results provide an additional direction for future study on the relationship between 
aspirin use and risk of ovarian cancer.  Low-dose and continuous aspirin use had modest 
protective association with about 20 to 30% risk reduction, but without a dose-response 
relationship.   A protective effect was not found in moderate to high-dose groups, which could 
have been due to smaller sample sizes with insufficient power.  Our results agree with a study 
conducted by Hannibal et al.,18 in which there were similar findings with aspirin use. However, 
findings were null in a randomized controlled trial19 and 521-25 of 8 cohort studies,20-27 and 
inconsistent in 12 previous case-control studies.7,18,28-37 Ten7,20,22-24,28,30,31,34,35 studies found no 
association with aspirin use regardless of the duration or frequency of use, 4 studies found 
protective effects,25,32,33,36 and 2 studies found harmful effects on ovarian cancer.18,37  Our results 
of null associations with NA-NSAIDs use support findings in 57,23,24,26,,30 of 9 previous 
studies.7,20,23, 24,26,,27,30,32,37 Two studies7,31 showed protective results of acetaminophen, not found 
in our study or 10 others.18,20,21,23,24,25,29,32,33,37  These inconsistent findings may reflect inhibition 
of the progression, rather than the induction, of ovarian cancer; differences in the definition of 
regular analgesics use; incomplete or lack of information of dose, frequency, indication, and the 
list of medications queried; and different exposure assessments.  Most analgesic use is sporadic, 
and recall of sporadic use may be less accurate.  Furthermore, cumulative exposure could be 
assessed only approximately, due to incomplete information on dose and duration.  Some studies 
evaluated dose in numbers of pills or tablets per week. However, different brands may not 
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contain standardized amounts of the active ingredient.  The list of NA-NSAIDs queried is 
heterogeneous and not comprehensive.  This could lead to a misclassification of users and non-
users, which would bias the results towards the null and attenuate the protective effect.  The 
methodologic differences in assessing exposure remains an issue until validated operational 
definitions can be developed. 
Given that most analgesic use may be episodic, it is conceivable that low-dose and 
continuous aspirin use for antithrombotic therapy may be more effective than sporadic use in 
reducing the synthesis of prostaglandins, further inhibiting chronic inflammation, cell 
proliferation, DNA synthesis, and suppressing immune response to neoplastic cells.38  The 
biologic explanations for the protective association between aspirin or selective COX-2 
inhibitors and ovarian cancer could be due to anti-carcinogenic effects via inhibition of COX-2 
and COX-independent mechanisms.  Aspirin and selective COX-2 inhibitors could also suppress 
carcinogenesis through pathways independent of prostaglandins.  Increased COX-2 expression 
appears to be involved in the development of cancer by promoting cell division, inhibiting 
apoptosis, altering cell adhesion and stimulating angiogenesis.  Some tumors expressing COX-2 
are reported to exhibit more aggressive phenotype and poor clinical prognosis.39  Recent 
preclinical data demonstrated that prostaglandin E2 is strongly associated with surrounding 
stroma in the tumor microenvironment in ovarian cancer and tumor progression.40  COX-2 is 
expressed in epithelial ovarian cancer; the rate of expression ranges from 31% to 89%.39  
Furthermore, aspirin and selective COX-2 inhibitors could act indirectly by inhibiting 
ovulation.41  In our study, the protective effect of selective COX-2 inhibitors was only found in 
using celecoxib.  Rofecoxib is a more potent COX-2 inhibitor than celecoxib, although Gorsch et 
al42 found that celecoxib had unique and stronger anti-carcinogenic activity. 
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Our study is the second largest case-control study in ovarian cancer research, with a 
population-based design that contributes to generalizability of the results.  The population had 
relatively high use of OTC and prescription analgesics, and provided detailed information on 
types, frequency, dose, duration and indications.  The study collected data on a large number of 
potential confounders, which allowed for robust multivariate analyses.  Complete dosage 
information allowed us to evaluate the risk by standardized daily doses and to conduct stratified 
analysis of selective COX-2 inhibitors. 
Our study has certain limitations and biases that may have contributed to the observed 
results.  First, we had no data on the characteristics of excluded and non-responding cases.  
Based on additional sensitivity analyses, the protective results for aspirin at low-standardized 
daily dose, continuously and recently, would be nullified if the responding controls had at least 
twice the exposure of non-responding controls, or if non-responding cases had at least 1.7 times 
the exposure of the responding cases.  Although responders and non-responders might not have 
the same analgesic exposure, it is unlikely that non-responders in either the case or control 
groups would have double or half of the exposure of the responders.  Therefore, we believe the 
results are robust even with the non-responders.  Second, cases may be more motivated to 
remember their analgesic use than controls.  However, any tendency for the cases to better recall 
exposures would result in ORs greater than 1.0 rather than the protective effects observed here.  
Alternatively, controls might exaggerate their exposure relative to cases, if controls believed 
analgesics have a chemoprotective effect.  This bias could over-estimate the protective effect.  
To reduce the impact of recall bias, a defined reference date was used for assessing exposures.  
The protective effects of recent aspirin use might be due to recall limitation since patients were 
more likely to recall the medications used recently.  Third, measurement and misclassification 
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errors are presumably present when relying on self-reported and single measurement of 
analgesics use without verification.43 Regular use was defined to improve recall; however, this 
means that sporadic analgesic use could not be assessed.  Including sporadic use in the non-user 
group, or evaluating aspirin/NA-NSAID use without excluding acetaminophen users, might 
attenuate the association and bias results toward the null.  The results from additional analyses 
were similar when comparing non-regular users of any analgesics with 7 mutually exclusive 
groups (aspirin only, NA-NSAID only, aspirin plus NA-NSAID, acetaminophen only, aspirin 
plus acetaminophen, NA-NSAID plus acetaminophen, aspirin plus NA-NSAID plus 
acetaminophen) (Table 22).  However, duration and dose-response effects could not be 
evaluated due to small sample sizes in the last 4 of these subgroups. 
Fourth, we did not collect comprehensive information on medical co-morbidities related 
to cardiovascular disease, health-conscious behaviors, or factors related to adverse histories of 
aspirin use.  Although the observed effect might be biased by the residual or unmeasured 
confounding, little change was found when two health-related behavior factors (i.e., how often 
having a routine gynecologic check-up or engaging in physical activities) were included in a 
separate analysis (for aspirin use, OR= 0.79 [95% CI= 0.62–0.99]; for NA-NSAIDs, 1.04 [0.82–
1.32]).  Fifth, while different NA-NSAIDs may have different effects on ovarian cancer, all were 
grouped into a single category.  This limits our ability to evaluate the effect of individual NA-
NSAIDs.  Sixth, survival bias is possible.  Since aspirin is used in the primary and secondary 
prevention of coronary heart disease, especially among high-risk women, it is possible that 
earlier mortality among aspirin users (e.g., from heart disease) precludes diagnosis of ovarian 
cancer and therefore produces a false impression of beneficial effect.  Finally, the majority of 
women were white, limiting generalizability of the results to other ethnicities.   
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Our data suggest a lower risk of ovarian cancer among women who used aspirin at a low-
standardized daily dose continuously, or who used selective COX-2 inhibitors. These results 
should be interpreted with caution due to inherent study limitations and biases.  Future research 
on these associations should better characterize accompanying medical conditions, health and 
lifestyle behaviors, the dose, frequency, and duration of analgesic use, age of therapy initiation, 
genetic susceptibility, and the overall risk-benefit balance. 
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5.7 TABLES 
Table 15. Characteristics of Ovarian Cancer Cases and Controls in the HOPE Study 
 Case  
(n = 902) 
No. (%)a 
Control  
(n = 1,802) 
No. (%)a 
ORb 
(95% CI) 
Age (years); mean (SD) 58.29 (12.8) 57.02 (12.4) - 
Race 
  Whitec 
  Black 
  Other 
 
856 (95) 
35 (4) 
11 (1) 
 
1758 (97) 
29 (2) 
15 (1) 
 
1.00  
2.23 (1.35–3.68) 
1.43 (0.65–3.14) 
Education 
  Not high school graduatec 
  High school graduate  
  Post-high school 
  College graduate or post-college  
 
83 (9) 
303 (34) 
251 (28) 
265 (29) 
 
82 (4) 
535 (30) 
553 (31) 
632 (35) 
 
1.00 
0.56 (0.40–0.78) 
0.45 (0.32–0.64) 
0.43 (0.30–0.60) 
Contraceptive used 
  Never usec 
  Any hormonal  
  Non-hormonal  
 
120 (13) 
481 (53) 
297 (33) 
 
121 (7) 
1168 (65) 
508 (28) 
 
1.00 
0.41 (0.31–0.55) 
0.58 (0.43–0.77) 
Oral contraception used, years 
  Never usec 
  <1-4  
  <5-9  
  >9  
 
367 (41) 
321 (35) 
142 (16) 
71 (8) 
 
531 (30) 
667 (37) 
331 (18) 
273 (15) 
 
1.00 
0.69 (0.56–0.85) 
0.61 (0.47–0.78) 
0.37 (0.27–0.51) 
No. of full-term birthse(%) 
  Never pregnantc 
  0 
  1 
  2 
  ≥ 3 
 
167 (19) 
46 (5) 
120 (13) 
264 (29) 
305 (34) 
 
167 (9) 
63 (4) 
231 (13) 
601 (33) 
740 (41) 
 
1.00 
0.75 (0.49–1.17) 
0.52 (0.38–0.71) 
0.43 (0.33–0.56) 
0.37 (0.29–0.48) 
Ever breastfeeding 
  Never pregnantc 
  Ever pregnant but never breastfeeding 
  Any breastfeeding 
 
167 (18) 
432 (48) 
303 (34) 
 
167 (9) 
747 (42) 
888 (49) 
 
1.00 
0.56 (0.44–0.72) 
0.33 (0.26–0.43) 
Postmenopausal hormone used 
  Never usec 
  Estrogen only 
  Estrogen + Progesterone 
 
603 (67) 
155 (17) 
118 (13) 
 
1137 (63) 
304 (17) 
307 (17) 
 
1.00 
0.87 (0.69–1.09) 
0.67 (0.53–0.85) 
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Table 15 (Continued) 
 Case  
(n = 902) 
No. (%)a 
Control  
(n = 1,802) 
No. (%)a 
ORb 
(95% CI) 
History of tubal ligationd 
  Noc 
  Yes 
 
666 (74) 
201 (22) 
 
1162 (65) 
616 (34) 
 
1.00 
0.57 (0.47–0.68) 
BMI (kg/m2)d 
  < 25c 
  25-29                     
  ≥ 30        
 
300 (33) 
267 (30) 
334 (37) 
 
670 (37) 
528 (29) 
603 (34) 
 
1.00 
1.12 (0.91–1.37) 
1.25 (1.03–1.51) 
Self-reported comorbiditiesf 
  Arthritis 
  Hypertension  
  Diabetes  
 
335 (37) 
329 (37) 
86 (10) 
 
825 (46) 
662 (37) 
217 (12) 
 
0.63 (0.51–0.73) 
0.90 (0.76–1.09) 
0.74 (0.57–0.96) 
Family history of breast and ovarian cancers in 
first-degree relativesd,g  
  No known family historyc 
  Breast cancer only  
  Ovarian cancer only  
  Breast and ovarian cancer  
 
 
715 (79) 
147 (16) 
32 (4) 
6 (1) 
 
 
1491 (83) 
255 (14) 
44 (2) 
10 (1) 
 
 
1.00 
1.16 (0.93–1.45) 
1.49 (0.93–2.37) 
1.24 (0.45–3.46) 
Annual household incomed 
  < $20,000c 
  $20,000 – $34,999 
  $35,000 – $69,999 
  ≥ $70,000 
  Refused 
 
137 (15) 
166 (19) 
304 (34) 
201 (23) 
75 (9) 
 
245 (14) 
307 (17) 
615 (35) 
436 (25) 
151 (9) 
 
1.00 
0.99 (0.74–1.31) 
0.96 (0.74–1.24) 
0.87 (0.66–1.16) 
0.96 (0.68–1.37) 
NSAIDsh regular usei 
   Non-users c, j   
   Aspirin only  
   NA-NSAIDs only 
   Aspirin plus NA-NSAIDs  
 
456 (51) 
169 (19) 
167 (18) 
110 (12) 
 
850 (47) 
360 (20) 
336 (19) 
256 (14) 
 
1.00 
0.79 (0.63–0.98) 
0.91 (0.73–1.13) 
0.74 (0.57–0.95) 
Acetaminophen regular usei 
   Non-users c, k 
   Acetaminophen  
 
738 (82) 
164 (18) 
 
1447 (80) 
355 (20) 
 
1.00 
0.90 (0.73–1.11) 
a Except for age 
b:Except for age, all the ORs were adjusted by age (continuous), region of residence, interview calendar year in the logistic regression. 
c Reference category. 
d Data were not summed to total due to the missing or unknown values.  
e Number of full-term births, including both live and stillbirths; full-term is >6 months; twins and other multiples count as 1. 
f Reference category is no arthritis, no hypertension, and no diabetes; respectively 
g first-degree relatives including natural father and mother and blood-related brothers, sisters, sons and daughters. 
h NSAID: includes aspirin or all other reported NA-NSAIDS. 
i Regular use defined as ≥ 2 tablets/week for ≥ 6 months. 
i Non-user:  women who indicated that they didn’t use aspirin or NA-NSAID (but might or might not have used acetaminophen) ≥ 2 tablets/week 
for ≥ 6 months (“minimal level”). 
k Non-user:  women who indicated that they didn’t used acetaminophen (but might or might not have used aspirin or NA-NSAID)≥ 2 tablets/ 
week for ≥ 6 months (“minimal level”). 
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Table 16. Regular Use of Aspirin or NA-NSAIDs and Risk of Ovarian Cancer in the HOPE study 
 Aspirin only NA-NSAID only Aspirin plus NA-NSAID  
 No. 
Cases 
No. 
Controls 
OR  
(95% CI)a 
No. 
Cases 
No. 
Controls 
OR  
(95% CI)a 
No. 
Cases 
No. 
Controls 
OR  
(95% CI)a 
Nonusers b  456 850 1.00 456 850 1.00 456 850 1.00 
Regular users c 169 360 0.81 (0.63–1.03) 167 336 1.06 (0.83–1.36) 110 256 0.95 (0.70–1.27) 
Types of users d          
    Continuous 121 283 0.71 (0.54–0.94) 96 199 1.10 (0.78–1.55) 93 211 0.99 (0.72–1.36) 
    Current 6 17 0.50 (0.19–1.32) 11 31 0.93 (0.64–1.37) 4 12 0.76 (0.23–2.57) 
    Past 42 60 1.34 (0.86–2.10) 60 106 1.19 (0.77–1.84) 13 33 0.76 (0.37–1.55) 
Standardized-daily dosee          
    Low 92 227 0.72 (0.53–0.97) 102 189 1.12 (0.83–1.51) 69 163 0.88 (0.62–1.24) 
    Moderate 46 81 0.84 (0.55–1.28) 42 97 0.96 (0.62–1.47) 26 57 1.21 (0.72–2.05) 
    High     31 52 1.08 (0.66–1.79) 23 50 1.01 (0.58–1.78) 15 36 0.90 (0.46–1.75) 
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Table 16 (Continued) 
 Aspirin only NA-NSAID only Aspirin plus NA-NSAID  
 No. 
Cases 
No. 
Controls 
OR  
(95% CI)a 
No. 
Cases 
No. 
Controls 
OR  
(95% CI)a 
No. 
Cases 
No. 
Controls 
OR  
(95% CI)a 
Age at first use (years)              
    < 45 50 75 1.32 (0.73–1.61) 77 162 1.04 (0.74–1.46) 62 79 1.10 (0.77–1.59) 
    ≥ 45 119 285 0.66 (0.50–0.88) 90 174 1.08 (0.78–1.49) 48 177 0.79 (0.53–1.17) 
Age at last use (years)              
    < 55 48 90 1.08 (0.73–1.61) 91 200 1.04 (0.76–1.42) 40 79 1.12 (0.73–1.75) 
    ≥ 55 121 270 0.70 (0.53–0.93) 76 136 1.10 (0.77–1.56) 70 177 0.85 (0.59–1.21) 
a: The ORs were adjusted by age at reference year, interview year, region of residence, race, education, breastfeeding, numbers of full-term births , duration of oral contraception use (years), body 
mass index, postmenopausal hormone use, arthritis, diabetes, and prior tubal ligation.  
b: Non-user:  Women who indicated that they did not use aspirin or NA-NSAIDs ≥ 2 tablets/week for ≥ 6 months (“minimal level”). Reference category. 
c: Regular user: women who indicated that they had used aspirin/NA-NSAIDs/aspirin plus NA-NSAIDs ≥ 2 tablets/week for ≥ 6 months 
d: Duration of use was defined by three indicators: (1) continuous (had used for at least 1 year and until or beyond the reference date); (2) current (used only less than a year and used on the 
reference date); (3) past users (discontinued use at least 1 year before the reference date).   
e: To examine dose-response effects, the average daily dose was converted to a standardized daily dose by dividing by 325 mg for aspirin and minimal effective analgesic doses per day for other 
agents. Dosages were categorized into three clinically relevant categories: low-dose (≤ 0.5 standardized daily dose), moderate-dose  (0.5-1 standardized daily dose) and high-dose (> 1 
standardized daily dose). 
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Table 17. Regular use of Aspirin by Self-Reported Indications and Risk of Ovarian Cancer in the HOPE study 
 No. Cases No. Controls OR (95% CI)a 
Nonusers b  623 1186 1.00 
Regular usersc by indicationsd    
    Prevention for CVD 159 392 0.72 (0.57–0.97) 
    Arthritis/bursitis, rheumatism 44 93 0.80 (0.53–1.21) 
    Headache 51 94 1.04 (0.71–1.52) 
    Other pain or injuries 50 75 1.27 (0.85–1.90) 
a: ORs and p-values were adjusted by age at reference year, interview year, region of residence, race, education, breastfeeding, numbers of full-term births, duration of oral contraception use 
(years), body mass index, postmenopausal hormone use, arthritis, diabetes, and prior tubal ligation.  
b: Non-user: women who indicated that they had not used aspirin ≥ 2 tablets/week for ≥ 6 months (“minimal level”). Reference category. 
c: Regular user: women who indicated that they had used aspirin  ≥ 2 tablets/week for ≥ 6 months 
d:  If patients used aspirin for different major indications before the reference date, each episode was counted separately 
 
 
Table 18. Regular Use of Non-Selective or Selective NA-NSAID and Risk of Ovarian Cancer among NA-NSAID Only Users in the HOPE Study 
 No. Cases No. Controls OR (95% CI)a 
Nonusers b  456 850 1.00 
Non-selective NA-NSAIDs c users 139 261 1.00 (0.78–1.30) 
Selective COX-2 NA-NSAIDsc users 28 75 0.60 (0.39–0.94) 
a: ORs and p-values were adjusted by age at reference year, interview year, region of residence, race, education, breastfeeding, numbers of full-term births, duration of oral contraception use 
(years), body mass index, postmenopausal hormone use, arthritis, diabetes, and prior tubal ligation.  
b: Non-user: women who indicated that they had not used aspirin or NA-NSAIDs ≥ 2 tablets/week for ≥ 6 months (“minimal level”). Reference category. 
c: selective COX-2 NA-NSAIDs users include rofecoxib, celecoxib and valdecoxib, and the rest of NA-NSAIDs were included in non-selective NA-NSAIDs based on the most recent record 
daily dose of acetaminophen, so we combined moderate- and high-standardized daily dose into one group (moderate-high)  
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Table 19. Regular use of Acetaminophen and risk of ovarian cancer in the HOPE study 
 No of Cases No. of Controls OR (95% CI)a 
Nonuserb  738 1,447 1.00 
Regular usersc 164 355 0.98 (0.79, 1.23) 
Types of usersd 
    Continuous  
    Current 
    Past 
 
98 
9 
57 
 
212 
24 
119 
 
0.98 (0.74, 1.30) 
0.81 (0.36, 1.83) 
1.02 (0.72, 1.45) 
Standardized daily dosee 
    Low 
    Moderate-High 
 
136 
28 
 
291 
64 
 
0.99 (0.77, 1.26) 
0.98 (0.60, 1.60) 
Age at first use (years)     
    < 45 
    ≥ 45 
 
86 
78 
 
175 
180 
 
1.02 (0.75, 1.37) 
0.95 (0.70, 1.30) 
Age at last use (years)     
    < 55 
    ≥ 55 
 
84 
80 
 
183 
172 
 
0.98 (0.72, 1.32) 
0.99 (0.73, 1.35) 
Time since first use (years) 
    < 10 
    ≥ 10 
 
82 
81 
 
167 
188 
 
1.05 (0.78, 1.43) 
0.91 (0.68, 1.23) 
Time since last use (years) 
    < 4 
    ≥ 4 
 
114 
49 
 
256 
99 
 
0.94 (0.72, 1.22) 
1.08 (0.74, 1.56) 
a: ORs and p-values are adjusted by age at reference year, interview year, study center, race, education, breastfeeding, numbers of full-term, duration of oral contraception use (years), body mass index, 
postmenopausal hormone use, arthritis, diabetes, and prior tubal ligation.  
b: Non-user:  Women who indicated that they had not used acetaminophen (but may or may not use aspirin or NA-NSAIDs) ≥ 2 tablets/per week for at least 6 months (“minimal level”). Reference 
category. 
c: Regular user: women who indicated that they had used acetaminophen (but may or may not use aspirin or NA-NSAIDs)  ≥ 2 tablets/per week for at least 6 months 
d: Duration of use was defined by three indicators: (1) continuous (had used for at least 1 year and until or beyond the reference date); (2) current (used only less than a year and used on the reference 
date); (3) past users (discontinued use at least 1 year before the reference date).   
e: Only 6 cases and 9 controls used high standardized daily dose of acetaminophen, so we combined moderate- and high-standardized daily dose into one group (moderate-high)  
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Table 20. Regular use of NA-NSAIDs only or Acetaminophen by self-reported indications and risk of ovarian cancer in the HOPE study 
 NA-NSAIDs only Acetaminophen 
No. Cases No. Controls OR (95% CI)a No. Cases No. Controls OR (95% CI)a 
Nonusers b  456 850 1.00 738 1447 1.00 
Regular usersc by indicationsd       
    Arthritis/bursitis, 
rheumatism 
74 191 0.85 (0.59, 1.21) 62 161 0.88 (0.62, 1.25) 
    Headache 16 38 0.99 (0.51, 1.91) 50 100 1.05 (0.72, 1.53) 
    Other pain or injuries 85 127 1.33 (0.96, 1.85) 65 125 1.04 (0.73, 1.46) 
a: ORs and p-values were adjusted by age at reference year, interview year, region of residence, race, education, breastfeeding, numbers of full-term births, duration of oral contraception use (years), 
body mass index, postmenopausal hormone use, arthritis, diabetes, and prior tubal ligation.  
b: Non-user: for NA-NSAIDs only, women who indicated that they had not used aspirin or NA-NSAIDs ≥ 2 tablets/week for ≥ 6 months (“minimal level”); for acetaminophen, Women who indicated 
that they had not used acetaminophen (but may or may not use aspirin or NA-NSAIDs) ≥ 2 tablets/per week for at least 6 months. Reference category. 
c: Regular user: women who indicated that they had used aspirin  ≥ 2 tablets/week for ≥ 6 months 
d:  If patients used NA-NSAIDs (or acetaminophen) for different major indications before the reference date, each episode (indication) was counted separately 
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Table 21. Regular use of Aspirin, NA-NSAID, Acetaminophen and Risk of Ovarian Cancer by Tumor Behaviors and Histologic Types in the HOPE 
study 
 OR (95% CI)a among Regular usersb 
Aspirin only NA-NSAID only Aspirin plus NA-NSAID 
Nonusers c  1.00 1.00 1.00 
Tumor Behaviors     
    Borderline or low-malignant potential  0.66 (0.43, 1.02) 1.04 (0.60, 1.60) 0.74 (0.44, 1.24) 
    Invasive  0.79 (0.62, 1.02) 1.06 (0.82, 1.39) 0.99 (0.73, 1.34) 
Histologic Types    
    Serous 0.79 (0.59, 1.05) 0.95 (0.70, 1.30) 0.75 (0.52, 1.08) 
    Non-Serouse 0.83 (0.58, 1.19) 1.27 (0.90, 1.78) 1.30 (0.87, 1.93) 
a: The ORs were adjusted by age at reference year, interview year, region of residence, race, education, breastfeeding, numbers of full-term births , duration of oral contraception use (years), body 
mass index, postmenopausal hormone use, arthritis, diabetes, and prior tubal ligation.  
b: Regular user: women who indicated that they had used aspirin/NA-NSAIDs/aspirin plus NA-NSAIDs ≥ 2 tablets/week for ≥ 6 months 
c: Non-user:  Women who indicated that they did not use aspirin or NA-NSAIDs ≥ 2 tablets/week for ≥ 6 months (“minimal level”). Reference category 
e: Non-serous types include mucinous (n=66), endometrioid (n=100), clear cell (n=54), mixed cells (n=77), and other/unknown epithelial tumors (n=89). Except serous type, other histologic types 
had small sample sizes, resulting in imprecise estimates. 
190 
Table 22. Regular Use of Aspirin, NA-NSAID or Acetaminophen and Risks of Ovarian Cancer in the HOPE 
Study (Definition of non-users: without use any analgesics regularly) 
 No. of Cases No. of Controls OR (95% CI)a 
Nonuserb  411 784 1.00 
Regular users 491 1018 0.97 (0.81, 1.16) 
    Aspirin only 136 285 0.79 (0.61, 1.04) 
        Types of users c    
            Continuous 102 234 0.73 (0.54, 0.98) 
Current 5 15 0.50 (1.18, 1.44) 
Past 29 36 1.43 (0.82, 2.51) 
        SDDd    
Low 77 197 0.68 (0.49,0.94) 
Moderate 41 61 0.97 (0.62, 1.53) 
High 18 27 1.07 (0.54, 2.10) 
    NA-NSAID only 119 232 1.13 (0.86, 1.49) 
        Types of users c    
Continuous 65 131 1.14 (0.80, 1.62) 
Current 8 22 0.85 (0.35, 2.06) 
Past 46 79 1.30 (0.85, 2.01) 
        SDDd    
Low 68 120 1.25 (0.88, 1.79) 
Moderate 24 58 0.96 (0.56, 1.65) 
High 27 54 1.19 (0.70, 2.02) 
    Aspirin + NA-NSAID 72 146 1.09 (0.76, 1.55) 
        Types of users c    
 Continuous 61 125 1.07 (0.74, 1.57) 
 Current 4 5 2.62 (0.63, 0.80) 
 Past 7 16 0.82 (0.31, 2.16) 
        Standardized daily dosed    
 Low 42 94 0.89 (0.58, 1.38) 
 Moderate 17 34 1.39 (0.72, 2.67) 
High 13 18 1.70 (0.78, 3.70) 
    Acetaminophen onlye 45 66 1.26 (0.81, 1.95) 
    Aspirin plus 
Acetaminophene 
33 75 0.92 (0.58, 1.47)  
    Acetaminophen plus NA-
NSAIDe 
48 104 0.94 (0.62, 1.44) 
    Aspirin plus 
Acetaminophen plus NA-
NSAID 
38 110 0.83 (0.53, 1.30) 
a: The ORs were adjusted by age at reference year, interview year, region of residence, race, education, breastfeeding, numbers of full-term births, 
duration of oral contraception use (years), body mass index, postmenopausal hormone use, arthritis, diabetes, and prior tubal ligation.  
b: Non-user:  Women who indicated that they did not used any aspirin, NA-NSAIDs or acetaminophen  ≥ 2 tablets/week for ≥ 6 months 
(“minimal level”).  Reference category. 
c: Duration of use was defined by three indicators: (1) continuous (had used for at least 1 year and until or beyond the reference date); (2) current 
(used only less than a year and used on the reference date); (3) past users (discontinued use at least 1 year before the reference date).   
d: To examine dose-response effects, the average daily dose was converted to a standardized daily dose by dividing it minimal effective analgesic 
doses per day. Dosages were categorized into two clinically relevant categories: low-dose (≤ 0.5SDD), moderate-to-high dose (>0.5 SDD). 
e: Subgroup analyses of dose- and duration-effects were not shown due to relatively small sample size in cases. 
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6.0  DISCUSSION 
6.1 SUMMARY OF STUDY FINDINGS AND CONTRIBUTIONS TO THE 
LITERATURE 
6.1.1 Changes in Cholesterol-Lowering Medication Use Over a Decade in Community-
Dwelling Older Adults 
The first study of this dissertation found that the use of cholesterol-lowering medications in the 
elderly nearly tripled during the period of 1997-2008 (14.9% to 42.6%).  As expected, statins 
were the most common drug class used in the cohort studied.  It was interesting to find that only 
half of those with known CHD and/or diabetes received any cholesterol lowering agent.  In 
addition, this study showed that the release of guideline and evidence-based data had no 
immediate impact (i.e., change in level) on cholesterol-lowering medication use.  Instead, there 
was a decrease in the yearly rate of increase (i.e., decrease in slopes) of cholesterol-lowering 
medication use. 
To the best knowledge of the author, our study was the first one to formally assess the 
impact that the guideline publications and evidence-based data had on use of cholesterol-
lowering medications in the elderly.  The recommendation to use statins for older adults with 
established CHD or at high risk for developing CHD were primarily based on the results from 
subgroup analyses in clinical trials.189-193  Conclusively extrapolating the results from the 
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subgroup analyses to all older adults is controversial, since most of these trials had a defined 
inclusion upper age limit of 70-75 years.190,191,193  There is limited information about the use of 
cholesterol-lowering medications before and after 2002 in older adults aged ≥ 85 years.194  In 
addition, these publications are somewhat inconsistent regarding the need for cholesterol-
lowering medications in the elderly (e.g., those with diabetes but without CHD).195-200  The 
findings from this work are significant and help to fill the gap in the literature by examining the 
utilization patterns of cholesterol-lowering medications in community-dwelling older adults aged 
70 and older before and after the release of the NCEP ATP III guidelines195 and results from the 
PROSPER in 2002.196 
6.1.2 Associations between Statin Use and Gait-Speed Decline in Community-Dwelling 
Older Adults 
The second study of this dissertation showed that statin use, compared to non-users, had a 
decreased risk decline in gait speed of 0.05 m/s or more per year in community-dwelling older 
adults.201 In addition, low-dose statin use had a decreased risk of gait speed decline of 0.1 m/s or 
more per year.201  
 Gait speed is a simple, but important indicator of functional status in older adults.202-204  
Declines in gait speed consistently predict future physical disability, mortality, and major health-
related outcomes in older adults.4,6-10  Despite its importance, a paucity of literature has identified 
risk or protective factors (except for physical exercise) for age-related gait speed decline, or the 
magnitude of important gait decline in gait speed associated with these factors.205 The evidence 
that exists shows the mixed results.   The beneficial effects of statins in physical function decline 
were mainly found in smaller studies in individuals that had PAD.85,206-209  In contrast, two large 
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longitudinal cohort studies did not find that statins lowered the risk of self-reported mobility 
limitation in older women, or physical function decline in community-dwelling older 
adults.210,211  These later findings may be related to muscle-related adverse events may occur 
with statin use.212-218  The contribution of this study to literature is that this is the first study to 
examine statin use and gait-speed decline over a 20-m walk in community-dwelling older adults. 
Given the controversial findings previously described, the overall results of this dissertation 
work provide additional information to a growing body of literature suggesting that low-dose 
statin may be beneficial for slowing age-related decline in physical function in community-
dwelling adults.  It is also encouraging that there is no evidence from this study that statin use is 
associated with deteriorating gait speed decline.  Having said this, the muscle-related adverse 
events should not be a concern of the use of low-dose statins, especially in the older adults with 
CHD, who received statins for secondary prevention.   
6.1.3 Aspirin, non-aspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and 
risk of ovarian cancer 
The third study of this dissertation found that aspirin or selective COX-2 inhibitors were 
associated with reduced risk of ovarian cancer, especially among middle aged and older women 
who took aspirin at low doses (or for prevention of cardiovascular disease) continuously over a 
long period of time.  The results do not support the regular use of non-selective NA-NSAIDs and 
acetaminophen in the chemoprevention of ovarian cancer. 
 Several studies have examined associations between aspirin or NA-NSAIDs use and the 
risk of ovarian cancer, but the findings have been contradictory and inconclusive.  Previous 
studies were relatively small and lacked information or statistical power to assess the effects of 
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dose, duration, drug classes, or indications.  This is the first study able to evaluate the risk of 
ovarian cancer and examine dose-response and duration-response relationships comprehensively.  
This is also the first study with sufficient sample size to perform stratified analyses by indication 
for analgesic use and by types of NA-NSAIDs.   
6.2 PUBLIC HEALTH SIGNIFICANCE 
In general, pharmacoepidemiologic studies have emerged as an important tool for comparative 
effectiveness research of treatment effects, especially in populations with multiple chronic 
conditions, or older adults aged ≥ 80 years, which were usually excluded from RCTs.  In 
addition, pharmacoepidemiologic studies are robust tools to screen for adverse drugs effects, 
understand barriers to drug use and to improve health outcomes and quality.  Data derived from 
pharmacoepidemiologic studies inform clinical medicine, health promotion, health policy and 
planning in public health.  
Cardiovascular disease remains the leading cause of death and disability among the 
elderly in the US.  With regard to further reducing the burden of CHD morbidity and mortality, 
the emphasis is on the treatment of acute events and secondary or primary prevention through 
treatment and control of risk factors, such as control of dyslipidemia.  However, most of the 
clinical trials reviewed did not include older adults aged ≥ 80 years or those with multiple 
comorbidities.  Therefore, it is important and relevant to public health to better understand the 
utilization patterns of cholesterol-lowering medication use and the impact of guidelines and 
evidence-based data on their use in older adults.  The public health significance of the first study 
is that the results suggest that more efforts are needed to overcome barriers to disseminate and 
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implement of clinical guidelines of cholesterol-lowering medication use in clinical practice.  
Different dissemination methods may be needed for clinicians to quickly accept evidence-based 
data. 
The public health challenge of age-related disability and loss in physical function will 
continue to grow in our rapidly aging population.219  Loss in physical function seriously 
threatens the independence and quality of life for older adults and has a significant impact on 
family and society as well.220  Maintaining function and preventing or reducing disability are 
areas of interests to clinicians, policymakers, and older adults themselves.221,222  Gait speed is a 
simple, but important indicator of functional status in older adults.202-204   Declines in gait speed 
consistently predict future physical disability, mortality, and major health-related outcomes in 
older adults.193,195-199  Despite its importance, a paucity of literature has identified risk or 
protective factors other than physical exercise for age-related gait speed decline, or the 
magnitude of important gait decline in gait speed associated with these factors.205  Therefore, 
identifying modifiable factors to delay age-related gait speed decline in older adults is emerging 
as a significant priority of public health interest.  The results of the second study (i.e., statin use 
and gait speed decline) in this dissertation provide additional evidence and new insight that statin 
use may have a decreased risk of clinically important gait speed decline.  Low-dose and 
hydrophilic statin use may reassure in the context of concerns of statin-related muscular adverse 
events, especially in older adults. 
Ovarian cancer is the second most common gynecologic cancer, following uterine cancer, 
and causes more deaths per year than any other cancer of the female reproductive system.223  It 
afflicts approximately 1 in 70 women, and is the fifth leading cause of cancer death among 
females in the United States.5,223    However, ovarian cancer has a poorly understood etiology 
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and natural history.  Thus, strategies that focus on prevention may provide the most rational 
approach for meaningful reductions in the incidence and deaths attributable to ovarian cancer.  
Moreover, aspirin, NA-NSAIDs and acetaminophen are three of the most frequently used 
medication classes in the United States,224,225  Because of the widespread use of aspirin, NA-
NSAIDs and acetaminophen, any association with an increased or decreased cancer risk may 
influence many users.  The results of the third study (i.e., analgesics use and risk of ovarian 
cancer) in this dissertation suggest that aspirin or selective COX-2 inhibitors were associated 
with a decreased risk of ovarian cancer, especially among middle aged and older women who 
took aspirin at low doses continuously over a long period of time.  The regular use of non-
selective NA-NSAIDs and acetaminophen were not associated with the risk of ovarian cancer.  
The risk-benefit balance need to be evaluated in the use of aspirin or COX-2 inhibitors in older 
adults because of potential gastric side effects (e.g., peptic ulcer disease) from aspirin use and 
cardiovascular side effects from COX-2 inhibitor use. 
6.3 STUDY LIMITATIONS 
The results in this dissertation work should be interpreted with caution due to inherent study 
design, limitations and potential biases.  In general, despite employing several strategies to 
address confounding by indication, including adjustment, sensitivity and subgroup analyses, all 
observational studies of pharmacological exposures are subject to this problem.182  This could 
obscure or mask protective association of medication use because of initial poorer health status 
of users compared to non-users.   
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Some limitations should be considered when interpreting the results of the “Changes in 
Cholesterol-Lowering Medications Use over a Decade” and “Statin Use and Gait Speed Decline” 
Studies using the data from the Health ABC study.  Inherent to most longitudinal studies 
examining older adults, the potential for survivor bias should be considered.  This may bias the 
results towards null.  However, the results from sensitivity analyses, restricted to participants in 
the study for the entire period of follow-up, yielded similar results.  It is also possible that use of 
medications may be underestimated as medication use was measured at multiple fixed annual 
time points.  Unmeasured confounders such as family history of CHD, adherence to medications 
which were not collected in the Health ABC study, cannot be ruled out.  Given the high rates of 
non-adherence in statin users, it is possible that the protective effects of statins from gait speed 
decline were underestimated.   
The third study of examining analgesics and the risk of ovarian cancer in a case-control 
study has several limitations and biases.  First, we had no data on the characteristics of excluded 
and non-responding cases.  The protective results for aspirin use would be nullified if non-
responders in either the case or control groups would have had double or half of the exposure of 
the responders.  Second, cases may be more motivated to remember their analgesic use than 
controls.  However, any tendency for the cases to better recall exposures would result in ORs 
greater than 1.0 rather than the protective effects observed here.  To reduce the impact of recall 
bias, a defined reference date was used for assessing exposures.  The protective effects of recent 
aspirin use might be due to recall limitation since patients were more likely to recall the 
medications used recently.  Third, measurement and misclassification errors are presumably 
present when relying on self-reported and single measurement of analgesics use without 
verification.43 Fourth, we did not collect comprehensive information on medical co-morbidities 
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related to cardiovascular disease, health-conscious behaviors, or factors related to adverse 
histories of aspirin use.  The observed effect might be biased by the residual or unmeasured 
confounding.     
Finally, limiting generalizability of the results to other populations (e.g., different 
ethnicities) should be considered in all of the three studies.   
6.4 FUTURE RESEARCH 
The findings from the study that examined the changes in cholesterol-lowering medication use 
from 1997-2008 implicate the need for future studies to better guide cholesterol-lowering therapy 
and investigate the potential barriers of treatment among the oldest old elders (≥ 80 years) with 
CHD or at high risk.  The results from the study that evaluated the association between statin use 
and gait speed decline was the first study to show that statin user may benefit in a decreased risk 
of clinically important age-related gait speed decline over a 20-m walk.   Taken together with 
mixed results of statin use and physical function decline, further studies and RCTs are needed to 
confirm the observed associations between statin use and declines in gait speed in diverse 
populations (e.g., aged 85 years and older).  The results from the study regarding analgesic use 
and risk of ovarian cancer call for future research with better characterized accompanying 
medical conditions, health and lifestyle behaviors, genetic susceptibility, and the overall risk-
benefit balance of low-dose aspirin use.  Ultimately and ideally, randomized, controlled trials are 
warranted to confirm the beneficial effects of low-dose statin in preventing or delaying 
functional decline, and the effects of low-dose aspirin use in preventing ovarian cancer. 
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  APPENDIX 
OTHER MEDICATIONS WITH ANTI-INFLAMMATORY EFFECTS 
Type Non-steroidal anti-
inflammatory Drugs 
(NSAIDs) 
Other drugs with anti-inflammatory effect 
Systematic 
glucocorticosteroids (Oral 
only) 
Immunosuppressive 
drugs 
Other Miscellaneous 
Drugs 
Medication 
(by 
alphabetical 
order) 
Aspirin( > 
1200mg/day), 
Celecoxib, 
Choline salicylate, 
magnesium 
salicylate, 
Diclofenac, 
Diflunisal, 
Etodolac, 
Fenoprofen, 
Flubiprofen, 
Ibuprofen, 
Indomethacin, 
Ketoprofen, 
Ketorolac, 
Meclofenamate 
Mefenamic acid, 
Meloxicam, 
Nabumetone, 
Naproxen, 
Oxaprozin, 
Phenyl salicylate, 
Piroxicam,  
Rofecoxib, 
Salicylamide, 
Salsalate,  
Sulindac, 
Tolmetin, 
Trolamine salicylate 
Valdecoxib 
Budesonide, 
Hydrocortisone, 
Methylprednisolone, 
Prednisolone, 
Prednisone, 
Triamcinolone acetonide 
Dexamethasone 
Azathioprine, 
Chlorambucil 
Cyclophosphamide, 
Cyclosporine, 
Leflunomide, 
Methotrexate, 
Mercaptopurine, 
Mycophenolate mofetil, 
Sirolimus, 
Tacrolimus 
Alefacept 
Anakinra, 
Anti-thymocyte globulin, 
Olsalazine, 
Efalizumab, 
Etanercept, 
Hydroxychloroquine, 
Infliximab, 
Muromonab-CD3 
(OKT3), 
Montelukast, 
Natalizumab, 
Omalizumab, 
Rituximab, 
Sulfasalazine, 
Thalidomide, 
Zafirlukast, 
Zileuton 
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